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Abstract
Background: Vitamin D deficiency is markedly prevalent in children and adolescents with type 1 diabetes
mellitus (T1DM). Despite accumulating evidence to support the link between vitamin D deficiency and both
impaired glucose metabolism and altered immune responses in vitro and in vivo, it is not known whether
vitamin D deficiency is linked to poor glycemic control and/or systemic levels of inflammatory cytokines in
children and adolescents with T1DM. Aims: The purpose of this study was to examine the relationship
between 25-hydroxyvitamin D (the functional indicator of vitamin D status) and HbA1c (the standardized
index of glycemic control); and to determine whether inflammatory cytokines IL-6, IL-8, and IL-10 mediate
this relationship in metabolically stable children and adolescents with T1DM. Methods: A cross-sectional
design was used to examine these relationships in a convenience sample of 197 children and adolescents with
T1DM 7-18 years, recruited from the Diabetes Center for Children at the Children’s Hospital of Philadelphia.
Non-fasting serum levels of 25-hydroxyvitamin D, IL-6, IL-8, IL-10, and blood glucose were measured. Data
on socio-demographic and disease-related variables including HbA1c were abstracted from medical records.
Age- and sex-specific body mass index standard deviation scores (BMI z-score) were calculated. General linear
modeling was used to examine the hypothesized relationships between primary variables, while controlling
for select socio-demographic and disease-related covariates. Results: Mean HbA1c was 8.6±1.4%; 22.8%
subjects had poor glycemic control. Mean 25-hydroxyvitamin D was 54.6±17.8nmol/L; 90.0% subjects had
25-hydroxyvitamin D levels less than 75nmol/L. Mean serum IL-6 was highest in overweight/obese
adolescent females (1.57±1.29pg/ml). Mean serum IL-10 was highest in African Americans with poor
glycemic control (15.2±22.5pg/ml). Serum levels of IL-8 were not detected in this sample.
25-hydroxyvitamin D was not associated with HbA1c (β=0.008; P=0.108), nor with IL-6 (β=-0.005;
P=0.175) or IL-10 (β=0.004; P=0.356). IL-6 was not associated with HbA1c (β=0.09; P=0.418). IL-10 was
significantly associated with HbA1c (β=0.21; P=0.008). Conclusions: In this study sample of metabolically
stable children and adolescents with T1DM, neither 25-hydroxyvitamin D nor IL-6 were significantly
associated with HbA1c. IL-10 was significantly associated with HbA1c. Clinical controlled trials are needed to
confirm these results and assess the effect of varied doses of vitamin D supplements on inflammatory
cytokines and ultimately measure the effect of inflammatory cytokines on HbA1c in T1DM.
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ABSTRACT 
A CROSS-SECTIONAL STUDY OF VITAMIN D, GLYCEMIC CONTROL, AND 
INFLAMMATORY CYTOKINES IN CHILDREN AND ADOLESCENTS WITH 
TYPE 1 DIABETES MELLITUS 
Sarah Ibrahim Al Sawah 
Terri H Lipman, PhD, CRNP, FAAN 
Background: Vitamin D deficiency is markedly prevalent in children and adolescents 
with type 1 diabetes mellitus (T1DM). Despite accumulating evidence to support the link between 
vitamin D deficiency and both impaired glucose metabolism and altered immune responses in 
vitro and in vivo, it is not known whether vitamin D deficiency is linked to poor glycemic control 
and/or systemic levels of inflammatory cytokines in children and adolescents with T1DM. Aims: 
The purpose of this study was to examine the relationship between 25-hydroxyvitamin D (the 
functional indicator of vitamin D status) and HbA1c (the standardized index of glycemic control); 
and to determine whether inflammatory cytokines IL-6, IL-8, and IL-10 mediate this relationship 
in metabolically stable children and adolescents with T1DM. Methods: A cross-sectional design 
was used to examine these relationships in a convenience sample of 197 children and adolescents 
with T1DM 7-18 years, recruited from the Diabetes Center for Children at the Children’s 
Hospital of Philadelphia. Non-fasting serum levels of 25-hydroxyvitamin D, IL-6, IL-8, IL-10, 
and blood glucose were measured. Data on socio-demographic and disease-related variables 
including HbA1c were abstracted from medical records. Age- and sex-specific body mass index 
standard deviation scores (BMI z-score) were calculated. General linear modeling was used to 
examine the hypothesized relationships between primary variables, while controlling for select 
socio-demographic and disease-related covariates. Results: Mean HbA1c was 8.6±1.4%; 22.8% 
subjects had poor glycemic control. Mean 25-hydroxyvitamin D was 54.6±17.8nmol/L; 90.0% 
subjects had 25-hydroxyvitamin D levels less than 75nmol/L. Mean serum IL-6 was highest in 
vi 
 
overweight/obese adolescent females (1.57±1.29pg/ml). Mean serum IL-10 was highest in 
African Americans with poor glycemic control (15.2±22.5pg/ml). Serum levels of IL-8 were not 
detected in this sample. 25-hydroxyvitamin D was not associated with HbA1c (β=0.008; 
P=0.108), nor with IL-6 (β=-0.005; P=0.175) or IL-10 (β=0.004; P=0.356). IL-6 was not 
associated with HbA1c (β=0.09; P=0.418). IL-10 was significantly associated with HbA1c 
(β=0.21; P=0.008). Conclusions: In this study sample of metabolically stable children and 
adolescents with T1DM, neither 25-hydroxyvitamin D nor IL-6 were significantly associated with 
HbA1c. IL-10 was significantly associated with HbA1c. Clinical controlled trials are needed to 
confirm these results and assess the effect of varied doses of vitamin D supplements on 
inflammatory cytokines and ultimately measure the effect of inflammatory cytokines on 
HbA1c in T1DM.  
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CHAPTER ONE: INTRODUCTION 
Type 1 diabetes mellitus (T1DM) is the third most prevalent chronic disease of 
childhood, affecting one in every 400 to 600 children and adolescents in the United States 
(SEARCH for Diabetes in Youth Study Group et al., 2006; Centers for Disease Control 
and Prevention [CDC], 2008). The Philadelphia Pediatric Diabetes Registry showed that 
the age-adjusted incidence rate of T1DM in children 0-14 years was 18.2 per 
100,000/year in White children, 14.0 per 100,000/year in Black children, and 14.0 per 
100,000/year in Hispanic children from 2000 to 2004 (Lipman et al., 2009). Children and 
adolescents with T1DM are at increased risk to develop micro- and macro-vascular 
complications such as nephropathy, neuropathy, retinopathy, and coronary and peripheral 
vascular disease later in life (Diabetes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications (DCCT/EDIC) Research Group et al., 2009). 
Their mortality rate is two to three times higher, and their life expectancy is markedly 
lower than their healthy counterparts (Bruno et al., 2009; Patterson et al., 2007; SEARCH 
for Diabetes in Youth Study Group et al., 2006). The Diabetes Control and Complications 
Trial (DCCT), a landmark multicenter trial, has shown that tight glycemic control slows 
or prevents the development of micro- and macro-vascular complications in T1DM 
(Chrisholm, 1993; Nathan et al., 2005). Furthermore, tight glycemic control has been 
linked to enhanced quality of life in adolescents with T1DM (Ingerski, Laffel, Drotar, 
Repaske, & Hood, 2010).  
Despite the knowledge gained from the DCCT, poor glycemic control remains 
prevalent in children and adolescents with T1DM (Hanberger, Samuelsson, Lindblad, 
Ludvigsson, & Swedish Childhood Diabetes Registry SWEDIABKIDS, 2008; Petitti et 
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al., 2009). Studies have shown that glycemic control can vary with age, sex, ethnicity, 
socio-economic status, disease duration, daily insulin dose, type of insulin regimen, 
frequency of blood glucose monitoring, frequency of clinic visit, blood glucose level, and 
body mass index (BMI) (DCCT/EDIC Research Group et al., 2009; Helgeson, 
Honcharuk, Becker, Escobar, & Siminerio, 2010; Paris et al., 2009; Petitti et al., 2009). 
Factors such as parental education, parental involvement in diabetes management, family 
dynamics, and adherence may also affect glycemic control (Forsander, Sundelin, & 
Persson, 2000; Hood, Peterson, Rohan, & Drotar, 2009; Moreland, Tovar, Zuehlke, 
Butler, Milaszewski, & Laffel, 2004; Petitti et al., 2009), thus suggesting an increased 
complexity to manage and achieve tight glycemic control in children and adolescents 
with T1DM.  
 Vitamin D status is yet another factor that may be linked to glycemic control in 
children and adolescents with T1DM. Recent studies have found a marked prevalence of 
vitamin D deficiency in this population (Bener et al., 2008; Di Cesar, Ploutz-Snyder, 
Weinstock, & Moses, 2006; Greer et al., 2007; Svoren, Volkening, Wood, & Laffel, 
2009). Furthermore, there has been increasing evidence linking vitamin D deficiency to 
the increased risk of T1DM, impaired glucose metabolism, and altered immune responses 
in vitro and in vivo (Bouillon et al., 2008). Both glucose metabolism and immune 
responses are altered in T1DM (Kaufman, 2008). Therefore, it is both pertinent and 
timely to examine the relationships among vitamin D status, glycemic control, and 
inflammatory cytokines in metabolically stable children and adolescents with T1DM. 
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Vitamin D Deficiency in T1DM 
There are few studies in the literature that describe the prevalence of vitamin D 
deficiency in individuals with TIDM (Bouillon et al., 2008; Greer et al., 2007; Svoren et 
al., 2009). In the U.S., Svoren and colleagues evaluated vitamin D status in 128 children 
and adolescents with TIDM (mean age 10.8 ± 4.3 years; mean disease duration 4.1 ± 5.6 
years) residing in Boston, Massachusetts. Vitamin D deficiency (25-hydroxyvitamin D 
less than 50nmol/L) and insufficiency (25-hydroxyvitamin D equal or more than 
50nmol/L and less than 75nmol/L) was prevalent in 15.0% and 61.0% of the patients, 
respectively. Vitamin D deficiency was more prevalent among adolescents 12-18 years of 
age as compared to the younger age group, and among patients with longer disease 
duration as compared to those with shorter disease duration (Svoren et al., 2009).  
These data are comparable to the prevalence of vitamin D deficiency in healthy 
children and adolescents residing in the U.S. According to the National Health and 
Nutrition Examination Survey (NHANES) 2001-2004, vitamin D deficiency (defined in 
this study as 25-hydroxyvitamin D less than 37nmol/L) was found to affect 9.0% of the 
pediatric population (aged 1-21 years) representing 7.6 million U.S. children and 
adolescents. In addition, vitamin D insufficiency (defined in this study as 25-
hydroxyvitamin D equal or more than 37nmol/L and less than 72nmol/L) was evident in 
61.0% of the pediatric population representing 50.8 million U.S. children and 
adolescents. Vitamin D deficiency was more frequent in non-Hispanic Blacks as 
compared to Hispanics and non-Hispanic Whites, and in adolescents aged 13-21 years as 
compared to the younger age group (Kumar, Muntner, Kaskel, Hailpern, & Melamed, 
2009). Furthermore, an observational study including 382 healthy children and 
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adolescents (aged 6-21 years) residing in Philadelphia, PA, found hypovitaminosis D (25-
hydroxyvitamin D less than 75nmol/L) in 55.0% of study subjects (Weng et al., 2007). 
Hypovitaminosis D was evident in more than 90.0% of Blacks during winter.  
Vitamin D Status and Risk of Developing T1DM 
 Evidence supporting the link between vitamin D deficiency and the increased 
incidence of T1DM comes from ecological correlations, animal studies, and population-
based epidemiological studies. Ecologically, the highest incidence of T1DM was 
observed in countries with the furthest distance from the equator where low ultraviolet B 
radiation results in low vitamin D cutaneous synthesis. Alternatively, the incidence of 
T1DM approaches zero in countries with high ultraviolet B radiation (Mohr et al., 2008). 
In addition, the incidence of T1DM has been suggested to follow a seasonal pattern, with 
the highest rate observed during winter at the time of lowest vitamin D cutaneous 
synthesis, and the lowest rate observed during summer at the time of highest vitamin D 
cutaneous synthesis (Levy-Marchal et al., 1995).   
 Animal studies, particularly experiments in non-obese diabetic (NOD) mice, have 
provided the strongest evidence supporting the link between vitamin D deficiency and the 
increased incidence of T1DM. High doses of 1,25(OH)2D or its analogs, given to young 
NOD mice, reduced the incidence of insulitis (a histological lesion in pancreatic islets of 
Langerhans caused by infiltrating immune cells which precedes the clinical presentation 
of diabetes) and prevented T1DM (Gysemans et al., 2005; Mathieu et al., 1992; Giulietti 
et al., 2004; Gregori, Giarratana, Smiroldo, Uskokovic, & Adorini, 2002; Mathieu, Waer, 
Laureys, Rutgeerts, & Bouillon, 1994). Also, high doses of vitamin D3 analog and 
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cyclosporine A given to NOD mice with insulitis, halted the progression of insulitis to an 
overt clinical disease (Casteels et al., 1998).  
 Observational studies in humans have linked the intake of vitamin D-containing 
supplements or vitamin D-rich food during pregnancy to the decreased development of 
diabetes-related auto-antibodies in offsprings throughout the first year of life (Brekke & 
Ludvigsson, 2007; Fronczak et al., 2003). Similarly, a large cohort epidemiologic study, 
using data from the 1966 Northern Finland Birth Cohort, suggested an association 
between vitamin D supplementation (2000 IU daily) during the first year of life and the 
decreased incidence of T1DM (86.0% reduction) after 30 years of follow-up (Hypponen, 
Laara, Reunanen, Jarvelin, & Virtanen, 2001).  
Vitamin D Status and Glucose Metabolism 
 Evidence supporting the link between vitamin D status and glucose metabolism 
comes from both animal and human studies examining the effect of vitamin D deficiency 
on insulin secretion and sensitivity. Animal studies have shown that 1,25(OH)2D may be 
locally produced by pancreatic β-cells. Furthermore, 1,25(OH)2D increases intracellular 
free Ca2+ and subsequently increases insulin secretion in pancreatic β-cells in vitro 
(Norman et al., 1980; Sergeev & Rhoten, 1995; G. G. Schwartz et al., 2004).  
 In humans, there is increasing evidence to support the link between vitamin D 
deficiency and altered glucose metabolism in both children and adults. In a group of 
obese children and adolescents, a 10-unit increase in serum 25-hydroxyvitamin D 
(nmol/L) was linked to a 0.5% (P=0.015) and 0.4% (P=0.025) decrease in fasting glucose 
level (mmol/L) in boys and girls, respectively (Delvin et al., 2010). In a similar cohort of 
obese children and adolescents, 25-hydroxyvitamin D was inversely associated with both 
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HbA1c (r =−0.23, P=0.01) and fasting glucose (r=–0.20, P<0.001) (Alemzadeh, Kichler, 
Babar, & Calhoun, 2008; Johnson, Nader, Weaver, Singh, & Kumar, 2010). Furthermore, 
cross-sectional studies including both non-diabetic elderly and adults with impaired 
glucose tolerance have shown that 25-hydroxyvitamin D levels are associated with 1-
hour glucose concentration (r=-0.23, P<0.01) and total insulin concentration (r=-0.18 to -
0.23, P<0.05), and positively associated with insulin sensitivity index (r=0.46, P=0.0007) 
during a standard 75g oral glucose tolerance test (Baynes, Boucher, Feskens, & 
Kromhout, 1997;  Chiu, Chu, Go, & Saad, 2004).  
 The following three sections provide an overview on the immune modulatory role 
of vitamin D in vitro and in vivo, the link between inflammation and micro- and macro-
vascular complications in T1DM, and the link between pro- and anti-inflammatory 
cytokines and glycemic control in T1DM.    
Vitamin D Status and Immune Modulation 
 Vitamin D is an immune modulatory hormone that exerts its effect on the immune 
system by interacting with vitamin D receptors found in antigen presenting cells, 
dendritic cells, activated T cells and B cells, monocytes, and macrophages (van Etten & 
Mathieu, 2005). 1,25(OH)2D directly inhibits T cells proliferation, inhibits dendritic cells 
differentiation and maturation, down-regulates the expression of MHC class II, co-
stimulatory molecules (CD40, CD80, and CD86) and interleukin (IL)-12, and enhances 
the production of anti-inflammatory cytokines including IL-10, thereby inhibiting 
dendritic cell-dependent T cell activation in vitro (Bouillon et al., 2008; van Etten & 
Mathieu, 2005). The consequential down-regulation of IL-12 and up-regulation of IL-10 
alter the cytokine milieu and shift the differentiation of CD4+ T cells towards a T helper 
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type 2 (Th2) phenotype, thus inhibiting the production of Th1 cytokines interferon 
gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and IL-2 while promoting the 
production of Th2 IL-4, IL-5, and IL-10 (Boonstra et al., 2001; Bouillon et al., 2008). 
Furthermore, 1,25(OH)2D indirectly impedes the activation of immune-related 
transcription factors, nuclear factor of activated T cells, nuclear factor κappa B (NF B), 
and activating protein-1, thereby decreasing the production of IL-8, IL-12, IL-2, and IL-4 
in vitro (Alroy, Towers, & Freedman, 1995; D'Ambrosio et al., 1998; Harant, Wolff, & 
Lindley, 1998; Staeva-Vieira & Freedman, 2002; Takeuchi et al., 1998; Towers, Staeva, 
& Freedman, 1999; Yu, Bellido, & Manolagas, 1995).  
 The immune modulatory role of vitamin D has been examined, as previously 
described, in NOD mice where treatment with vitamin D or its analogs halted or slowed 
the progression of the disease. Similarly, the immune modulatory role of vitamin D was 
examined in vitro on the expression of inflammatory cytokines by freshly isolated 
monocytes from patients with type 2 diabetes mellitus (T2DM), T1DM and healthy 
controls. The addition of vitamin D to activated monocytes down-regulated the 
expression of TNF-α, IL-6, IL-1, and IL-8 in monocytes from both T2DM and T1DM 
patients. However, only the down-regulation of IL-8 in monocytes from T1DM patients 
reached statistical significance (P<0.05). 1,25(OH)2D3 had no effect on IL-10 expression 
in either group (Giulietti et al., 2007). 
 In humans, there have been no studies examining the effect of vitamin D 
supplements on systemic markers of inflammation in T1DM. However, this effect has 
been observed in patients with other inflammatory conditions such as end-stage renal 
disease, in elderly women post hip-fracture, in patients with chronic kidney disease, and 
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in patients with congestive heart failure (Stubbs, Idiculla, Slusser, Menard, & Quarles, 
2010; Miller et al., 2007; Neves et al., 2010; Schleithoff et al., 2006).  
Inflammation and T1DM Complications 
 T1DM is a pro-inflammatory state characterized by increased systemic markers of 
inflammation and monocyte activity, both of which have been linked to the increased risk 
of micro- and macro-vascular complications (Devaraj et al., 2006; Devaraj et al., 2007; 
Schalkwijk et al., 1999). In vitro studies have reported increased monocyte activity in 
T1DM patients as compared to healthy controls. This increased monocyte activity was 
more prominent in T1DM patients with micro-vascular complications. In monocytes of 
T1DM patients with micro-vascular complications, there was a significant increase of 
toll-like receptor 2 (TLR2) and TLR4 surface expression as compared to monocytes from 
T1DM patients with no micro-vascular complications and healthy controls (P<0.01) 
(Devaraj, Jialal, Yun, & Bremer, 2010). The increase in TLR2 and TLR4 surface 
expression is significantly and positively associated with increased NFκB activity which 
contributes to the increased monocytic release of IL-1β, IL-1, IL-6, and TNF-α (Devaraj 
et al., 2007; Devaraj et al., 2010).  
 Cross-sectional studies and prospective observational studies of adolescents and 
adults with T1DM have reported significant associations between progressive 
nephropathy and elevated systemic levels of pro-inflammatory cytokines including 
soluble intercellular adhesion molecule-1, C-reactive protein, soluble tumor necrosis 
factor-alpha receptor-1, and vascular cell adhesion molecule-1 (Clausen et al., 2000; Lin 
et al., 2008; Saraheimo, Teppo, Forsblom, Fagerudd, & Groop, 2003; Zoppini et al., 
2001). A cross-sectional examination of the follow-up data of the EURODIAB 
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Prospective Complications Study, showed a significant association between markers of 
inflammation (C-reactive protein, IL-6, and TNF), combined in a Z-score, and 
albuminuria, retinopathy, and coronary artery disease in adults with T1DM (Schram et 
al., 2005). 
 Moreover, case-control studies have reported significantly increased systemic 
levels of C-reactive protein and IL-6 in adolescents with T1DM as compared to healthy 
controls (P<0.0001) (Mangge et al., 2004; Snell-Bergeon et al., 2010). In one of the case-
control studies, elevated levels of C-reactive protein and IL-6 were independent of 
race/ethnicity, sex, hyperglycemia, and obesity, thus suggesting the presence of 
alternative mechanisms that may be related to elevated levels of C-reactive protein and 
IL-6 in this population (Snell-Bergeon et al., 2010). C-reactive protein has been 
associated with systemic inflammation and is considered a systemic predictor of early 
atherosclerotic lesions and subsequent risk of coronary artery disease (Hayaishi-Okano et 
al., 2002; Ridker, Rifai, Rose, Buring, & Cook, 2002).  
Inflammation and Glycemic Control 
There is accumulating evidence that systemic markers of inflammation (e.g. C-
reactive protein, IL-6, IL-8, and IL-18) are related to glycemic control in T1DM 
(Erbagci, Tarakcioglu, Coskun, Sivasli, & Sibel Namiduru, 2001; Foss-Freitas, Foss, 
Rassi, Donadi, & Foss, 2008; Lo, Lin, & Wang, 2004; Van Sickle et al., 2009; 
Zozulinska, Majchrzak, Sobieska, Wiktorowicz, & Wierusz-Wysocka, 1999; Scholin et 
al., 2004). However, to my knowledge, only one study examined the association between 
IL-10 and HbA1c in T1DM. Sanda and colleagues found an association between higher 
mean number of IL-10 producing cells, measured at the time of T1DM diagnosis, and 
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improved glycemic control (r2=0.68; P=0.08) measured three months after diagnosis 
(Sanda, Roep, & von Herrath, 2008). 
Aims and Hypotheses 
 Accordingly, the purpose of this study was to examine the relationship between 
25-hydroxyvitamin D and HbA1c; and to determine whether inflammatory cytokines IL-
6, IL-8, and IL-10 mediate this relationship in metabolically stable children and 
adolescents with T1DM. Children and adolescents with less than one year duration of the 
disease has been excluded, since they may experience partial remission and thus may 
exhibit a different immunologic profile as compared to patients with longer disease 
duration (Muhammad, Swift, Raymond, & Botha, 1999). The following aims were 
identified:   
1. Quantify the relationship between 25-hydroxyvitamin D and HbA1c excluding 
inflammatory cytokines (IL-6, IL-8, and IL-10). 
Hypothesis: 25-hydroxyvitamin D is inversely related to HbA1c. 
2. Quantify the relationship between 25-hydroxyvitamin D and inflammatory 
cytokines (IL-6, IL-8, and IL-10) excluding HbA1c. 
Hypothesis: 25-hydroxyvitamin D is inversely related to IL-6 and IL-8, and 
directly related to IL-10. 
3. Quantify the relationship between inflammatory cytokines (IL-6, IL-8, and IL-10) 
and HbA1c excluding 25-hydroxyvitamin D. 
Hypothesis: IL-6 and IL-8 are directly related to HbA1c. IL-10 is inversely 
related to HbA1c. 
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4. Quantify the total indirect effect and specific indirect effects of 25-
hydroxyvitamin D on HbA1c through three mediators (IL-6, IL-8 and IL-10).  
Hypothesis: IL-6, IL-8 and IL-10 mediate the relationship between 25-
hydroxyvitamin D and HbA1c.  
In addition, if a direct and non-linear relationship between 25-hydroxyvitamin D and 
HbA1c exist, then: 
5. Determine a threshold value for minimum mean 25-hydroxyvitamin D level 
beyond which greater improvements in HbA1c may be expected. 
Conceptual Framework 
The marked prevalence of vitamin D deficiency in children and adolescents with 
T1DM, and the hypothesized relationships among vitamin D status, glycemic control, and 
inflammatory cytokines in metabolically stable children and adolescents with T1DM, 
outline the conceptual framework of this proposal. 25-hydroxyvitamin D, the functional 
indicator of vitamin D status, was selected as the primary independent variable (Heaney, 
Dowell, Hale, & Bendich, 2003). HbA1c, the standardized index of glycemic control, 
was the proposed primary outcome (Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) 
Research Group et al., 2009; Goldstein et al., 1994; Steffes et al., 2005). Pro-
inflammatory cytokines IL-6 and IL-8, and the anti-inflammatory cytokine IL-10, which 
reflect the state of inflammation in T1DM, were selected as hypothetical mediators that 
may be related to both 25-hydroxyvitamin D and HbA1c.  
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Dependent Variable - HbA1c 
 In the mid 1970s, the relationship between HbA1c and mean blood glucose level 
was established. In the mid 1980s HbA1c was widely used as the standardized index of 
glycemic control. In the 1990s, the DCCT study established HbA1c as a measure of risk 
for the development of micro- and macro-vascular complications in T1DM (DCCT/EDIC 
Research Group et al., 2009; Goldstein et al., 1994; Steffes et al., 2005). Therefore, the 
use of HbA1c in this study provides a clinically meaningful indicator for glucose control 
and a common ground for comparability with previously reported data in diabetes 
research.  
 According to the American Diabetes Association (ADA) guidelines, age-specific 
HbA1c target values are 7.5% to 8.5% for ages 0-6 years, less than 8.0% for ages 6-12 
years, and less than 7.5% for ages 12-18 years (Silverstein et al., 2005). Glycemic control 
has been classified as “good” in individuals who met their target HbA1c, “intermediate” 
in individuals with HbA1c between their target HbA1c and 9.5% or “poor” in individuals 
with HbA1c greater than 9.5% (Petitti et al., 2009). Studies have shown that age, sex, 
ethnicity, socio-economic status, disease duration, daily insulin dose, type of insulin 
regimen, frequency of blood glucose monitoring, frequency of clinic visit, blood glucose 
level, and BMI explain a considerable percent of variance in HbA1c (DCCT/EDIC 
Research Group et al., 2009; Forsander et al., 2000; Helgeson et al., 2010; Hood et al., 
2009; Moreland, Tovar, Zuehlke, Butler, Milaszewski, & Laffel, 2004; Paris et al., 2009; 
Petitti et al., 2009). 
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Independent Variable - 25-hydroxyvitamin D 
In 1997, serum 25-hydroxyvitamin D level was accepted as the functional 
indicator of vitamin D status by the Food and Nutrition Board of the Institute of Medicine 
(IOM) (Heaney et al., 2003). Serum 25-hydroxyvitamin D has a relatively long half-life 
of 2-3 weeks and is considered the best estimate of vitamin D supply from both 
cutaneous synthesis and dietary intake (Norman, 2008; Prentice, Goldberg, & 
Schoenmakers, 2008). It is well established that serum 25-hydroxyvitamin D 
concentration varies with age, gender, ethnicity, skin pigmentation, BMI, season, and 
latitude (Compher, Badellino, & Boullata, 2008; Jacques et al., 1997; Macdonald et al., 
2008; Yetley, 2008).   
To date, there is still no consensus between the IOM and vitamin D experts on the 
cut off point for vitamin D sufficiency (Looker et al., 2011; Holick et al., 2011). 
Recently, the IOM defined four categories of vitamin D status: a) at risk of vitamin D 
deficiency (25-hydroxyvitamin D less than 30nmol/L), b) at risk of vitamin D inadequacy 
(25-hydroxyvitamin D between 30 and 49nmol/L), c) sufficient in vitamin D (25-
hydroxyvitamin D between 50 and 125nmol/L), and d) possibly harmful vitamin D (25-
hydroxyvitamin D greater than 125nmol/L) (IOM, 2010). On the other hand, the 
Endocrine Society in consensus with vitamin D experts classify vitamin D status into 3 
categories: a) deficiency (25-hydroxyvitamin less than 50nmol/L), b) insufficiency (25-
hydroxyvitamin D equal or more than 50nmol/L and less than 75nmol/L) and c) 
sufficiency (25-hydroxyvitamin D equal or more than 75nmol/L and less than 
250nmol/L) (Holick, 2007; Holick, 2008; Prentice et al., 2008; Rovner & O'Brien, 2008; 
Holick et al., 2011).  
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Pro-Inflammatory Cytokine IL-6 
 IL-6 is a pro-inflammatory cytokine that has been associated with the 
pathogenesis of T1DM, hyperglycemia, and glycemic control (Choudhary & Ahlawat, 
2008; Rosa et al., 2008; Targher, Zenari, Bertolini, Muggeo, & Zoppini, 2001; 
Mohamed-Ali, Armstrong, Clarke, Bolton, & Pinkney, 2001; Targher et al., 2001). 
Furthermore, studies have reported associations between elevated systemic levels of IL-6 
and the increased risk of micro- and macro-vascular complications in T1DM (Devaraj et 
al., 2007; Schram et al., 2005). Not only this, systemic levels of IL-6 have been 
associated with disease severity in patients with T2DM, septic shock, trauma, severe 
acute pancreatitis, and cardiogenic shock (Berney et al., 1999; Choudhary & Ahlawat, 
2008; Gebhard et al., 2000; Geppert et al., 2002; Martin, Boisson, Haccoun, Thomachot, 
& Mege, 1997). In addition, IL-6 has a relatively longer half-life than other pro-
inflammatory cytokines including TNF-α and IL-1β (Hirasawa, Oda, & Nakamura, 2009; 
Oda et al., 2005). As such, IL-6 has been selected as a hypothetical mediator that may be 
related to both vitamin D status and glycemic control in metabolically stable children and 
adolescents with T1DM.  
Pro-inflammatory Cytokine IL-8 
 Studies have found a consistent link between elevated systemic levels of IL-8 and 
hyperglycemia, poor glycemic control, and diabetes complications in patients with T1DM 
(Erbagci et al., 2001; Foss-Freitas et al., 2008; Lo et al., 2004; Van Sickle et al., 2009; 
Zozulinska et al., 1999). IL-8 is produced in response to other pro-inflammatory 
cytokines, such as IL-1β and TNF-α, by a series of cells including monocytes, 
macrophages, T lymphocytes, neutrophils, fibroblasts, keratinocytes, hepatocytes, 
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chondrocytes, endothelial cells, glioblastoma cells, and mesothelial cells (Lo et al., 2004). 
An acute increase in pro-inflammatory cytokines induces intracellular IL-8 mRNA which 
reaches maximal expression within four hours of cell stimulation and gradually decreases 
thereafter. Sustained exposure to IL-1β has been shown to stabilize intracellular IL-8 
mRNA expression which may explain the previously reported increase in serum 
concentration of IL-8 in patients with T1DM. As such, IL-8 has been selected as a 
hypothetical mediator that may be related to both vitamin D status and glycemic control 
in metabolically stable children and adolescents with T1DM.  
Anti-Inflammatory Cytokine IL-10 
 IL-10 is an anti-inflammatory cytokine that is produced by a variety of cells 
including monocytes and T cells. It is known to inhibit Th1 responses, inhibit pro-
inflammatory cytokines, and increase the expression of Foxp3+ in T cells, thus changing 
their phenotype into T regulatory cells. Furthermore, studies have shown that vitamin D 
enhances the development of IL-10 producing cells which then reduces the number of IL-
6 producing cells (Correale, Ysrraelit, & Gaitan, 2009). To date, there is only one study 
that has reported an association between the frequency of IL-10 producing cells at the 
time of T1DM diagnosis and glycemic control measured three months thereafter (Sanda 
et al., 2008). Given its well established association with vitamin D, IL-10 has been 
selected as a hypothetical mediator that may be related to both vitamin D status and 
glycemic control in metabolically stable children and adolescents with T1DM.  
Significance of the Study 
 This nursing research is unique; it integrates both clinical and bench research, 
where biological markers have been used to address important clinical research questions 
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on the relationships among vitamin D status, glycemic control, and inflammatory 
cytokines in metabolically stable children and adolescents with T1DM. The knowledge 
gained from this research may guide the direction of future research and may be useful 
for developing clinical guidelines to reduce the magnitude of vitamin D deficiency and 
insufficiency in children and adolescents with T1DM. 
 
Figure 1.1 This figure is a visual representation of the hypothesized relationships among 25-
hydroxyvitamin D, HbA1c, and inflammatory cytokines IL-6, IL-8, and IL-10, adjusted for 
important covariates.  
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CHAPTER TWO: REVIEW OF LITERATURE 
 The purpose of this study was to examine the relationship between 25-
hydroxyvitamin D and HbA1c; and to determine whether inflammatory cytokines IL-6, 
IL-8, and IL-10 mediate this relationship in metabolically stable children and adolescents 
with T1DM. Chapter two starts with overviews on the incidence and prevalence of 
T1DM in the U.S., pathogenesis of T1DM, clinical presentation and honeymoon phase, 
medical management of T1DM, and lessons learned from the Diabetes Control and 
Complications Trial (DCCT). The subsequent section provides overviews on predictors 
of glycemic control in children and adolescents with T1DM and glycated hemoglobin 
(HbA1c). Section three reviews sources of vitamin D, predictors of vitamin D status, 
vitamin D metabolism, the suggested link between vitamin D deficiency and the 
increased risk of developing T1DM, the role of vitamin D in glucose homeostasis, and 
the role of vitamin D in immune modulation.  
Section One 
Incidence and Prevalence of T1DM in the US 
 T1DM is one of the leading chronic diseases of childhood and adolescence, 
affecting one in every 400 to 600 children and adolescents in the United States (SEARCH 
for Diabetes in Youth Study Group, 2006; Centers for Disease Control and Prevention 
[CDC], 2007). In the 1990’s, the World Health Organization (WHO) Multinational 
Project for Childhood Diabetes (WHO DIAMOND Project) reported a mean annual 
increase in T1DM incidence of 5.5% among children and adolescents, 0-14 years, 
residing in the U.S. (DIAMOND Project Group, 2006). It was not until the year 2000 that 
the SEARCH for Diabetes in Youth Study (SEARCH) (a population-based, observational 
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study of physician-diagnosed diabetes among youth <20 years of age) was initiated to 
estimate the overall prevalence and incidence of diabetes in children and adolescents 
residing in the U.S. SEARCH, which is still ongoing till present, collected data from six 
centers located in California, Colorado, Hawaii, Ohio, South Carolina, and Washington. 
In 2001, SEARCH estimated the overall prevalence of diabetes in children and 
adolescents at 1.82 cases per 1000 youth; of which 0.76 cases per 1000 and 2.80 cases per 
1000 were children 0-9 years and adolescents 10-19 years with T1DM, respectively (The 
SEARCH for Diabetes in Youth Study Group, 2006). The prevalence of T1DM was 2.0 
cases per 1000 in non-Hispanic Whites 0-19 years, 0.57 cases per 1000 in African 
Americans 0-9 years, and 2.04 cases per 1000 in African Americans 10-19 years (Bell et 
al., 2009; Mayer-Davis et al., 2009). Furthermore, diabetes was found in 781 out of 
641,414 Hispanic Americans, of which 99.3% of children younger than 10 years, 85.5% 
of adolescents 10-14 years, and 71.3% of adolescents 15-19 years had T1DM (Lawrence 
et al., 2009). Furthermore, in 2002 and 2003, the overall incidence rate of diabetes was 
24.3 cases per 100 000 person-years; with the highest incidence rate observed among 
adolescents 10-14 years (33.9 cases per 100 000 person-years) and non-Hispanic Whites 
(26.1 cases per 100 000 person-years) (Writing Group for the SEARCH for Diabetes in 
Youth Study Group et al., 2007).  
 In addition to SEARCH, several other population-based diabetes registries have 
been established in the U.S. including the Wisconsin Diabetes Registry, Chicago 
Childhood Diabetes Registry, Allegheny County Childhood-Onset T1DM Registry, and 
the Philadelphia Pediatric Diabetes Registry (Barcelo, Bosnyak, & Orchard, 2007; 
Lipman et al., 2006; Palta & LeCaire, 2009; Smith, Drum, & Lipton, 2007; Lipman et al., 
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2009). Of relevance to this study, the Philadelphia Pediatric Diabetes Registry 
demonstrated that the age-adjusted incidence rate of T1DM in children 0-14 years was 
18.2 per 100,000/year in White children, 14.0 per 100,000/year in Black children and 
14.0 per 100,000/year in Hispanic children from 2000 to 2004 (Lipman et al., 2009). 
Interestingly, the age-adjusted incidence rate of T1DM in White children, 0-14 years, 
residing in Philadelphia has increased from 12.8 per 100,000/year from 1995 to 1999 to 
18.2 per 100,000/year from 2000 to 2004 (Lipman et al., 2006; Lipman et al., 2009).  
Pathogenesis of T1DM 
 T1DM is characterized by the immune destruction of pancreatic β-cells, slow and 
progressive loss of endogenous insulin production and subsequent hyperglycemia (Zipris, 
2009; Kaufman, 2008). An inflammatory model has been suggested for the pathogenesis 
of T1DM (Bergholdt et al., 2004). Environmental factors, most likely common viruses, 
induce a T cell mediated destruction of the β-cells of the pancreas in genetically 
susceptible individuals. CD8+ T cells recognize MHC I restricted presentation of β-cell 
antigen and cause limited β-cell damage via the release of cytotoxic cytokines. Limited β-
cell damage initiates the release of glycosylated immature β-cell components, such as 
insulin or glutamic acid decarboxylase (GAD) not previously “seen” by the immune 
system and therefore recognized by the immune system as non-self antigens. 
Glycosylated immature β-cells components are taken up by dendritic cells in the islets 
and transported to regional pancreatic lymph nodes, where antigens are processed and 
presented to CD4+ T cells. Activated CD4+ T cells will then orchestrate the buildup of 
specific and non-specific inflammatory cells in the pancreatic islets causing inflammatory 
insulitis. Pro-inflammatory cytokines induce proapoptotic signaling in β-cells and/or 
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induce β-cells expression of Fas ligand thus labeling β-cells for MHC II non-restricted 
CD4+ T cells mediated killing (Bergholdt et al., 2004).  
Clinical Presentation and Honeymoon Phase 
 In T1DM, hyperglycemia becomes evident when 60.0% to 80.0% of pancreatic β-
cells are destroyed (Notkins & Lernmark, 2001; Kaufman, 2008). At the time of 
diagnosis, individuals with T1DM present with an array of clinical symptoms secondary 
to uncontrolled hyperglycemia including polyuria, polydipsia, polyphagia, blurred vision, 
fatigue, weight loss, and often ketoacidosis (Kaufman, 2008). Once the T1DM diagnosis 
is confirmed, exogenous insulin therapy is initiated to prevent rapid and severe 
dehydration, catabolism, ketoacidosis, and death (Jacobsen, Henriksen, Hother-Nielsen, 
Vach, & Beck-Nielsen, 2009). Individuals with a clinical diagnosis of T1DM receive 
exogenous insulin therapy for life.  
 Interestingly, newly diagnosed children and adolescents with T1DM experience a 
partial remission phase, known as the honeymoon phase, during the first year after 
diagnosis. It has been documented that the honeymoon phase affects approximately 
50.0% of children diagnosed with T1DM (Muhammad et al., 1999). Patients 
experiencing partial remission have improved production of endogenous insulin, achieve 
close to normal blood glucose control, and thus require lower daily insulin dose of less 
than 0.5unit/kg/day --expected daily insulin dose for children and adolescents with 
T1DM is approximately 1unit/kg/day (Sanda et al., 2008; Kaufman, 2008). It is therefore 
suggested that patients experiencing partial remission may not exhibit the same profile of 
immunologic changes observed in patients who have recovered from remission, and are 
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beyond the first year of diagnosis. For this reason, children and adolescents with less than 
one year duration of T1DM have been excluded from this study.  
Medical Management of T1DM  
 Medical management of T1DM is complex, ongoing, and requires the 
collaboration among the patient, parents, and members of the diabetes healthcare team. 
The goal of T1DM medical management is to achieve and maintain tight glycemic 
control while decreasing the frequency of hypoglycemia. The DCCT (1983-1989) firmly 
established the significance of tight glycemic control in slowing down the development 
and progression of diabetes related micro- and macro-vascular complications in T1DM 
(DCCT/EDIC Research Group et al., 2009). Based on these findings, intensive insulin 
therapy was adopted as the gold standard therapy for achieving tight glycemic control in 
children and adolescents with T1DM. Intensive insulin therapy may be either multiple 
daily injections (MDI) of three or more insulin injections per day or continuous 
subcutaneous insulin infusion (CSII or insulin pump) (Silverstein et al., 2005). To date, 
randomized controlled trials and observational studies have shown that CSII may be 
better than MDI in achieving better glycemic control, however, the associated risk of 
severe and non-severe hypoglycemia remains unchanged (Misso, Egberts, Page, 
O'Connor, & Shaw, 2010; Sherr, Cengiz, & Tamborlane, 2009). The DCCT reported a 
three-fold increase in the frequency of severe hypoglycemia associated with intensive 
insulin therapy (DCCT/EDIC Research Group et al., 2009). Severe hypoglycemia may 
increase the risk of hypoglycemia unawareness, neurocognitive damage, and emotional 
morbidity in young children with T1DM (Shalitin & Phillip, 2008).  
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 To balance the risks and benefits of intensive insulin therapy in children and 
adolescents with T1DM, the ADA designed age-specific glycemic goals. Age-specific 
glycemic goals for ages 0-6 years, 6-12 years, and 12-18 years are 7.5% to 8.5%, less 
than 8.0%, and less than 7.5%, respectively (Silverstein et al., 2005). Glycemic control 
has been classified as “good” in individuals who met their target HbA1c, “intermediate” 
in individuals with HbA1c between their target HbA1c and 9.5%, or “poor” in 
individuals with HbA1c greater than 9.5% (Petitti et al., 2009).  
 From the patient and family’s end, self-monitoring of blood glucose (SMBG) 
serves as a guide for diabetes self-management. As per the ADA guidelines, SMBG 
should be performed three or more times daily for patients using MDI or CSII (American 
Diabetes Association, 2010). SMBG provides information on the hour-to-hour 
effectiveness of insulin therapy, whether glycemic targets are achieved, whether insulin 
doses need to be adjusted, whether there is an impending risk of hypoglycemia, or 
whether nutrition or physical therapy needs to be modified (American Diabetes 
Association, 2010).  
Lessons Learned from Diabetes Control and Complications Trial (DCCT) 
 The DCCT (1983-1989) and subsequently the Epidemiology of Diabetes 
Interventions and Complications (EDIC; 1994-present) study provided the basis for our 
understanding of the relationship between glycemic control and the risk of developing 
diabetes-related micro- and macro-vascular complications later in life. The DCCT study 
enrolled 1,441 patients with TIDM 13-39 years with mild to moderate retinopathy 
(disease duration ranged from 1-15 years) that were randomly assigned to either intensive 
insulin therapy or conventional therapy (one or two insulin injections per day), and then 
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followed up participants for 6.5 years (Jacobsen et al., 2009; Springer et al., 2006). The 
intensive treatment group sustained a significantly lower mean HbA1c as compared to the 
conventional treatment group (7.4% vs. 9.1%, P<0.0001; respectively) and had markedly 
lower risk for progression of retinopathy and development of micro-albuminuria (urinary 
albumin excretion ≥40 mg/24 h), clinical proteinuria (urinary albumin excretion ≥300 
mg/24 h) and clinical neuropathy (Tamborlane & Ahern, 1997). In 1994, EDIC followed 
up 96.0% of the surviving cohort from the DCCT. All participants of the conventional 
treatment group were offered intensive therapy based on the beneficial outcomes of the 
DCCT. From 1994 till 2005, mean HbA1c was 8.0% in the former conventional 
treatment group and 7.8% to 8.1% in the former intensive treatment group. Despite 
equalization of glycemic indices in both treatment groups, the former intensive treatment 
group sustained a lower cumulative incidence of proliferative retinopathy (21.0%), 
nephropathy (9.0%), and cardiovascular disease (9.0%) after 30 years of diabetes, as 
compared to the conventional treatment group (50.0%, 25.0%, and 14.0%, respectively) 
(DCCT/EDIC Research Group et al., 2009).  
Section Two 
Predictors of Glycemic Control in Children and Adolescents with T1DM 
 Despite the lessons learned from DCCT and EDIC, there remain a significant 
number of children and adolescents with intermediate or even poor glycemic control. A 
cross-sectional study including 2,837 children and adolescents with T1DM from 22 
centers world-wide including North America, Europe, and Japan found good or 
intermediate glycemic control (HbA1c <8.0%) in 41.0% of children younger than 11 
years and only in 29.0% of adolescents 12-18 years (Mortensen et al., 1998). According 
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to SEARCH study, poor glycemic control (HbA1c >9.5%) was evident in 36.0% of 
African-Americans, 52.0% of American Indians, 27.0% of Hispanics, 26.0% of 
Asian/Pacific Islanders, and 12.0% of Whites with T1DM (Petitti et al., 2009). The same 
study found intermediate or poor glycemic control (HbA1c >7.5 %) in more than 70% of 
adolescents regardless of their insulin regimen (Paris et al., 2009). These data are 
concerning and further highlight the complexity of achieving and maintaining tight 
glycemic control in children and adolescents with T1DM.  
 Glycemic control has been linked to a series of disease-related and socio-
demographic variables (DCCT/EDIC Research Group et al., 2009; Forsander et al., 2000; 
Helgeson et al., 2010; Hood et al., 2009; Moreland, Tovar, Zuehlke, Butler, Milaszewski, 
& Laffel, 2004; Paris et al., 2009; Petitti et al., 2009). In a cross-sectional analysis 
including 300 children and adolescents with T1DM 7-16 years residing in Boston, 
HbA1c was directly associated with age (P<0.001), duration of diabetes (P< 0.001), 
insulin dose (P<0.001), and BMI (kg/m2) (P<0.001), and inversely associated with 
frequency of blood glucose monitoring (FBGM) (P=0.004), family structure (P=0.002), 
and father’s highest educational level (P= 0.002) (Levine et al., 2001). On the other hand, 
a cross-sectional study examining the effect of ethnicity on HbA1c in 183 children and 
adolescents with T1DM 1-21 years (99 non-Hispanic Whites and 84 Hispanics), found 
poorer glycemic control in Hispanics as compared to non-Hispanic Whites (0.45% 
difference in HbA1c levels, P=0.02). In a multivariate model, poor glycemic control was 
associated with low house-hold income (P=0.0024) and was not related to insurance 
status, parental level of education, family structure, or ethnicity (Gallegos-Macias, 
Macias, Kaufman, Skipper, & Kalishman, 2003). These data may suggest a significant 
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impact of family structure, parental level of education, and house-hold income on health-
related behaviors including adherence and diabetes self-management, which are very 
likely to affect glycemic control. 
 The SEARCH for diabetes in youth, found significant direct associations between 
HbA1c and age at the time of examination (P<0.0001), sex (P=0.027), ethnicity 
(P<0.0001), diabetes duration (P<0.0001), and BMI percentile (P=0.0018), and 
significant inverse associations between HbA1c and family structure (P=0.0003), and 
parental education (P<0.0001) (Paris et al., 2009; Petitti et al., 2009). Of note, HbA1c 
was lowest in youth receiving CSII than in those receiving MDI; however, both 
increasing age and infrequent SBGM (≤ 2 times per day) were associated with higher 
mean HbA1c, regardless of the insulin regimen (Paris et al., 2009). A recent review of the 
literature by Sherr et al., (2009) showed consistent results from 17 non-randomized 
pediatric studies regarding the significant reduction in HbA1c in children and adolescents 
with T1DM receiving CSII versus MDI (Sherr et al., 2009). Moreover, a meta-analysis of 
23 randomized controlled trials comparing CSII with MDI in 976 patients with T1DM 
reported a significantly better HbA1c in the CSII group (weighted mean difference -
0.3%; 95% CI -0.1 to -0.4) (Misso et al., 2010). Furthermore, there is increasing evidence 
to support the association between HbA1c and FBGM and the idea that this relationship 
may vary considerably with age. A cross-sectional study including 229 children and 
adolescents 9-15 years attending the Florida Camp for children and youth with diabetes 
reported significant associations between age and both HbA1c (r=0.18, P=0.02) and 
FBGM (r=−0.16, P=0.01) (Haller, Stalvey, & Silverstein, 2004). Also, a retrospective 
study of 26,723 children and adolescents 0-18 years with T1DM residing in Germany 
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found a significant difference in FBGM per age group, with it being highest in children 
younger than 6 years as compared to children 6-12 years or adolescents older than 12 
years (6.0/d vs. 5.3/d vs. 4.4/d, P<0.001) (Ziegler et al., 2010). The same study showed a 
higher FBGM in children on CSII compared to children on MDI or conventional therapy 
(P<0.001). In a multivariate model, after adjusting for covariates of glycemic control, a 
one-unit increase in FBGM was associated with a 0.20% decrease in HbA1c (P<0.001) 
(Ziegler et al., 2010).  
 Interestingly, a retrospective chart review, by Hochhauser and his colleagues 
examined the relationship between age at the time of T1DM diagnosis, gender, and 
glycemic control in 201 children and adolescents with T1DM (48.0% females). This 
study found no effect of age at the time of diagnosis on HbA1c; however, girls diagnosed 
at ages 6-12 years had significantly higher HbA1c levels compared to those diagnosed 
when they were younger or older and boys of the same age group. Although these 
findings have not been reported in previous studies, they suggest a significant interactive 
effect of age at diagnosis and gender on glycemic control in females 6-12 years. This 
interaction between age at diagnosis and gender may be related to pubertal changes and 
associated insulin resistance occurring during Tanner stages two to four (Hochhauser, 
Rapaport, Shemesh, Schmeidler, & Chemtob, 2008).  
 Other factors that may affect glycemic control include diet and exercise. The 
relationship between diet and glycemic control in children and adolescents with T1DM is 
complex simply because diet is individualized and is adjusted according to a patient’s 
food preferences, cultural influences, physical activity patterns, and family eating 
patterns and schedules (Silverstein et al., 2005).  A retrospective study examined the 
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relationship between HbA1c and diet composition in 532 patients with T1DM who 
participated in the DCCT, were on intensive insulin treatment, and had complete dietary 
data over 5 years of follow-up (Delahanty et al., 2009). A diet high in fat and low in 
carbohydrate was associated with higher HbA1c (P=0.001); however this relationship 
seemed to be confounded by exercise level, serum triglycerides, and BMI (P=0.02) and 
was no longer significant after adjustment for baseline HbA1c and concurrent insulin 
dose. On the other hand, studies examining the relationship between exercise and 
glycemic control have found weak or no associations. A cross-sectional observational 
study, part of the Hvidoere Study Group on Childhood Diabetes, including 2,093 
adolescents 11-18 years, found no association between physical activity and HbA1c; 
however more time spent doing school homework (r=−0.09; P<0.001) and less time spent 
on the computer (r=0.06; P<0.05) were associated with lower HbA1c (Aman et al., 
2009). A smaller-scale cross-sectional study in 142 children and adolescents with T1DM 
6-18 years, found a significant correlation between physical activity and daily insulin 
dose (r=- 0.193, P=0.0014) but not HbA1c. The same study reported a significant 
association between BMI and HbA1c (r=0.277, P=0.007) (Raile et al., 1999). In essence, 
studies examining the relationship between glycemic control and diet or exercise found 
either no or weak associations.  
 Family factors; including family structure, level of parental education, and 
household income may affect glycemic control in children and adolescents with T1DM 
(Levine et al., 2001; Paris et al., 2009; Petitti et al., 2009). In line with the previously 
cited studies, a survey analysis, including 153 youth 8-16 years with T1DM in Boston, 
found lower HbA1c levels in youth who have less negative affect related to blood glucose 
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monitoring, whose parents have higher diabetes-specific knowledge, and whose parents 
have less parental-perceived burden of diabetes management (r2=0.31; P<0.0001) (Butler 
et al., 2008). Also, Moreland and colleagues found significant associations between 
HbA1c and level of child-reported diabetes-specific family conflict, FBGM, and CSII 
(r2=0.20, P<0.001) in 153 children and adolescents with T1DM (Moreland, Tovar, 
Zuehlke, Butler, Milaszewski, & Laffel, 2004).  
 Insurance status has been consistently and significantly linked to glycemic control 
in bivariate analyses in children and adolescents with T1DM. However, this relationship 
loses statistical significance when adjusted for family structure, level of parental 
education, and household income in multivariate analyses (Gallegos-Macias et al., 2003; 
Levine et al., 2001; Paris et al., 2009; Petitti et al., 2009). Insurance have been used as a 
proxy for socio-economic status because of the absence of alternative direct measures of 
socio-economic status in this study. Furthermore, insurance status may be considered as a 
proxy for the aforementioned family factors that may affect glycemic control in this 
population. An interesting study by the Consortium for Quality Improvement in Safety 
Net Hospitals including 47,978 adults with diabetes (57±13 years) found significant 
associations between glycemic control and age (P<0.01), race (P<0.01), gender (P=0.01) 
and health insurance coverage (P=0.01). Poor glycemic control (HbA1c >9.5%) was 
more common in younger patients (P<0.0001), in patients who were never insured 
(P=0.004), in non-Hispanic Whites patients (P<0.0001), and in females (P=0.017) (Chew, 
Schillinger, Maynard, Lessler, & Consortium for Quality Improvement in Safety Net 
Hospitals, 2008). Future studies will be needed to confirm these results in children and 
adolescents with T1DM.  
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Glycated Hemoglobin  
Glycated hemoglobin (Hb) is formed by the non-enzymatic binding of glucose to 
hemoglobin (Peterson et al., 1998). Similarly, HbA1c is formed by the non-enzymatic 
binding of glucose to hemoglobin A, which comprises approximately 90.0% of the total 
hemoglobin (Bunn, Haney, Kamin, Gabbay, & Gallop, 1976). Red blood cells are freely 
permeable to glucose, and therefore the rate of formation of HbA1c is directly 
proportional to mean blood glucose level (Koenig & Cerami, 1979). Furthermore, red 
blood cells have an average life span of 120 days; thus HbA1c reflects mean blood 
glucose level over the preceding two to three months (approximately 120 days) (Saudek, 
Derr, & Kalyani, 2006). Interestingly, there have been several studies investigating the 
link between mean glucose level and HbA1c. In adults with diabetes, a one-percent 
increase in HbA1c was equivalent to a 32 to 36mg/dl increase in mean glucose level 
(Nathan, Turgeon, & Regan, 2007; Rohlfing, Wiedmeyer, Little, England, Tennill, & 
Goldstein, 2002b). In studies including children and adolescents with T1DM, a one-
percent increase in HbA1c corresponded to an 18 to 19 mg/dl increase in mean glucose 
level, which implies that a slight improvement in mean glucose level may translate into 
greater improvements in HbA1c in this young population (Diabetes Research in Children 
Network (DirecNet) Study Group, Wilson, & Kollman, 2008; Tamborlane et al., 2005).  
 Historically, HbA1c has been used to determine the extent of glycemic control in 
persons with a clinical diagnosis of diabetes (Selvin et al., 2010). In the last two decades, 
it has been used as a measure of risk for future development of micro- and macro-
vascular complications in T1DM (DCCT/EDIC Research Group et al., 2009; Goldstein et 
al., 1994; Steffes et al., 2005). Recently, the ADA has supported the use of HbA1c in 
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establishing a diabetes diagnosis (American Diabetes Association, 2009). Compared to 
fasting glucose, HbA1c has higher repeatability (reliability), can be assessed in non-
fasting state, and provides a clinically meaningful estimate of both glycemic control and 
future risk of micro- and macro-vascular complications (Selvin, Crainiceanu, Brancati, & 
Coresh, 2007; Selvin et al., 2010). Currently, HbA1c point-of-care instruments are 
available and have been widely used to efficiently evaluate glycemic control in diabetes 
clinics. According to a recent review by Lenters-Westra and Slingerland, only two point-
of-care instruments, Afinion and the DCA Vantage, meet the criteria of the National 
Glycohemoglobin Standardization Program (NGSP) for clinical accuracy (CV<3%) 
compared to the conventional laboratory-based ion-exchange high-performance liquid 
chromatography method used to quantify HbA1c in DCCT (Lenters-Westra & 
Slingerland, 2010; Rohlfing, Wiedmeyer, Little, England, Tennill, & Goldstein, 2002). 
The DCA Vantage was used to measure HbA1c in this study. 
Section Three 
Sources of Vitamin D 
Vitamin D (vitamin D without a subscript represents either vitamin D2 or D3) is a 
9,10-seco steroid that exists in two distinct forms; vitamin D2 and vitamin D3. Vitamin D2 
(ergocalciferol) is a 28-carbon molecule derived from the plant sterol ergosterol, whereas 
vitamin D3 (cholecalciferol) is a 27-carbon derivative of cholesterol (Hollis, 2008). 
Humans acquire vitamin D from three different sources including exposure to sunlight, 
diet, and dietary supplements. Exposure to sunlight contributes to approximately 80.0% 
to 90.0% of the body's requirement for vitamin D (Holick, 1994). During exposure to 
sunlight, the ultraviolet B photons (wavelength, 290-315nm) get absorbed by 7-
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dehydrocholesterol (provitamin D), a four-member ring steroid, in the epidermis and 
dermis (Holick, 1994; Webb & Holick, 1988). This causes the provitamin D ring to open 
at C9-C 10 to yield a 6,7-cis-hexatriene derivative known as previtamin D. Previtamin D 
is biologically inert and undergoes a temperature-dependent isomerization with shifting 
of the double bonds followed by a rotation about the single C6-C7 bond to yield 
cholecalciferol (vitamin D3), a thermodynamically stable 5,6-cis isomer (Holick, 1994; 
Webb & Holick, 1988). Cholecalciferol exits the skin into the dermal capillaries where it 
binds to the vitamin D-binding protein (Holick, 1994; Holick, 2007).  
Upon prolonged exposure to sunlight, the skin will convert approximately 15.0% 
of its total 7-dehydrocholesterol to previtamin D (Holick, 1994). This is particularly 
essential to prevent vitamin D toxicity. Once previtamin D is formed, it can absorb 
energy between 240-320nm and can undergo a series of reversible reactions that differ 
from the cholecalciferol pathway (Holick, 1994; Webb & Holick, 1988). Previtamin D 
can either reverse back to its parent provitamin D, photoisomerize into the biologically 
inactive photoisomers lumisterol and tachysterol, or isomerize to form a 6,7-trans isomer 
tachysterol (Holick, 1994; Webb & Holick, 1988).  
Few foods naturally contain vitamin D3 and the amounts of naturally occurring 
vitamin D3 vary widely within human food sources. Dietary sources of vitamin D3 
include oily fish, egg yolks, and fortified products such as margarine, fluid milk, and 
cereal (Prentice et al., 2008). Vitamin D2 is found in mushrooms. Fluid milk is the only 
dairy food that is vitamin D3 fortified and its content varies significantly from one 
manufacturer to another (Holick, 2007). It has been reported that meats from poultry, 
pork, and beef contain small amounts of vitamin D that probably come from vitamin D-
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fortified animal feed. Vitamin D2 is the common form of vitamin D used in over-the-
counter vitamin D supplements in the United States, although vitamin D3 supplements are 
available (Holick, 2007). Vitamin D from both diet and dietary supplements is absorbed 
in the small intestine via both the lymphatic system (as part of chylomicrons) and the 
portal vein (bound to vitamin D-binding protein) to the liver (Brannon, Yetley, Bailey, & 
Picciano, 2008; Prentice et al., 2008).     
Predictors of Vitamin D Status 
 Melanin is one of the main endogenous factors that regulate the cutaneous 
synthesis of vitamin D. It is a natural sunscreen that absorbs ultraviolet B radiation 
between 290 and 320nm (Holick, 1995). The concentration of melanin in the skin is 
inversely proportional to the cutaneous production of vitamin D. Sunscreen with a sun 
protection factor (SPF) 15 is an exogenous factor that absorbs 99.0% of ultraviolet B 
photons, and therefore decreases the cutaneous synthesis of vitamin D by approximately 
99.0%. Individuals with skin types five (dark intermediate) and six (dark) have a natural 
SPF of approximately eight to 30 because of the high melanin concentration in their skin, 
and therefore are considered at a high risk for developing vitamin D deficiency (Holick, 
1994).  
Age is another endogenous factor that regulates the cutaneous synthesis of 
vitamin D. Studies have shown that after 20 years of age, skin thickness as well as the 
concentration of 7-dehydrocholesterol decreases linearly with age (Holick, 1995). The 
amount of 7-dehydrocholesterol in the epidermis of a 70 years old is approximately 
25.0% of that in a 20 years old (Holick, 2008).  
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 Season is an exogenous determinant of the cutaneous synthesis of vitamin D. 
Studies have reported an increased prevalence of rickets during the winter season and its 
decline during summer and fall (Holick, 1995). During the winter, people are more likely 
to stay indoors and wear clothing that covers the entire surface area of their skin, thereby 
decreasing their exposure to sunlight. Furthermore, during fall and winter seasons, the 
zenith angle of sunlight is so oblique that it increases the absorption of ultraviolet B 
radiation in the earth’s ozone layer and decreases the amount of ultraviolet B radiation 
reaching the surface of the earth. Thus, there is little or no production of vitamin D3 in the 
skin (Holick, 1995; Holick, 1996). Furthermore, the efficiency of cutaneous conversion 
of 7-dehydrocholesterol to previtamin D has been associated with latitude, month, and 
time of the day. At 42◦N latitude, maximum cutaneous conversion of 7-
dehydrocholesterol to previtamin D was reached during June and July followed by a 
decline after August reaching less than 4.0% during October (Holick, 1995). At the same 
latitude, there was no detectable production of previtamin D from November through 
March. In areas closer to the equator, such as Los Angeles (34◦N) and Puerto Rico (18◦N) 
previtamin D production has been shown to occur throughout the year (Holick, 1995).  
Vitamin D Metabolism 
Vitamin D, whether synthesized in the skin or ingested in the diet, is biologically 
inert. It is transported to the liver mostly bound to vitamin D-binding protein which 
circulates at a much higher concentration than vitamin D and its metabolites (Prentice et 
al., 2008). In the liver, vitamin D undergoes first hydroxylation to 25-hydroxyvitamin D 
which is biologically inert and is the major circulating form of vitamin D with a relatively 
long half-life of two to three weeks. 25-hydroxyvitamin D undergoes a second 
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hydroxylation in the kidney by the enzyme 1α-hydroxylase to form 1, 25(OH)2D which 
has a half-life in the circulation of approximately four to six hours (Prentice et al., 2008). 
1, 25(OH)2D  binds with high affinity to specific nuclear receptors; the vitamin D 
receptors, and induces genomic responses by regulating as many as 500 genes in the 
human genome (Holick, 1994; Norman, 2008; Prentice et al., 2008; Norman, Frankel, 
Heldt, & Grodsky, 1980). 1,25(OH)2D also induces nongenomic responses by rapidly 
activating a variety of signal transduction pathways at or near the plasma membrane. 
Vitamin D receptors have been detected in thirty-six tissues, including intestine, skin, 
kidneys, bone, parathyroid glands, pancreas, ovary, uterus, placenta, breast, lymphocytes, 
monocytes, macrophages, and embryonic liver and muscle (Holick, 1994; Norman, 2008; 
Prentice et al., 2008). They have also been found in tumor cell lines including breast 
cancer, malignant melanoma, and leukemia cells (Holick, 1994). Under controlled 
experimental conditions, the interaction of 1,25(OH)2D with vitamin D receptors in 
tissues can result in a large array of different effects such as stimulating calcium-binding-
protein activity in certain regions of the brain, inhibiting interleukin IL-2 production in 
activated T lymphocytes, enhancing IL-1 production in activated monocytes, inhibiting 
parathyroid hormone synthesis, enhancing thyrotropin action, and inhibiting the 
proliferative activity of cultured human fibroblasts (van Etten & Mathieu, 2005).  
1α-hydroxylase is also present in extrarenal tissues, including osteoclasts, skin, 
macrophages, placenta, colon, brain, prostate, endothelium, and parathyroid glands; 
however, its expression varies with the physiologic state of the individual (Brannon et al., 
2008). The extrarenal production of 1,25(OH)2D generates its effect locally and is 
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thought to play an important role in cell differentiation, proliferation, and immune 
function (Norman, 2008).  
 25-hydroxyvitamin D can undergo a different type of hydroxylation in the renal 
tissues to form 24,25(OH)2D (Prentice et al., 2008). 24,25(OH)2D is the first product of a 
metabolic pathway needed to inactivate and degrade 25-hydroxyvitamin D (Prentice et 
al., 2008). It is found in the circulation bound to vitamin D-binding protein and is thought 
to affect osteoblast and osteoclast function, bone strength, and parathyroid gland 
function. 
Vitamin D Status and Risk of T1DM 
 The strongest evidence suggesting a link between vitamin D deficiency and the 
increased risk of developing T1DM comes from both animal and human studies. In 
young NOD mice with no evidence of insulitis (a histological lesion in pancreatic islets 
of Langerhans caused by infiltrating immune cells which precedes the clinical 
presentation of diabetes) treatment with high doses of 1,25(OH)2D decreases chemokine 
and cytokine expression by the pancreatic islets and therefore reduces the incidence of 
insulitis (Gysemans et al., 2005; Mathieu et al., 1992). Treating NOD mice with high 
doses of 1,25(OH)2D or its analogs at an early age can prevent T1DM, while having a 
vitamin D deficient state at an early age aggravates it (Giulietti et al., 2004; Gregori et al., 
2002; Mathieu et al., 1994). In adult NOD mice, the combined treatment of vitamin D3 
analog and cyclosporine A can prevent the progression of insulitis to an overt clinical 
disease and shift the cytokine expression in the pancreas from Th1 to Th2 (Casteels et al., 
1998). At the cellular level, treating adult NOD mice with vitamin D3 analog inhibits IL-
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12 production, blocks pancreatic infiltration of Th1 cells, enhances CD4+CD25+ 
regulatory cells, and arrests the progression of T1DM (Gregori et al., 2002). 
 In humans, controversial reports exist on the association between vitamin D 
receptor gene polymorphisms including FokI, BsmI, ApaI, and TaqI, and the increased 
incidence of T1DM (Ban et al., 2001; Chang et al., 2000; Fassbender et al., 2002; 
McDermott et al., 1997; Nejentsev et al., 2004; Pani et al., 2000; Turpeinen et al., 2003). 
Alternately, human population studies have shown a link between the intake of vitamin 
D-containing supplements or vitamin D-rich food during pregnancy with the decreased 
development of diabetes-related auto-antibodies in offspring throughout the first year of 
life (Brekke & Ludvigsson, 2007; Fronczak et al., 2003). A large cohort epidemiological 
study by Hypponen and colleagues suggested a protective role of high-dose vitamin D 
supplement (2000 IU daily) intake during the first year of life as manifested by a 
decreased incidence (86.0%) of T1DM over 30 years of follow up (Hypponen et al., 
2001). One open-label randomized trial, explored the effect of 0.25µg Calcitriol (vitamin 
D analog) given every other day to a group of 34 children with new onset T1DM, on 
residual pancreatic β-cell function after one year of treatment (Pitocco et al., 2006). 
Calcitriol did not halt or slow the progression of β-cell destruction; however, it reduced 
insulin requirement at three and six months but not at one year from the time of initiation 
of treatment. Another case-control pilot study evaluated the effect of 0.25µg 1-alpha-
hydroxyvitamin D3 (vitamin D analog), given twice daily to 17 patients with adult-onset 
latent autoimmune diabetes (LADA), on residual pancreatic β-cell function (Li et al., 
2009). After one year of treatment, preserved β-cell function was only observed in 
patients with less than one year duration of the disease. In summary, there is 
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accumulating evidence that vitamin D sufficiency may play a protective role early in the 
pathogenesis of T1DM, but causation has not been established. 
Vitamin D Status and Glucose Metabolism 
 Another intriguing role of vitamin D is its effect on glucose metabolism via 
increased insulin secretion and increased insulin sensitivity. In the 1980s, Norman and his 
colleagues showed the beneficial effect of vitamin D repletion on insulin secretion in 
vitamin D-deficient rats (Norman et al., 1980). In the 1990s, Sergeev and Rhoten found 
that vitamin D increases intracellular free Ca2+ concentration which subsequently 
increases insulin secretion in pancreatic β-cells (Sergeev & Rhoten, 1995). Furthermore, 
animal studies have shown an increased activity of 1-alpha hydroxylase in pancreatic β-
cells, which suggest a possible autocrine effect of vitamin D on insulin secretion 
(Schwartz et al., 2004). Also, it has been suggested that vitamin D may preserve 
pancreatic β-cells through its effect on cell proliferation, differentiation, and apoptosis 
(Dusso, Brown, & Slatopolsky, 2005).  
 There is increasing evidence to support the link between vitamin D deficiency and 
altered glucose metabolism in elderly and in adults. In a cross-sectional analysis of 142 
non-diabetic elderly 70-88 years in the Netherlands, vitamin D status was inversely 
associated with 1-hour glucose concentration (r=-0.23, P<0.01), area under the glucose 
curve (r=-0.26, P<0.01), and total insulin concentration (r=-0.18 to -0.23, P<0.05) during 
a standard 75-g oral glucose tolerance test (Baynes, Boucher, Feskens, & Kromhout, 
1997). Another cross-sectional study including 126 adults with impaired glucose 
tolerance residing in California found a positive association between vitamin D status and 
insulin sensitivity index (r=0.46, P=0.0007) and a negative association between vitamin 
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D status and plasma glucose concentration at 60 min (r=-0.28, P=0.0011), 90 min (r=-
0.28, P=0.0011), and 120 min (r=-0.29, P=0.0007) of the oral glucose tolerance test using 
bivariate analysis (Chiu, Chu, Go, & Saad, 2004). Furthermore, data from the NHANES 
(1988–1994) including 6,228 adults (2,766 non-Hispanic Whites, 1,736 non-Hispanic 
Blacks, and 1,726 Mexican Americans) showed an inverse association between vitamin 
D status and both insulin resistance and fasting glucose level in non-Hispanic Whites and 
Mexicans but not in non-Hispanic Blacks (Scragg, Sowers, Bell, & Third National Health 
and Nutrition Examination Survey, 2004).   
 The relationship between vitamin D status and glucose metabolism has also been 
examined in children and adolescents. In a cross-sectional study of 1,745 obese and 
Caucasian children and adolescents residing in Québec, hypovitaminosis D (25-
hydroxyvitamin D <75nmol/L) was found in more than 93.0% of boys and girls. 
Furthermore, there was a 0.5% (P=0.015) and 0.4% (P=0.025) decrease in fasting glucose 
level with every 10nmol/L increase in serum 25-hydroxyvitamin D in boys and girls, 
respectively (Delvin et al., 2010). In a similar cohort of 127 obese children and 
adolescents (13.0 ± 3.0 years) residing in the Wisconsin, 25-hydroxyvitamin D was 
inversely associated with HbA1c (r=− 0.23, P=0.01). However, when this relationship 
was examined after stratifying patients by ethnicity; 25-hydroxyvitamin D remained 
significantly and inversely associated with HbA1c for Caucasians (r=−0.31; P=0.05), 
showed a trend toward significance for Hispanics (r=−0.28; P=0.085), but was not 
significant for African Americans (r=0.13; P=0.43) (Alemzadeh, Kichler, Babar, & 
Calhoun, 2008). Similarly, in a retrospective study of 302 non-diabetic children and 
adolescents (63.6% females; 72.5% Caucasian; 65.2% had 25-hydroxyvitamin D < 
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75nmol/L) residing in Minnesota, 25-hydroxyvitamin D was significantly and inversely 
associated with fasting glucose (r=–0.20, P<0.001) (Johnson et al., 2010).  
Vitamin D Status and Immune Modulation in Vitro and in Vivo 
 The immune modulatory role of vitamin D was first recognized upon the 
identification of the vitamin D receptor in human peripheral blood monocytes and 
activated T cells (Bhalla, Amento, Clemens, Holick, & Krane, 1983). To date, the 
vitamin D receptor has been identified in various cells of the immune system including 
antigen presenting cells, dendritic cells, activated T and B cells, monocytes, and 
macrophages (Mahon, Wittke, Weaver, & Cantorna, 2003; van Etten, Stoffels, 
Gysemans, Mathieu, & Overbergh, 2008; Veldman, Cantorna, & DeLuca, 2000). Also, 1-
α hydroxylase (CYP27B1), the enzyme that converts 25-hydroxyvitamin D to its 
biologically active metabolite 1,25(OH)2D, is expressed in activated dendritic cells, 
macrophages, and T and B cells (Chen et al., 2007; Hewison et al., 2007; Overbergh et 
al., 2000). At later stages of immune activation, 1-α hydroxylase is up-regulated and the 
local production of 1,25(OH)2D is increased, thus creating a late negative feedback loop 
that down-regulates immune responses and subsequently down-regulates vitamin D 
receptor expression on macrophages and dendritic cells (Fritsche, Mondal, Ehrnsperger, 
Andreesen, & Kreutz, 2003; Kreutz et al., 1993). Furthermore, 24-hydroxylase, the 
enzyme that converts 1,25(OH)2D to its inactive form 24,25(OH)2D is expressed in 
immune cells and its expression is highly regulated (Chen et al., 2007; Vidal, Ramana, & 
Dusso, 2002). 
 At the cellular level, the arrangement of the 1,25(OH)2D/vitamin D receptor 
complex initiates a series of intracellular signaling events, recruits an RXR dimerization 
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partner, and then binds directly to intracellular vitamin D responsive elements in the 
promoter region of 1,25(OH)2D target genes (Haussler et al., 1998; Schrader, Kahlen, & 
Carlberg, 1997). Of note, previously reported immune-related 1,25(OH)2D target genes 
include cytokine genes TNF  and IFN  (Hakim & Bar-Shavit, 2003). In essence, the 
1,25(OH)2D/vitamin D receptor complex indirectly impedes the activation of immune-
related transcription factors, nuclear factor of activated T cells, NF B, and activating 
protein-1, thereby decreasing the production of a series of cytokines including IL-8, IL-
12, IL-2, and IL-4 (Alroy et al., 1995; D'Ambrosio et al., 1998; Harant et al., 1998; 
Staeva-Vieira & Freedman, 2002; Takeuchi et al., 1998; Towers et al., 1999; Yu et al., 
1995).  
 In vitro, 1,25(OH)2D exerts its effect on CD4+ T cells both directly and indirectly 
via the regulation of dendritic cells. In the absence of antigen presenting cells, 
1,25(OH)2D directly inhibits CD4+ T cells differentiation towards Th17, Th1, and T 
follicular helper phenotypes as observed by the decreased production of IL-17, IFN , and 
IL-21, respectively (Jeffery et al., 2009). Furthermore, 1,25(OH)2D increases the 
expression of CTLA-4 and FoxP3 and enhances the production of IL-10, thus 
differentiating CD4+ T cells into regulatory T cells. On the other hand, 1,25(OH)2D 
modulates immature DCs differentiation, maturation and activation, down-regulates the 
expression of MHC class II, co-stimulatory molecules (CD40, CD80, CD86) and IL-12, 
and enhances the production of anti-inflammatory cytokines including IL-10, thereby 
inhibiting dendritic cell-dependent T cells activation in vitro (Bouillon et al., 2008; van 
Etten & Mathieu, 2005). 1,25(OH)2D-treated DCs become tolerogenic, give way to the 
induction of regulatory T cells and therefore inhibit CD4+ T cells activation and 
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proliferation (D'Ambrosio et al., 1998; Penna-Martinez et al., 2009). Furthermore, both 
the down-regulation of 1L-12 and up-regulation of IL-10 alter the cytokine milieu and 
shift the differentiation of CD4+ T cells towards a Th2 phenotype, thus inhibiting the 
production of Th1 cytokines (IFN- γ, TNF- α and IL-2) while promoting the production 
of Th2 cytokines IL-4, IL-5, and IL-10 (Boonstra et al., 2001; Bouillon et al., 2008).  
 Recently, an in vitro study by Giulietti and colleagues examined the anti-
inflammatory role of 1,25(OH)2D3 on the expression of inflammatory cytokines by 
freshly isolated monocytes from patients with T2DM, T1DM and healthy controls. 
Monocytes from individuals with T2DM (P<0.01) and T1DM (P<0.05) expressed higher 
levels of pro-inflammatory cytokines TNF-α, IL-6, IL-1, IL-8, COX-2, ICAM-1, and B7-
1 and similar levels of anti-inflammatory cytokine IL-10 compared to monocytes from 
healthy controls. Furthermore, the addition of 1,25(OH)2D3 to activated monocytes, 
down-regulated the expression of TNF-α, IL-6, IL-1, and IL-8 in monocytes from T2DM 
and T1DM. However, only the down-regulation of IL-8 in monocytes from T1DM 
reached statistical significance (P<0.05). 1,25(OH)2D3 had no effect on IL-10 expression 
in either group. 
 In vivo, the immune modulatory effect of 1,25(OH)2D on CD4+ T cells has been 
observed in animal models of autoimmune diseases including T1DM, systemic lupus 
erythematosis, experimental autoimmune encephalomyelitis, and inflammatory bowel 
disease (Bouillon et al., 2008; Mathieu et al., 1994; Zella, McCary, & DeLuca, 2003). 
Also, populations-based observational studies reported an increased incidence of multiple 
sclerosis, T1DM, rheumatoid arthritis, and inflammatory bowel disease in Canada, the 
northern parts of the United States, and Europe compared to the incidence of these 
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autoimmune diseases in countries closer to the equator (Cantorna & Mahon, 2004; Zipitis 
& Akobeng, 2008). Scientists have hypothesized that the availability of vitamin D in the 
environment through either sunlight or food sources is an environmental factor that may 
affect the prevalence of autoimmune diseases. Furthermore, individuals with autoimmune 
diseases were found to have genetic polymorphisms for vitamin D regulatory genes, 
which may increase their susceptibility to multiple sclerosis, T1DM, rheumatoid arthritis, 
and inflammatory bowel disease (Cantorna & Mahon, 2004).  
 In humans, the immune modulatory effect of vitamin D has been examined in 
patients with inflammatory conditions including end-stage renal disease, in elderly 
women post hip-fracture, in patients with chronic kidney disease, and in patients with 
congestive heart failure. A prospective study examined the effect of 25-hydroxyvitamin 
D repletion on serum inflammatory cytokine levels in seven patients with end-stage renal 
disease. After eight weeks of cholecalciferol therapy (50,000 U twice per week) an 
increase in mean serum 25-hydroxyvitamin D level from 35±5.5 to 135±8.2nmol/L was 
associated with a 55.0%, 30.0%, and 60.0% decrease in serum IL-8, IL-6, and TNF-α 
levels, respectively (Stubbs et al., 2010). Another prospective study found a significantly 
negative association (P=0.02) between vitamin D deficiency (25-hydroxyvitamin D 
<37nmol/L) and systemic levels of pro-inflammatory cytokine IL-6 in a cohort of elderly 
women in the year following hip-fracture (Miller et al., 2007). Interestingly, Neves and 
colleagues tested the effect of oral vitamin D (alfacalcidol or calcitriol-daily dose ranged 
from 0.25 to 1.0lg with a median of 0.5lg) on systemic levels of C-reactive protein and 
pro-inflammatory cytokine IL-6 in a follow up cohort of 95 patients with stages four and 
five chronic kidney disease. After approximately 2 years, patients who did not receive 
43 
 
vitamin D had higher levels of C-reactive protein (P=0.014) and a trend to higher IL-6 
levels (P=0.077) compared to patients who did (Neves et al., 2010). Furthermore, a 
double-blind, randomized controlled trial showed that daily oral vitamin D (50 µg 
vitamin D3 plus 500 mg Calcium) taken for 9 months, significantly increased systemic 
levels of anti-inflammatory cytokine IL-10 (P=0.042) in patients with congestive heart 
failure as compared to healthy controls (Schleithoff et al., 2006).  
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CHAPTER THREE: RESEARCH METHODS 
Research Design and Target Population 
The purpose of this study was to examine the relationship between 25-
hydroxyvitamin D and HbA1c; and to determine whether inflammatory cytokines IL-6, 
IL-8, and IL-10 mediate this relationship in metabolically stable children and adolescents 
with T1DM. A cross-sectional design was used to examine these relationships in a 
convenience sample of children and adolescents with T1DM recruited from the Diabetes 
Center for Children (DCC) at the Children’s Hospital of Philadelphia (CHOP). Children 
and adolescents were recruited based on the following inclusion and exclusion criteria.  
Inclusion Criteria  
1) Confirmed clinical diagnosis of T1DM 
2) Age between 7 and 18 years 
3) Disease duration of more than one year 
4) Ability and willingness of the parents or guardian to grant consent 
5) Ability of children and adolescents to grant assent  
Exclusion Criteria  
1) Smoking 
2) Mean HbA1c >12.0% over the past year 
3) Any episode of ketoacidosis within the past month 
4) Presence of an inflammatory disorder (e.g. rheumatoid arthritis, inflammatory bowel 
disease) 
5) Abnormal complete blood count, liver, or renal function 
6) Any type of cancer 
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7) Malabsorption 
8) Celiac disease 
9) Current infections 
10) Recent surgery 
11) Use of oral steroid therapy, anti-inflammatory drugs, immunosuppressive drugs, 
metformin, ACE inhibitors, angiotensin II inhibitors, and/or aspirin within the past 
month 
12) Female patients will be excluded if pregnant  
 Children and adolescents with less than one year duration of T1DM were 
excluded from this study since they may experience partial remission and thus may 
exhibit a different immunologic profile as compared to patients with more than one year 
duration of the disease (Muhammad, Swift, Raymond, & Botha, 1999). Exclusion criteria 
ensured that all participating children and adolescents were metabolically stable and had 
no co-morbid conditions other than T1DM that may affect HbA1c values or systemic 
levels of pro- and anti-inflammatory cytokines. 
Sample Size and Power 
 The relationship between 25-hydroxyvitamin D (primary independent variable) 
and HbA1c (primary dependent variable) has not been previously examined as a primary 
endpoint in children and adolescents with T1DM. Therefore, to determine sample size: 
1. I specified the smallest clinically meaningful change in HbA1c (%) as a function 
of 25-hydroxyvitamin D (nmol/L). As such, a 10nmol/L increase in 25-
hydroxyvitamin D may correspond to a 0.5% decrease in HbA1c. From the 
SEARCH for diabetes in Youth Study (Petitti et al., 2009), mean HbA1c, in 3,947 
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youth with T1DM residing in the U.S., was 8.5±1.7%. Therefore, the standardized 
effect size was calculated by dividing 0.05 by the standard deviation 1.7, which 
yielded a value of 0.03. 
2. I specified the type I error rate at 5.0%, which is the probability of rejecting the 
null hypothesis when it is actually true. I also specified the type II error rate at 
20.0%, which is the probability of failing to reject the null hypothesis when it is in 
fact not true.  
3. I selected a cross-sectional design to examine the relationship between 25-
hydroxyvitamin D and HbA1c while controlling for 14 other covariates. Based on 
literature review, I have estimated that selected covariates explain approximately 
30.0% of the variance in HbA1c. However, to be conservative, I ran sample size 
calculation based on a series of values corresponding to variance in HbA1c as 
explained by 14 selected covariates ranging from 20.0% to 50.0% (table 3.1). 
Table 3.1 Power analyses and sample size calculation one 
 Effect Size of Tested  
IV on DV 
Alpha Power R-Squared of 14 Controlled IVs Sample Size 
1 0.03 0.05 80.0% 0.20 204 
2 0.03 0.05 80.0% 0.30 178 
3 0.03 0.05 80.0% 0.40 152 
4 0.03 0.05 80.0% 0.50 126 
Independent variable (IV); Dependent variable (DV) 
From the table 3.1, I concluded that a sample size of 204 (178, 152, or 126) 
achieves 80.0% power to detect an R-Squared of 0.03 attributed to one independent 
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variable, 25-hydroxyvitamin D (nmol/L), using an F-Test with a significance level of 
0.05. The variables tested were adjusted for an additional 14 independent variables with 
an R-Squared of 0.20 (0.30, 0.40, or 0.50). 
 Alternatively, Alemzadeh et al. (2008) found an inverse and significant 
association between 25-hydroxyvitamin D and HbA1c (r=− 0.23, P=0.01) in a cohort of 
127 obese children and adolescents 13.0±3.0 years residing in Wisconsin (Alemzadeh, 
Kichler, Babar, & Calhoun, 2008). Accordingly, I used a correlation of −0.2 (which 
corresponds to an R-Squared of 0.04) to calculate the sample size for this study (table 
3.2). 
Table 3.2 Power analysis and sample size calculation two 
 Effect Size of Tested  
IV on DV 
Alpha Power R-Squared of 14 Controlled IVs Sample Size 
5 0.04 0.05 80.0% 0.20 152 
Independent variable (IV); Dependent variable (DV) 
 Table 3.2 showed that a sample size of 152 achieves 80.0% power to detect an R-
Squared of 0.04 attributed to one independent variable, 25-hydroxyvitamin D (nmol/L), 
using an F-Test with a significance level of 0.05. As before, the variables tested were 
adjusted for an additional 14 independent variables with an R-Squared equal to 0.20. 
 I have selected the most conservative estimates of both the R-Squared (0.03) and 
variance in HbA1c that is explained by 14 selected covariates (20.0%). Therefore, a 
sample size of 204 was considered sufficient to detect a clinically and statistically 
meaningful change in HbA1c as a function of 25-hydroxyvitamin D while adjusting for 
14 other covariates.  
 
48 
 
Access to Target Population 
 Terri Lipman, PhD, CRNP, FAAN, my dissertation chair, has a clinical 
appointment at the Division of Endocrinology at CHOP. Dr. Lipman has granted me a 
non-traditional personnel (NTP) status to access my patient population and conduct my 
doctoral research at the DCC at CHOP. The NTP status provided me with access to 
CHOP IRB, facilities, intranet, patients’ records (EPIC), DCC clinic schedule, and 
training in human subject protection including HIPAA (http://www.citiprogram.org).  
Case Ascertainment 
 On average, children and adolescents with T1DM follow up with their diabetes 
provider at the DCC clinic three to four times a year. For this study, children and 
adolescents were recruited during their routine clinic visit at the DCC. The initial phase 
of recruitment entailed identifying potential participants to be informed about the study. 
One day prior to the clinic visit, I reviewed the clinic schedule and identified potential 
participants based on pre-specified inclusion and exclusion criteria. On the day of clinic 
visit, all potential participants had their height measured using a stadiometer (Holtain, 
Crymych, UK), their weight measured using a digital scale (Scale-Tronix, White Plains, 
New York, USA), and their HbA1c measured using point-of-care HbA1c testing (DCA 
Vantage, Siemens diagnostics, Tarrytown, NY). Only potential participants with HbA1c 
less than 12.0% and their parents were informed about the study. The following was the 
recruitment script:   
Hello, my name is Sarah Al Sawah.  I am a 4th year doctoral student at the University of 
Pennsylvania, School of Nursing. I am conducting a study on vitamin D status and glucose 
control in children and adolescents with type 1 diabetes. My mentor is Dr. Terri Lipman who is 
also a nurse practitioner at the DCC at CHOP. 
 
Question 1: Is this a good time to talk to you to tell you more about the study? 
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You are being invited to take part in this research study because you have had type 1 diabetes 
mellitus for more than one year, your age is between 7 and 18 years, and your HbA1c is less than 
12.0%. Your participation in this study is completely voluntary. This means that you do not have 
to participate in this study unless you want to.  If there is anything you do not understand, please 
ask questions. 
 
Question 2: Would you be interested to hear more about this study? 
 
Good. The purpose of this research study is to find out whether vitamin D level is related to blood 
glucose level in children and adolescents with type 1 diabetes mellitus. Previous studies have 
shown that keeping vitamin D levels within the normal range is important for bone growth and 
development, and may be helpful in blood glucose control. The study will also look at how 
inflammation affects the relationship between vitamin D level and blood glucose level in young 
people with type 1 diabetes. 
 
We estimate that approximately 204 subjects will enroll in this study. If you agree to take part in 
this study, the following procedures will be performed: 
 
1. We will review your medical record to collect demographic information (e.g. age, sex, 
ethnicity, and insurance) as well as information about your diabetes. 
 
2. We will collect two teaspoons of your blood to measure vitamin D level and markers of 
inflammation. If you are due for your routine yearly blood tests and blood is being drawn 
at CHOP today, you will NOT need an extra needle stick for the two teaspoons of blood 
that will be collected for this study. If you go to an outside lab for blood drawing or if you 
are not due for your routine yearly blood tests you may still participate in the study. 
However, this would require an extra needle stick for the two teaspoon of blood in the 
CHOP laboratory. 
 
Your Vitamin D levels will be shared with your diabetes provider. If the results are abnormal, 
your diabetes provider may check your vitamin D level one more time at a local laboratory. Your 
participation will end once you give two teaspoons of blood. 
 
What are the risks of this study? 
 
Taking part in a research study involves inconveniences and risks. Taking blood may cause some 
pain, bleeding or bruising at the spot where the needle enters your body. Rarely, taking blood 
may cause fainting or infection. We will take your blood at the same time you are having blood 
drawn for clinical purposes. The amount of blood we will take is minimal and you will not need a 
separate needle stick. If you go to an outside lab for blood draw and you wish to participate in 
this study, you will have to undergo an additional blood draw procedure at CHOP laboratory. 
The risks of taking blood are the same as stated above. 
 
As with any study involving collection of data, there is the possibility of loss of confidentiality of 
data. Every precaution will be taken to secure participants' personal information to ensure 
confidentiality. 
 
Are there any benefits to taking part in this study? 
 
There will be no direct benefit to the management of your glycemic control from taking part in 
this study. We hope that the information learned from this study will help us understand more 
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about type 1diabetes and possibly benefit other children and adolescents with the same condition 
in the future. If the results of the study show that vitamin D is related to glycemic control and 
blood glucose levels, the results may encourage diabetes providers to include vitamin D in yearly 
screening tests. 
 
The direct benefit will come from testing your vitamin D level and providing vitamin D 
supplements if your vitamin D levels were low.   
 
Financial Considerations 
You will not be responsible for any costs of this study. The School of Nursing at the University of 
Pennsylvania and the Pediatric Endocrinology Nursing Society will pay for all costs of 
participating. You will be given a $5 gift card as a token of appreciation for taking part in this 
study. 
  
The informed consent was signed and HIPAA authorization was obtained once 
potential participants and their parents expressed willingness to be part of this study 
(Appendix). At the end of the clinic visit, study subjects and their parents were escorted 
to the local laboratory at CHOP for blood drawing procedure. A non-fasting 10ml blood 
sample was collected in two 5ml-serum separator tubes (SSTs) from each study subject. 
Furthermore, each study subject received a $5 CVS gift card as a token of appreciation 
for participating in this study.  
Sample Processing and Measurements  
Once the 10ml blood sample was collected, the two 5ml-SSTs were labeled, 
gently mixed by inversion five times (to mix the clot activator with the blood), placed in 
a vertical position for 30 minutes at room temperature to allow for blood clotting, and 
then transported to the Biobehavioral Research Lab at the University of Pennsylvania, 
School of Nursing. At the Biobehavioral Research Lab, the SSTs were centrifuged at 
3,000 rpm for 15 minutes to allow the separation of serum from the cellular components 
of blood. For each study subject, 75ul of serum was aliquoted into an eppendorf tube to 
instantly measure blood glucose. The remaining serum was then aliquoted into cryogenic 
vials and stored at −70°C until the time of batch analysis. Each study subject had four 
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cryogenic vials with 500ul serum in each to measure 25-hydroxyvitamin D, IL-6, IL-8, 
and IL-10 and a fifth cryogenic vial was labeled extra to be used if needed. All 
measurements were performed in duplicates to ensure reproducibility (reliability) and 
averages of duplicate measures were used in the final analyses (Lachin, 2004). Any extra 
or remaining serum will be discarded three months after publication.  
Measurement of Blood Glucose  
I measured blood glucose levels by glucose oxidase method using YSI 2300 
STAT Blood Glucose Analyzer (Yellow Springs Instruments, Yellow Springs, OH, USA) 
at the Biobehavioral Research Laboratory. Glucose oxidase is an enzyme that breaks 
down glucose in the presence of oxygen into hydrogen peroxide and gluconic acid. 
Hydrogen peroxide is then oxidized as it gets in contact with a platinum electrode, 
producing electrons. The resultant current is then measured and is proportional to glucose 
concentration in the sample. The YSI 2300 STAT Blood Glucose Analyzer can detect 
glucose concentration as high as 900mg/dL (9000mg/L, 50.0mmol/L) with a precision of 
±2.0%. YSI 2300 was calibrated at the start of every day and after every six samples. 
Each glucose reading required 25µl of serum and was measured in duplicate with the 
mean value used for statistical analyses. 
Measurement of 25-hydroxyvitamin D 
Liquid chromatography/tandem mass spectrometry (LC-MS/MS) was used to 
measure serum concentration of 25-hydroxyvitamin D (Eisman, Shepard, & DeLuca, 
1977). LC-MS/MS accurately distinguishes 25-hydroxyvitamin D2 and 25-
hydroxyvitamin D3. Serum 25-hydroxyvitamin D3 reflects endogenous cutaneous 
production, while serum 25-hydroxyvitamin D2 reflects mostly dietary intake and vitamin 
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D supplements (Hollis, 2008). ZRT Laboratory; a for-profit corporation having a 
principal place of business at 8605 SW Creekside Place, Beaverton, OR 97008 (“ZRT”), 
was the site for 25-hydroxyvitamin D measurement. ZRT follows the Clinical Laboratory 
Improvement Amendments (CLIA) instituted by Centers for Medicare and Medicaid 
Services (CMS). ZRT LC-MS/MS assay generates results comparable with DiaSorin 
RIA, which has been used in major studies (Bertone-Johnson et al., 2005; Bischoff-
Ferrari, Dietrich, Orav, & Dawson-Hughes, 2004; Chonchol & Scragg, 2007; Feskanich 
et al., 2004; Giovannucci, Liu, Hollis, & Rimm, 2008), thus providing clinically accurate 
and comparable results for this study. Serum samples to measure 25-hydroxyvitamin D 
were shipped on dry ice from the Biobehavioral Research Laboratory to ZRT using UPS 
2nd Day Air. 
Measurement of Cytokines  
I measured pro-inflammatory cytokines IL-6 and IL-8, and anti-inflammatory 
cytokine IL-10 using R&D Systems ELISA assays (Minneapolis, MN) at the 
Biobehavioral Research Laboratory (table 3.3). All three cytokines were measured in 
duplicates with the mean value used for statistical analyses. Only IL-6 and IL-10 were 
detected in serum of study subjects. The R&D CXCL8/IL-8 ELISA assay did not detect 
any levels of IL-8 in our study sample.  
Table 3.3 Inflammatory cytokines ELISA assays 
  Mean Recovery 
(Range) 
Intra-Assay Precision 
CV% 
Inter-Assay Precision 
CV% 
HS IL-6 
PHS600B 
94.0% 
(87.0-99.0%) 
6.9%, 7.8%, 7.4% 9.6%, 7.2%, 6.5% 
HS IL-8 
S8000C 
98.0%  
(88.0-106.0%) 
5.6%, 5.4%,  6.5% 7.4%, 9.7%, 6.1% 
HS IL-10 
PHS100B 
99.0%  
(88.0-112.0%) 
8.2%, 8.5%, 6.6% 15.6%, 10.2%, 8.1% 
Coefficient of Variation (CV) 
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Measurement of HbA1c 
 HbA1c is the gold standard index of glycemic control. It reflects mean blood 
glucose level over the preceding two to three months (Saudek et al., 2006). Point-of-care 
HbA1c testing (DCA Vantage, Siemens diagnostics, Tarrytown, NY) which is a 6-
minutes test that requires approximately 1µL of whole blood sample (taken from a finger 
prick) was used to quantify HbA1c at the DCC. DCA Vantage meets the criteria of the 
National Glycohemoglobin Standardization Program (NGSP) for clinical accuracy (CV 
<3%) and therefore it provides a relatively accurate and comparable HbA1c values with 
those of the DCCT (Lenters-Westra & Slingerland, 2010; Bode, Irvin, Pierce, Allen, & 
Clark, 2007; K. L. Schwartz, Monsur, Hammad, Bartoces, & Neale, 2009). The DCCT 
used a laboratory-based ion-exchange high-performance liquid chromatography method 
to quantify HbA1c (Rohlfing, Wiedmeyer, Little, England, Tennill, & Goldstein, 2002).  
Medical Record Review 
Electronic medical records were reviewed to collect data on socio-demographic 
covariates (age, sex, ethnicity and insurance status), and disease-related covariates 
(duration of T1DM, average total daily insulin dose, type of insulin regimen, frequency 
of blood glucose monitoring, frequency of clinic visit, and BMI z-score) that have been 
updated during the clinic visit.  
Selection of Covariates 
 By definition, a covariate is a variable related to the dependent variable that 
typically has a minimal relation to the independent variable (MacKinnon; 2008). For the 
purpose of this study, selection of covariates was based on an extensive search of the 
literature on predictors of and factors related to HbA1c in children and adolescents with 
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T1DM. Only covariates with moderate or strong associations with HbA1c were selected 
and were adjusted for in the multivariate analysis model. These covariates include age, 
sex, ethnicity, socio-economic status, duration of T1DM, average total daily insulin dose, 
type of insulin regimen, frequency of blood glucose monitoring, frequency of clinic visit, 
blood glucose level, and BMI z-score (DCCT/EDIC Research Group et al., 2009; 
Helgeson et al., 2010; Paris et al., 2009; Petitti et al., 2009; Rewers et al., 2002; Rohlfing, 
Wiedmeyer, Little, England, Tennill, & Goldstein, 2002). The Centers for Disease 
Control and Prevention (CDC) growth charts were used to calculate age- and sex-specific 
BMI z-scores; which is the “deviation of the value for an individual from the mean value 
of the reference population divided by the standard deviation for the reference 
population”, to facilitate comparisons across age groups (Kuczmarski et al., 2000). Of 
note, insurance was selected as a proxy for socio-economic status because of the absence 
of alternative direct measures of socio-economic status in this study. Furthermore, 
insurance per se has been associated with glycemic control in adult patients with T1DM 
(Chew et al., 2008; Gallegos-Macias et al., 2003; Sosa-Rubi, Galarraga, & Lopez-
Ridaura, 2009).  
Few of the selected covariates were defined as confounders because they are 
related to both HbA1c (dependent variable) and 25-hydroxyvitamin D (independent 
variable). Confounders include age, sex, ethnicity, and BMI z-score as they explain a 
significant percent of variance in 25-hydroxyvitamin D and thus may change the 
relationship between the independent variable and dependent variable (Compher et al., 
2008; Jacques et al., 1997; Macdonald et al., 2008; Yetley, 2008). Season which is a 
significant predictor of 25-hydroxyvitamin D but not of HbA1c was added to the list of 
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covariates and was categorized as spring (March–May), summer (June–August), fall 
(September–November), and winter (December–February). For this study, only winter, 
spring and summer were used since data collection took place from January till June 
2011.  In addition, covariates such as age, sex, ethnicity, BMI z-score, disease duration, 
type of insulin regimen, average total daily insulin dose, and blood glucose level are 
confounders that explain a significant percent of variance in both systemic levels of pro- 
and anti-inflammatory cytokines (hypothesized Mediators) and HbA1c (dependent 
variable) (Al-Isa, Thalib, & Akanji, 2010; Rosa et al., 2008; Schaumberg et al., 2005). 
All confounders were included as covariates in the multivariate analysis model (multiple 
regression analysis). 
Data Management  
All resultant data from 25-hydroxyvitamin D, cytokines, and blood glucose 
measurements were in digital printout forms (primary source documents). Also, data on 
covariates, which was retrieved from medical records, were recorded manually on a 
special study form “chart abstraction tool” (primary source document).  
 All data collected from medical record review and/or generated from the 
aforementioned laboratory assays, were coded and then entered manually into an 
electronic database. Each study participant was assigned a unique subject identifier that 
had no meaning external to this study. Personal identifiers are kept in a separate Excel 
sheet restricted to authorized personnel only. The electronic database is being backed-up 
daily. Backup CDs with data and primary source documents are stored separately in a 
securely locked storage facility and personal storage cabinet. The personal identifiers 
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excel sheet and primary source documents will be destroyed three months after 
publication. The electronic database will be retained for three years.  
Refusal Rate and Final Study Sample 
Patients were recruited between January 7, 2011 and June 17, 2011. A total of 400 
children and adolescents met the inclusion and exclusion criteria and were informed 
about the study. 206 of the 400 children and adolescents were recruited. The majority of 
patients were recruited during winter (40.0%, December to February) and spring (52.0%, 
March to May) and the remaining were recruited early summer (8.0%, June to August). 
Refusal rate was close to 48.5% which may be related to the blood drawing 
procedure required for participation in this study. Based on previously reported literature, 
refusal rate of children and families participating in clinical research have ranged from 
6.7% to 45.8% for studies that did not involve blood collection (Gattuso et al., 2005). It is 
therefore expected that refusal rates may increase for studies involving blood collection, 
which is evident by the relatively high refusal rate reported for this study.  
Another reason may be the fact that diabetes providers were ordering vitamin D 
tests on their patients more frequently at the end of the study (Mid-April through June) 
than at the beginning of the study (January through mid-April). Patients who already had 
their vitamin D test ordered as part of their annual screening did not agree to give 
additional blood sample for the measurement of inflammatory cytokines and therefore 
did not participate in this study. I was able to recruit 153 subjects January through mid-
April but only 53 subjects mid-April through June.       
Nine of the 206 subjects were excluded from the final analyses due to HbA1c 
values greater than 12.0% over the past year, coexistence of another autoimmune 
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condition, or presence of ketoacidosis. HbA1c values greater than 12.0% is an exclusion 
criteria. Six subjects with HbA1c values greater than 12.0% were mistakenly recruited 
due to improper documentation of their HbA1c by clinic staff or failure of PI to verify 
HbA1c values before recruiting subjects. One subject had celiac disease which is an 
exclusion criterion and was mistakenly recruited by the PI due to improper revision of the 
medical record. Two subjects had ketoacidosis two weeks prior to their clinic visit. 
Information about their ketoacidosis was documented after subjects were recruited. The 
final sample included 197 subjects.  
Missing Data Points from Final Sample (n = 197) 
Data for five variables [HbA1c, FBGM, blood glucose level, IL-6, and IL-10] 
were missing completely at random. HbA1c values were missing for two subjects 
because of insurance restrictions to perform the test at CHOP and subjects either failed to 
perform the test outside CHOP or failed to report results to their diabetes provider when 
the test was performed outside CHOP. For 29 patients, the FBGM was not documented 
by the diabetes provider in their medical records. One patient had a glucose level of 
2.6mg/dl which was most likely a measurement error and therefore this data point was 
excluded from the analysis. Four patients already had their vitamin D levels ordered by 
their diabetes provider as part of their annual screening and have agreed to participate in 
the study without giving an additional blood sample for measurement of inflammatory 
cytokines (IL-6, IL-8, and IL-10) and blood glucose level. For two patients IL-10 was not 
measured due to unavailability of additional IL-10 ELISA kit to perform the 
measurement. Table 3.4 summarizes the frequency of missing data. FBGM has the 
highest percent of missing data (14.7%). 
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Table 3.4 Percent of missing values from final sample 
Variable Missing Observations Percent Missing Observations 
HbA1c 2/197 1 
FBGM 29/197 14.7 
Blood Glucose Level 5/197 2.5 
IL-6 4/197 2 
IL-10 6/197 3 
 
Handling of Missing Data 
To accurately examine the hypothesized relationships among key variables as 
proposed in aims one through three, it was crucial to address the loss of statistical power 
imposed by the aforementioned missing data on multivariate analyses. As table 3.5 
indicates, only 160 study subjects have complete data points (i.e. missing value equals to 
zero).  
Table 3.5 Percent of subjects with zero, one, two, or three missing values 
 
Multiple imputation (Stata version 12) was selected for handling missing data 
since data was missing completely at random, the model used to generate the imputed 
values was theoretically correct and matches the models subsequently used for 
multivariate analyses addressing aims one through three (Allison, 2000). Furthermore, it 
has been suggested that multiple imputation introduces appropriate random error into the 
imputation process, thus increasing the probability of attaining unbiased estimates of all 
parameters (Allison, 2000). Multiple imputation uses the distribution of the observed data 
       T o t a l            1 9 7        1 0 0 . 0 0 
                                                 
           3              4          2 . 0 3        1 0 0 . 0 0 
           2              1          0 . 5 1         9 7 . 9 7 
           1             3 2         1 6 . 2 4         9 7 . 4 6 
           0            1 6 0         8 1 . 2 2         8 1 . 2 2 
                                                 
      v a l u e s          F r e q .       P e r c e n t          C u m . 
    # m i s s i n g    
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to impute missing values M times (for this analysis five times), therefore generating M 
complete (imputed) data sets. The imputed data sets are then analyzed individually but 
identically to obtain a set of parameter estimates. Finally, these parameter estimates are 
pooled into a single data set to generate overall parameter estimates, variances, and 
confidence intervals (White et al., 2011).  
To select the best approach to creating multiple imputation data sets; first the 
pattern of missing data was examined and was determined to be arbitrary (i.e. has no 
pattern). Second, I examined the type of variables with missing data; FBGM was treated 
as categorical while HbA1c, IL-6, IL-10, and blood glucose level were treated as 
continuous. Therefore, the Imputation by Chained Equation (ICE) was selected as the 
best approach to handle both arbitrary pattern of missing data and their type. ICE can 
automatically differentiate between categorical and continuous variables and therefore 
uses multinomial logistic regression (mlogit) for unordered categorical variables and 
linear regression (regress) for continuous variables in the imputation process.  
Prior to running Multiple Imputation with ICE, all continuous variables to be 
included in the imputation model were examined for normality with normal probability 
plots, histograms and the Shapiro-Wilk test; which is the standard test for normality in 
small and medium samples. Variables were considered non-normally distributed if both 
the Shapiro-Wilk test was significant at P<0.05 and the histogram showed extreme 
deviation from normality. Three non-normally distributed variables IL-6, IL-10, and 
blood glucose level were log transformed. In addition, non-normally distributed variable 
‘diabetes duration in months’ was categorized into three levels: 1 = 12-23 months, 2 = 
24-47 months, and 3 ≥48 months, to allow for comparability of the results with 
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previously published SEARCH for Diabetes in Youth study (Pettiti et al., 2009). FBGM 
which has values 0 through 4 and greater than 4 time per day was categorized into three 
levels: 1 =0-2 times per day, 2 =3-4 times per day, and 3 ≥4 times per day. Frequency of 
nurse practitioner visit which has values zero through 6 visits over the past year was 
categorized into two levels: 1 =1-3 visits over the past year, and 2 =4-6 visits over the 
past year. This step of treating variables was necessary to ensure that the model used to 
generate the imputed values match with subsequent multivariate models used to examine 
aims one through three. The table below (table 3.6) compares the regression output of 
imputed versus non-imputed model. Since the imputed model is based on a sample size 
of 197, it provides more accurate estimates of the regression coefficients as compared to 
the non-imputed model which is based on a sample size of 160. Furthermore, there are no 
concerning differences in regression coefficients and significance levels between the two 
models, except for insurance status which is only significant in the imputed model (n = 
197). Therefore, the imputed model was used for subsequent multivariate analyses. For 
descriptive statistics, the non-imputed data set was used.  
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Table 3.6 Comparison of regression output of imputed versus non-imputed model for  
HbA1c regressed on 25-hydroxyvitamin D while adjusting for select covariates  
 
       Imputed Model 1            Non-imputed Model 2                            
                                    (F=9.69, P=0.000)               (F=8.53, P=0.000)            
                                                                         (n = 197)                           (n = 160)         
                    
Age at examination, yearsC                 -0.016, 0.610                      -0.007, 0.829 
                                                   
SexCAT                                     0.026, 0.878                       0.137, 0.459 
                
EthnicityCAT                                            0.220, 0.035*                       0.318, 0.007**                           
                   
Insurance status  CAT                                        0.413, 0.024*                        0.311, 0.121     
                             
BMI z-scoreC                   0.028, 0.796                      -0.014, 0.905   
    
Diabetes duration, monthsCAT              0.322, 0.008*                       0.330, 0.011*  
  
Type of Insulin RegimenCAT                       0.261, 0.002**                       0.236, 0.012*  
  
Average Total Daily                                   0.679, 0.013*                       0.698, 0.013*   
Insulin Dose, units/kg/dayC                
 
Frequency of Blood                           -0.588, 0.000**                      -0.553, 0.000**   
Glucose Monitoring 
per DayCAT                          
 
Frequency of CRNP                                 -0.362, 0.028*                    -0.477, 0.008**   
Clinic Visit over the   
past YearCAT                        
 
25-hydroxyvitamin D, nmol/LC           0.007, 0.154                           0.006, 0.317                                
                           
Log-Mean Glucose, mg/dlC                      0.329, 0.018*                    0.282, 0.048*    
 
Log-IL-6, pg/mlC                           0.060, 0.564                   -0.022, 0.844    
 
Log-IL-10, pg/mlC                         0.201, 0.013*                    0.250, 0.004**  
   
*P <0.05, ** P < 0.01 
C, continuous variables; CAT, categorical variables 
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Statistical Analyses 
 Step 1: Descriptive statistics were used to summarize the socio-demographic and 
diabetes-related characteristics of the final sample (n=197) of children and adolescents 
with T1DM (table 4.1). Frequencies and percentages were used to describe categorical 
variables. Means and standard deviations were used to describe continuous variables that 
were normally distributed; while medians, minima, and maxima were used to describe 
continuous variables that were non-normally distributed. Normality of continuous 
variables was assessed using normal probability plots, histograms and the Shapiro-Wilk 
test; which is the standard test for normality in small and medium samples. Variables 
were considered non-normally distributed if the Shapiro-Wilk test was significant at 
P<0.05 and the histogram showed extreme deviation from normality. SPSS version 19 
was used for descriptive statistics. For the remaining analyses, Stata version 12 was used.  
Step 2: Univariate associations between HbA1c (primary dependent variable; 
treated as continuous) and socio-demographic and diabetes-related characteristics were 
tested for statistical significance using general linear modeling (GLM) (table 4.2a). The 
sample was stratified into percentages of individuals with good, intermediate, and poor 
glycemic control by socio-demographic and disease-related characteristics. Mean HbA1c 
was calculated for each stratification.   
Furthermore, the univariate associations between HbA1c and socio-demographic 
and diabetes-related characteristics were re-examined separately for Caucasians and 
African Americans (tables 4.2b and 4.2c). These associations were not examined for 
Hispanics or Others because of the small sample size associated with these categories 
(n=15 and n=8; respectively).  
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Step 3: Similarly, univariate associations between 25-hydroxyvitamin D (primary 
independent variable, treated as continuous) and socio-demographic and select diabetes-
related characteristics were tested for statistical significance using GLM (tables 4.3a and 
4.3b). In table 4.3a, the sample was stratified into percentages of individuals at risk of 
vitamin D deficiency, risk of vitamin D inadequacy, and sufficient in vitamin D--
according to IOM classification of vitamin D status. In table 4.3b, the sample was 
stratified into percentages of individuals with vitamin D deficiency, insufficiency, and 
sufficiency based on recent recommendations of the Endocrine Society. Mean 25-
hydroxyvtamin D was calculated for each stratification.   
Step 4: GLM was also used to examine the univariate associations between 
inflammatory cytokines (IL-6 and IL-10) and socio-demographic and diabetes-related 
characteristics (table 4.4a). For sake of consistency with the multivariate models, the log 
transformed forms of IL-6 and IL-10 were used for univariate analyses. Otherwise, means 
of IL-6 and IL-10 were calculated from non-log transformed values. Furthermore, the 
univariate associations between inflammatory cytokines and socio-demographic and 
disease related characteristics were re-examined separately for Caucasians and African 
Americans (tables 4.4b and 4.4c).  
Step 5: Pearson product-moment coefficient of correlation (r) was used to 
examine the extent to which select continuous variables correlate prior to their 
simultaneous inclusion in subsequent regression analyses. As shown in table 4.5, the 
correlation coefficients ranged from -0.0003 to 0.26 which were considered substantially 
low enough to allow the inclusion of all 8 variables simultaneously in multivariate 
models. 
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Step 6_Aim One: GLM was used to quantify the relationship between 25-
hydroxyvitamin D (independent variable) and HbA1c (dependent variable), while 
controlling for select covariates and excluding IL-6 and IL-10 from the multivariate 
model (tables 4.6 and 4.7). Covariates were included in the multivariate model if: a) they 
were correlated to HbA1c in univariate analyses at P<0.20 or b) they were known a priori 
to correlate to HbA1c.  
Step 7_Aim Two: GLM was used to quantify the relationship between 25-
hydroxyvitamin D (independent variable) and IL-6 (dependent variable), while 
controlling for select covariates and excluding HbA1c from the multivariate model 
(tables 4.8). Covariates were included in the multivariate model if: a) they were 
correlated to IL-6 in univariate analyses at P<0.20 or b) they were known a priori to 
correlate to IL-6.  
Step 8_Aim Two: GLM was used to quantify the relationship between 25-
hydroxyvitamin D (independent variable) and IL-10 (dependent variable), while 
controlling for select covariates and excluding HbA1c from the multivariate model (table 
4.9). Covariates were included in the multivariate model if: a) they were correlated to IL-
10 in univariate analyses at P<0.20 or b) they were known a priori to correlate to IL-10.  
Step 9_Aim Three: GLM was used to quantify the relationship between IL-6 
(independent variable) and HbA1c (dependent variable), while controlling for select 
covariates and excluding 25-hydroxyvitamin D from the multivariate model (table 4.10). 
Covariates were included in the multivariate model if: a) they were correlated to HbA1c 
in univariate analyses at P<0.20 or b) they were known a priori to correlate to HbA1c.  
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Step 10_Aim Three: GLM was used to quantify the relationship between IL-10 
(independent variable) and HbA1c (dependent variable), while controlling for select 
covariates and excluding 25-hydroxyvitamin D from the multivariate model (table 4.11). 
Covariates were included in the multivariate model if: a) they were correlated to HbA1c 
in univariate analyses at P<0.20 or b) they were known a priori to correlate to HbA1c.  
Step 11_Aim Four: Aim four was to determine whether the relationship between 
25-hydroxyvitamin D and HbA1c is mediated by inflammatory cytokines IL-6, IL-8, and 
IL-10. Pro-inflammatory cytokine IL-8 was not detected in this sample. Furthermore, 
based on previous analyses there was no association between 25-hydroxyvitamin D 
(independent variable) and HbA1c (dependent variable). Also, there was no association 
between 25-hydroxyvitamin D and inflammatory cytokines IL-6 or IL-10 (mediators). 
The hypothesis that inflammatory cytokines IL-6, IL-8, and IL-10 mediate the 
relationship between 25-hydroxyvitamin D and HbA1c did not hold true in this study 
sample. Therefore, no further analyses to assess the significance of mediated (indirect) 
effect using bootstrapping were conducted.    
Figure 3.1 This figure is a visual representation of the tested relationships among 25- 
hydroxyvitamin D, HbA1c, and inflammatory cytokines IL-6 and IL-10, adjusted for select 
covariates  
 
 
 
   
 
Independent Variable 
25-hydroxyvitamin D 
IL-6 
Dependent Variable 
HbA1c 
IL-10 
-0.005, 0.175 0.09, 0.418                    
0.004, 0.356 0.21, 0 .008** 
0.008, 0.108 
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Step 12_Aim Five: Aim five was to determine a threshold value for minimum 
mean 25-hydroxyvitamin D level beyond which greater improvements in HbA1c may be 
expected. Based on previous analyses, the relationship between 25-hydroxyvitamin D and 
HbA1c was found to be linear after adjusting for select covariates and therefore, it was 
not possible to determine a threshold value for minimum mean 25-hydroxyvitamin D 
beyond which greater improvements in HbA1c may exist (figure 3.2). 
Figure 3.2 Two way scatter plot depicting the linear relationship between 25-
hydroxyvitamin D and HbA1c 
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Protection of Human Subjects 
 Potential risk or harm for patients participating in this study was not greater than 
minimal. According to CHOP IRB SOP 401, minimal risk is defined as "...the probability 
and magnitude of harm or discomfort anticipated in the research are not greater in and of 
themselves than those ordinarily encountered in daily life or during the performance of 
routine physical or psychological examinations or tests...."  
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Informed Consent and HIPAA Authorization 
 The informed consent and HIPAA authorization were signed once patients and 
their parents agreed to participate in this study. The language of the informed consent 
was clear and comprehensive. It listed the anticipated risks and benefits associated with 
this study and the policy of the institution for public data sharing. Assent was obtained 
from all participating children and adolescents.  
Risk Assessment 
 Risks associated with blood withdrawal procedure were mild to moderate pain at 
the time of blood drawing procedure. Alternately, risks due to breach of confidentiality 
such as public or unauthorized disclosure of personal identifiers were nonexistent.  
Benefits of Study Participation 
 There was no direct benefit to the management of glycemic control for subjects 
taking part in this study. However, study subjects had their vitamin D testing at a CLIA 
certified laboratory free of charge. In addition, study subjects with vitamin D deficiency 
and insufficiency were followed up by the dietitian and were started on vitamin D 
supplements.  
Payment to subjects and families  
 Each study subject received a $5 CVS gift card as a token of appreciation for 
participating in this study. 
Time Line 
The total duration of this study was close to 10 months. Data collection and 
measurement took a total of 6 months. Data management, data analyses and write up 
were 4 months.  
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CHAPTER FOUR: RESULTS 
 The aim of this study was to examine the relationship between 25-hydroxyvitamin 
D and HbA1; and to determine whether inflammatory cytokines IL-6, IL-8, and IL-10 
mediate this relationship in metabolically stable children and adolescents with T1DM. A 
total of 206 subjects were recruited at the DCC at CHOP. Only 197 subjects were 
included in the final analyses.   
Socio-Demographics and Diabetes-Related Characteristics of Final Sample (Table 
4.1) 
The mean age of the study sample was 13±3years. The slight majority of study 
subjects were adolescents (55.3%), males (56.9%), and Caucasian (54.8%). Other 
racial/ethnic groups included African Americans (33.5%), Hispanics (7.6%), and Others 
(4.1%). The majority of study subjects had private insurance (70.0%). 63.5% of study 
subjects were below the 85th percentile for age- and sex- adjusted body weight (healthy 
weight), 23.4% were between the 85th and 95th percentile (overweight), and 13.2% were 
above the 95th percentile (obese).  
All study subjects were recruited after the first year of diagnosis to bypass the 
honeymoon phase. More than half of study subjects had T1DM for ≥48 months (57.9%), 
27.4% had T1DM for 24-47 months, and 14.7% had T1DM for 12-23 months. Mean 
HbA1c of the study sample was 8.6±1.4% with an average total daily insulin dose of 
0.87±0.3units/kg/day. Only 36.0% of study subjects received insulin replacement therapy 
via insulin pump, almost half of study subjects received multiple daily insulin injections 
(Lantus or NPH) while the remaining were taking mixed insulin twice per day (12.2%). 
Data on FBGM was missing for 29 study subjects. Among those who reported their 
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FBGM, approximately 88.0% checked their blood glucose levels ≥3 times per day. 
Furthermore, the slight majority of study subjects (60.9%) followed up with their nurse 
practitioner at least 4-6 times during the past year.  
Mean 25-hyroxyvitamin D for the final cohort was 54.6±17.8nmol/L. Median 
blood glucose level, pro-inflammatory cytokine IL-6 level, and anti-inflammatory 
cytokine IL-10 level were 160mg/dl (range; 44 to 710mg/dl), 0.7pg/ml (range; 0.1 to 
9.4pg/ml), and 4.5pg/ml (range, 0.6 to 152.9pg/ml), respectively. As previously reported 
in chapter three, systemic levels of pro-inflammatory cytokine IL-8 were not detected in 
this study sample.     
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Table 4.1 Socio-demographics and diabetes-related characteristics of final sample (n = 197) 
 
Age at examination, years (Mean ± SD)                                      13 ± 3 
 7-12 (n, percentage)                88 (44.7)  
 13-18 (n, percentage)             109 (55.3) 
 
Sex (n, percentage) 
 Male                           112 (56.9) 
 Female                 85 (43.1) 
 
Ethnicity (n, percentage) 
 Caucasian             108 (54.8)  
 African-American               66 (33.5) 
 Hispanic                             15 (7.6) 
 Other                   8 (4.1) 
 
Insurance (n, percentage) 
 Private                           138 (70.0)  
 Medicaid                            59 (30.0) 
 
BMI z-score (Mean ± SD)                                0.76 ± 0.78 
 
BMI Percentile (n, percentage) 
 Healthy weight (< 85th)             125 (63.5) 
Overweight (≥ 85th & < 95th)              46 (23.4) 
Obese (≥ 95th)                26 (13.2) 
 
Diabetes Duration, months [Median (min, max)]                 54 (12, 179) 
 12-23                  29 (14.7) 
 24-47                   54 (27.4) 
 ≥ 48                114 (57.9) 
 
Type of Insulin Regimen (n, percentage) 
 Insulin Pump                 71 (36.0)  
 Multiple Daily Injections, Lantus              59 (29.9) 
 Multiple Daily Injections, NPH               43 (21.8) 
 Mixed Insulin Twice per Day               24 (12.2) 
 
Average Total Daily Insulin Dose, units/kg/day (Mean ± SD)                0.87 ± 0.3 
 
Frequency of Blood Glucose Monitoring per Day (n, percentage) 
 0-2                              19 (9.6)  
 3-4                  71 (36.0) 
 > 4                                          78 (39.6) 
 Missing data                 29 (14.7)  
  
Frequency of CRNP Clinic Visit over the past Year (n, percentage) 
 1-3                             77 (39.1)  
 4-6                                       120 (60.9) 
 
HbA1c, % (Mean ± SD)                    8.6 ± 1.4 
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25-hydroxyvitamin D, nmol/L (Mean ± SD)                 54.6 ± 17.8 
 
Mean Glucose, mg/dl [Median (min, max)]              160 (44, 710) 
 
IL-6, pg/ml [Median (min, max)]                               0.7 (0.1, 9.4) 
 
IL-10, pg/ml [Median (min, max)]                               4.5 (0.6, 152.9) 
 
IL-8, pg/ml                   Not Detected 
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Stratification of Final Sample into Good, Intermediate, and Poor Glycemic Control 
by Socio-Demographic and Disease-Related Characteristics (n = 197) (Table 4.2a) 
The ADA has set target values for optimal HbA1c levels by age group. HbA1c 
levels less than 8.0% for ages 6-12 years and HbA1c levels less than 7.5% for ages 13-18 
years have been classified as good control. HbA1c levels equal to or more than 9.5% 
have been classified as poor glycemic control for all age groups. For any given age 
group, HbA1c levels between good and poor glycemic control have been classified as 
intermediate glycemic control. Using the ADA classification for glycemic control, 27.9% 
of the final sample had good glycemic control, 48.2% had intermediate control, and 
22.8% had poor control. Glycemic control was not statistically different for males versus 
females (P=0.355) or for study subjects across different BMI percentiles (P=0.396). 
Study subjects 13-18 years were more likely to have poor glycemic control as compared 
to the younger age group (P=0.084). African Americans and Hispanics were significantly 
more likely to have poor glycemic control as compared to Caucasians (P<0.000). 
Similarly, poor glycemic control was significantly more evident in subjects who had 
Medicaid versus subjects with private insurance (P<0.000); in subjects with ≥48 months 
disease duration as compared to subjects with ≤48 months disease duration (P<0.000); in 
subjects receiving insulin two times per day as compared to subjects receiving multiple 
daily injections per day (NPH and Lantus), or on insulin pump (P<0.000). Furthermore, 
HbA1c was significantly higher in study subjects reporting FBGM 0-2 times per day as 
compared to study subjects monitoring their blood glucose levels 3-4 times per day or ≥ 4 
times per day (P<0.000). Also, study subjects who followed with their nurse practitioner 
4-6 times during the past year were significantly more likely to have lower levels of 
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HbA1c as compared to study subjects who followed with their nurse practitioner 1-3 
times during the past year (P=0.005). Although not statistically significant, there was a 
trend of decreasing levels of HbA1c as 25-hydroxyvitamin D levels improved from levels 
at risk of deficiency towards sufficient states (P=0.286). The bivariate relationship 
between HbA1c and 25-hydroxyvitamin D almost reached statistical significance 
(P=0.057).  
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Table 4.2a Stratification of Sample into Good, Intermediate, and Poor Glycemic Control by 
Socio-Demographic and Disease-Related Characteristics (n = 197)          
                      
 HbA1c (%)Ϯ C                                
                     N         Mean        Good         Intermediate       Poor     P-value 
                                                                            HbA1c         (%)                 (%)                 (%) 
                            
All Sample         197    8.6±1.4       27.9               48.2              22.8       
 
Age at examination, years C         0.136 
  
Age at examination, years CAT         0.084 
 7-12           88     8.4±1.2       37.5               43.2              19.3        
 13-18         109     8.7±1.5       20.2               52.3              25.7        
 
Sex CAT           0.355 
 Male       112      8.6±1.4      26.8                46.4              25.0        
 Female                                  85      8.5±1.3      29.4                50.6              20.0        
                 
Ethnicity CAT                    <0.000** 
 Caucasian      108       8.1±1.1      37.0                54.6                 8.3        
 African-American       66       9.2±1.5      15.2                39.4               42.4        
 Hispanic         15       9.4±1.2        6.7                53.3               40.0        
 Others           8       8.2±1.7       50.0               25.0               25.0        
   
Insurance status CAT                              <0.000** 
 Private       138       8.3±1.3      34.1                48.6              15.9        
 Medicaid        59       9.2±1.3      13.6                47.5               39.0        
 
BMI z-score C          0.187 
 
BMI Percentile CAT                    0.396  
 Healthy weight       125       8.5±1.4      29.6                47.2               21.6        
 (< 85th)  
 Overweight          46       8.7±1.5      26.1                47.8               26.1        
 (≥ 85th & < 95th) 
 Obese (≥ 95th)            26       8.7±1.0      23.1                53.8               23.1        
 
Diabetes duration, months CAT                 <0.000** 
 12-23            29     8.0±1.2      44.8               37.9               13.8       
 24-47            54     8.3±1.2      33.3               46.3               18.5        
 ≥ 48         114     8.8±1.4      21.1               51.8               27.2        
 
Type of Insulin Regimen CAT                 <0.000** 
 Insulin Pump           71      8.1±1.1     38.0               52.1                 9.9        
 MDI, Lantus                     59      8.4±1.2     27.1               57.6               13.6       
 MDI, NPH           43      8.7±1.4     25.6               46.5               25.6        
 Mixed Insulin 2x/day          24    10.1±1.3       4.2               16.7               79.2        
 
Average Total Daily Insulin Dose, units/kg/day C              <0.000** 
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Frequency of Blood Glucose Monitoring per Day CAT                   <0.000** 
 0-2            19    10.0±1.3     31.6               63.2                 5.3      
3-4            71      8.9±1.4     16.9               52.1                29.6        
> 4            78      8.0±1.0     43.6               48.7                  7.7        
 
Frequency of CRNP Clinic Visit over the past Year CAT                       0.005** 
 1-3            77       8.9±1.4     22.1               42.9               32.5       
 4-6            120       8.3±1.3     31.7               51.7               16.7        
 
25-hydroxyvitamin D, nmol/L C                  0.057 
 
25-hydroxyvitamin D, nmol/L CAT                 0.286 
At risk of deficiency£           17      9.0±1.6      11.1             55.6                27.8        
 Risk of Inadequacy£             62      8.5±1.3       29.0            45.2                25.8        
 Sufficient-1£            96      8.6±1.3      28.9             47.4                22.7        
 Sufficient-2£                          20      8.2±1.4      35.0             55.0                10.0        
         
Log Mean Glucose, mg/dl C                   0.004** 
 
Log IL-6, pg/ml C                   0.253 
                          
Log IL-10, pg/ml C                   0.016*                        
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess univariate associations between HbA1c (treated as continuous) 
and select variables. P-value <0.05 is considered significant. 
 
ϮAmerican Diabetes Association target values for HbA1c stratified by age: HbA1c < 8.0% at age 6 to 12 
years and HbA1c < 7.5% at age 13-18 years is classified as good control. HbA1c ≥ 9.5 is classified as poor 
control for all age groups. HbA1c values between good and poor control are classified as intermediate 
control.   
 
£ The study sample was stratified into four quartiles according to the IOM classification for vitamin D 
status: at risk of deficiency (25-hydroxyvitamin D < 30 nmol/L), risk of inadequacy (25-hydroxyvitamin D 
30 to < 50nmol/L), sufficient-1 (25-hydroxyvitamin D 50 to < 75nmol/L), and sufficient-2 (25-
hydroxyvitamin D 75nmol/L to ≤ 125nmol/L). Patients classified sufficient in vitamin D were divided into 
two groups since they displayed a different relationship between 25-hydroxyvitamin D and HbA1c. 
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Stratification of Caucasians and African Americans into Good, Intermediate, and 
Poor Glycemic Control by Socio-Demographic and Disease-Related Characteristics 
(Tables 4.2b and 4.2c) 
The observed trend of decreasing levels of HbA1c with increasing levels of 25-
hydroxyvitamin D for the final study sample compelled further examination of this 
relationship by race/ethnicity. Table 4.2b re-examined univariate associations between 
HbA1c and socio-demographic and disease-related characteristics in Caucasians (n=108). 
Similar to the study sample (n=197), poor glycemic control was significantly more 
evident in subjects who had Medicaid versus subjects with private insurance (P=0.009), 
and in subjects reporting FBGM of 0-2 times per day as compared to subjects reporting 
FBGM of 3-4 times per day or ≥4 times per day (P<0.000). Interestingly, although not 
evident in the study sample (n=197), BMI z-score almost reached statistical significant as 
a predictor of glycemic control in Caucasians (P=0.053). Conversely, diabetes duration, 
type of insulin regimen, frequency of nurse practitioner clinic visit over the past year, and 
25-hydroxyvitamin D did not retain statistical significance.  
Table 4.2c re-examined univariate associatiosn between HbA1c and socio-
demographic and disease-related characteristics in African Americans (n=66). As 
compared to the final study sample (n=197), diabetes duration (P=0.002), type of insulin 
regimen (P=0.002), and FBGM (P=0.013) were significant determinants of poor 
glycemic control in African Americans; while BMI z-score, insurance status, frequency 
of nurse practitioner clinic visit in the past year, and 25-hydroxyvitamin D were not 
statistically significant.  
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As compared to African Americans, Caucasians were more likely to have private 
insurance (84.25% versus 46.96%), receive insulin replacement therapy via insulin pump 
(45.37% versus 19.69%), report monitoring their blood glucose levels ≥4 times per day 
(59.34% versus 22.8%), and follow up with nurse practitioner 4-6 times during the past 
year (66.6% versus 54.5%). These observed differences between Caucasians and African 
Americans suggest that insurance status, type of insulin regimen, FBGM, and frequency 
of clinic visit may be important determinants of glycemic control in this study sample. 
However, in previous studies, it has been reported that the relationship between insurance 
status and glycemic control loses statistical significance when adjusting for family 
structure, level of parental education, and household income in multivariate analyses 
(Gallegos-Macias et al., 2003; Levine et al., 2001; Paris et al., 2009; Petitti et al., 2009). 
In this study, I did not collect information on family structure, level of parental education, 
or household income. Therefore, it is unclear whether those observed differences 
associated with insurance status are related to socio-economic status, family structure or 
level of parental education in this sample. In addition, the observed difference related to 
type of insulin regimen and frequency of clinic visit may be related to diabetes provider 
bias, environmental barriers, or parental choices. It can also be argued that the value of 
HbA1c have influenced the choice of insulin regimen. Furthermore, data on FBGM is 
based on self-report and therefore the observed differences related to FBGM between 
Caucasians and African Americans may be inaccurate. It can also be argued that the 
observed differences in HbA1c between Caucasians and African Americans may be 
inherently physiologic. Recent studies have shown that African Americans have higher 
HbA1c levels than Caucasians across the full spectrum of glycemia (Zlemer et al., 2010).       
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Table 4.2b Stratification of Caucasians into good, intermediate, and poor glycemic control 
by socio-demographic and disease-related characteristics (n = 108)    
                            
          HbA1c (%) ϮC                                
          N         Mean          Good         Intermediate       Poor      P-value 
                                                                            HbA1c         (%)                 (%)                 (%) 
 
Caucasians        108     8.1±1.1       37.0                54.6               8.3        
 
Age at examination, years C         0.235 
  
Age at examination, years CAT         0.140 
 7-12           48     7.9±1.0       47.9               45.8               6.3        
 13-18           60     8.3±1.1       28.3               61.7              10.0        
 
Sex CAT           0.092 
 Male         69      8.3±1.1      33.3                56.5              10.1        
 Female                                  39      7.9±1.1      43.6                51.3                5.1        
 
Insurance status  CAT                                 0.009** 
 Private         91       8.0±1.1      42.9                50.5                 6.6        
 Medicaid        17       8.7±0.7        5.9                76.5               17.6        
 
BMI z-score C                       0.053 
 
BMI Percentile CAT                     0.181  
 Healthy weight        72       8.1±1.1      40.3                51.4                8.3        
 (< 85th)  
 Overweight          22       8.0±1.0      36.4                59.1                4.5       
 (≥ 85th & < 95th) 
 Obese (≥ 95th)           14       8.6±1.0      21.4                 64.3              14.3        
 
Diabetes duration, months CAT                    0.090 
 12-23            16     7.9±1.3      62.5               25.0               12.5       
 24-47            30     7.9±1.0      43.3               46.7               10.0        
 ≥ 48           62     8.3±1.0      27.4               66.3                  6.5        
 
Type of Insulin Regimen CAT                  0.226 
 Insulin Pump           49     8.0±1.1     38.8               55.1                 6.1        
 MDI, Lantus                     39     8.1±1.0     35.9               59.0                 5.1      
 MDI, NPH           18     8.3±1.3      38.9              44.4               16.7       
 Mixed Insulin 2x/day            2     9.1±0.7                           50.0               50.0       
 
Average Total Daily Insulin Dose, units/kg/day C               0.004** 
 
Frequency of Blood Glucose Monitoring per Day CAT                  <0.000** 
 0-2              5      9.3±1.4                           60.0                40.0      
3-4            32      8.4±1.2     25.0               62.5                12.5        
> 4            54      7.8±0.8     48.1               50.0                  1.9        
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Frequency of CRNP Clinic Visit over the past Year CAT                       0.440 
 1-3            36       8.9±1.4     36.1               55.6                 8.3       
 4-6              72       8.3±1.3     37.5               54.2                 8.3        
 
25-hydroxyvitamin D, nmol/L C                  0.966 
 
25-hydroxyvitamin D, nmol/L CAT                 0.523 
At risk of deficiency£             2      7.2±1.3      50.0             50.0                 -            
 Risk of Inadequacy£             31      8.0±1.1      41.9             51.6                 6.5        
 Sufficient-1£            62      8.3±1.0      33.9             54.8               11.3       
 Sufficient-2£                          13      7.9±1.2      38.5             61.5                 -     
         
Log Mean Glucose, mg/dl C                   0.035* 
 
Log IL-6, pg/ml C                   0.595 
                          
Log IL-10, pg/ml C                    0.695                        
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess univariate associations between HbA1c (treated as continuous) 
and select variables. P-value <0.05 is considered significant. 
 
ϮAmerican Diabetes Association target values for HbA1c stratified by age: HbA1c < 8.0% at age 6 to 12 
years and HbA1c < 7.5% at age 13-18 years is classified as good control. HbA1c ≥ 9.5 is classified as poor 
control for all age groups. HbA1c values between good and poor control are classified as intermediate 
control.   
 
£ The study sample was stratified into four quartiles according to the IOM classification for vitamin D 
status: at risk of deficiency (25-hydroxyvitamin D < 30 nmol/L), risk of inadequacy (25-hydroxyvitamin D 
30 to < 50nmol/L), sufficient-1 (25-hydroxyvitamin D 50 to < 75nmol/L), and sufficient-2 (25-
hydroxyvitamin D 75nmol/L to ≤ 125nmol/L). Patients classified sufficient in vitamin D were divided into 
two groups since they displayed a different relationship between 25-hydroxyvitamin D and HbA1c. 
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Table 4.2c Stratification of African Americans into good, intermediate, and poor glycemic 
control by socio-demographic and disease-related characteristics (n = 66)            
                    
             HbA1c (%) Ϯ C                                
                     N          Mean        Good          Intermediate        Poor     P-value 
                                                                             HbA1c         (%)                 (%)                 (%) 
 
African Americans         66       9.2±1.5      15.2                39.4               42.4        
 
Age at examination, years C         0.543 
  
Age at examination, years CAT         0.785 
 7-12           29     9.0±1.3       20.7               37.9              41.4        
 13-18           37     9.2±1.7       10.8               40.5              43.2        
 
Sex CAT           0.771 
 Male         29       9.3±1.7      17.2                27.6              48.3        
 Female                                  37      9.1±1.3      13.5                48.6              37.8        
 
Insurance status  CAT                                  0.357 
 Private         31       9.0±1.5      12.9                45.2               35.5        
 Medicaid        35       9.3±1.5      17.1                34.3               48.6        
 
BMI z-score C                       0.673 
 
BMI Percentile CAT                     0.979  
 Healthy weight        40       9.1±1.4      12.5                42.5              40.0        
 (< 85th)  
 Overweight          16       9.4±1.9      18.8                31.3              50.0       
 (≥ 85th & < 95th) 
 Obese (≥ 95th)           10       8.9±1.1      20.0                 40.0              40.0        
 
Diabetes duration, months CAT                    0.002** 
 12-23            12    8.3±0.9      16.7                58.3               16.7       
 24-47            16    8.7±1.6      25.0                37.5                31.3        
 ≥ 48           38    9.6±1.4      10.5                34.2                55.3        
 
Type of Insulin Regimen CAT                  0.002** 
 Insulin Pump           13     8.6±1.3     23.1               46.2              30.8        
 MDI, Lantus                     14     8.7±1.3     14.3               50.0              28.6      
 MDI, NPH           21     8.9±1.4     19.0               47.6              28.6       
 Mixed Insulin 2x/day          18   10.1±1.5       5.6               16.7              77.8       
 
Average Total Daily Insulin Dose, units/kg/day C                0.031* 
 
Frequency of Blood Glucose Monitoring per Day CAT                    0.013* 
 0-2            10    10.1±1.2                           20.0                70.0 
3-4            34      9.2±1.6       11.8             41.2                44.1                 
> 4            13      8.5±1.3     38.5               38.5                  23.1        
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Frequency of CRNP Clinic Visit over the past Year CAT                       0.194 
 1-3            30       9.5±1.5     10.0               30.0               53.3       
 4-6              36       8.9±1.5     19.4               47.2               33.3        
 
25-hydroxyvitamin D, nmol/L C                  0.578 
 
25-hydroxyvitamin D, nmol/L CAT                 0.365 
At risk of deficiency£           14      9.2±1.6        7.1             57.1               28.6           
 Risk of Inadequacy£             25      8.9±1.5      20.0             32.0               48.0        
 Sufficient-1£            25      9.4±1.4      16.0             36.0               44.0       
 Sufficient-2£                            2      9.5±0.9                          50.0               50.0     
         
Log Mean Glucose, mg/dl C                   0.094 
 
Log IL-6, pg/ml C                   0.655 
                          
Log IL-10, pg/ml C                    0.006**                        
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess univariate associations between HbA1c (treated as continuous) 
and select variables. P-value <0.05 is considered significant. 
 
ϮAmerican Diabetes Association target values for HbA1c stratified by age: HbA1c < 8.0% at age 6 to 12 
years and HbA1c < 7.5% at age 13-18 years is classified as good control. HbA1c ≥ 9.5 is classified as poor 
control for all age groups. HbA1c values between good and poor control are classified as intermediate 
control.   
 
£ The study sample was stratified into four quartiles according to the IOM classification for vitamin D 
status: at risk of deficiency (25-hydroxyvitamin D < 30 nmol/L), risk of inadequacy (25-hydroxyvitamin D 
30 to < 50nmol/L), sufficient-1 (25-hydroxyvitamin D 50 to < 75nmol/L), and sufficient-2 (25-
hydroxyvitamin D 75nmol/L to ≤ 125nmol/L). Patients classified sufficient in vitamin D were divided into 
two groups since they displayed a different relationship between 25-hydroxyvitamin D and HbA1c. 
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Stratification of Final Sample by Vitamin D Status (Tables 4.3a and 4.3b) 
 In November of 2010, the Institute of Medicine (IOM) released an update on the 
recommended daily allowance for calcium and vitamin D intake for the general healthy 
U.S. population. In this report, the IOM also redefined vitamin D status based on 
evidence from studies on vitamin D and calcium (IOM, 2010). According to the IOM, 
vitamin D status is classified into four categories: at risk of vitamin D deficiency (25-
hydroxyvitamin D less than 30 nmol/L), at risk of vitamin D inadequacy (25-
hydroxyvitamin D equal or more than 30nmol/L and less than 50nmol/L), sufficient in 
vitamin D (25-hydroxyvitamin D equal or more than 50 and equal or less than 
125nmol/L), and possibly harmful vitamin D (25-hydroxyvitamin D more than 
125nmol/L). Vitamin D levels in this study cohort ranged from 16nmol/L to 117nmol/L, 
and therefore none of the study subjects had possible harmful vitamin D levels. More 
than half of study subjects had sufficient vitamin D levels, 31.5% were at risk of vitamin 
D inadequacy, and only 9.1% were at risk of vitamin D deficiency (table 4.3a). The 
percent of study subjects at risk for vitamin D deficiency is comparable to what has been 
previously reported for the U.S. pediatric population (9% vitamin D deficiency defined in 
the NHANES study as 25-hydroxyvitamin D less than 37nmol/L) (Kumar, Muntner, 
Kaskel, Hailpern, & Melamed, 2009). 
 Vitamin D levels were significantly lower in study subjects 13-18 years as 
compared to the younger age group (P=0.001), in females as compared to males 
(P=0.034), and in African Americans as compared to Caucasians (P=0.000). Surprisingly, 
mean vitamin D levels were similar for subjects across different BMI levels (P=0.486), 
although risk of vitamin D deficiency was more evident in subjects with obesity (3.8%) 
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as compared to subjects who were overweight (10.9%) or healthy weight (9.6%). Also, 
the risk of vitamin D deficiency was higher during Winter (10.3%) as compared to Spring 
(8.7%) or Summer (6.3%) although the difference was not statistically significant 
(P=0.091). These results were expected since the majority of study subjects were 
recruited during Winter and Spring (91.87%).  
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Table 4.3a Stratification of final sample into sufficient, inadequate and deficient vitamin D 
status according to Institute of Medicine recommendations (n=197) 
   25-hydroxyvitamin D (25-(OH)D; nmol/L) Ϯ C                            
                            N           Mean           Risk of            Risk of         Sufficient  P-value                                                         
       25-(OH)D   Deficiency      Inadequacy         
                                                                                                   (%)                  (%)                (%) 
                                                                                                                                                                                                     
All Sample       197  54.6±17.8        9.1               31.5               59.4        
 
Age at examination, years C         0.001** 
 
Age at examination, years CAT         0.001** 
 7-12        88      59.3±17.3         3.4               26.1              70.5        
 13-18      109      50.8±17.4       13.8               35.8               50.5        
 
Sex CAT            0.034* 
 Male     112      56.9±16.7        4.5                31.3               64.3        
 Female                                85      51.5±18.8      15.3                31.8               52.9        
                 
Ethnicity CAT                       0.195 
 Caucasian    108       59.3±16.3        1.9                28.7               69.4        
 African-American     66       45.0±15.6      21.2                37.9               40.9        
 Hispanic       15       55.9±21.4      13.3                33.3               53.3       
 Others         8       68.7±15.0          -                  12.5               87.5        
   
Insurance status  CAT                                  0.022* 
 Private                 138       56.5±18.0        9.4                26.8               63.8        
 Medicaid      59       50.1±16.8        8.5                42.4               49.2        
 
BMI z-score C            0.486 
 
BMI Percentile CAT                      0.696  
 Healthy weight      125      54.8±18.9       9.6                 34.4               56.0        
 (< 85th)  
 Overweight         46      54.9±16.6      10.9                21.7                67.4        
 (≥ 85th & < 95th) 
 Obese (≥ 95th)          26      53.0±15.1         3.8               34.6                61.5       
 
Type of Insulin Regimen CAT                     0.001 
 Insulin Pump       71      58.8±19.2        7.0               25.4               67.6       
 MDI, Lantus                 59      54.9±16.1        5.1               37.3               57.6       
 MDI, NPH       43      52.8±16.3        9.3               34.9               55.8        
 Mixed Insulin 2x/day      24      44.6±17.0      25.0               29.2               45.8        
 
Average Total Daily Insulin Dose, units/kg/day C                  0.002** 
 
Season CAT          0.091 
 Winter                 78       53.5±17.5      10.3               34.6               55.1        
 Spring         103       53.7±16.9       8.7               33.0              58.3        
85 
 
 Summer          16       65.5±22.3       6.3                 6.3               87.5        
 
Log Mean Glucose, mg/dl C                    0.195 
 
Log IL-6, pg/ml C                    0.031* 
                          
Log IL-10, pg/ml C                     0.730 
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess univariate associations between 25-hydroxyvitamin D (treated 
as continuous) and select variables. P-value <0.05 is considered significant. 
 
Ϯ Study sample was stratified into three quartiles according to the IOM classification for vitamin D status: 
at risk of vitamin D deficiency (25-hydroxyvitamin D < 30 nmol/L), risk of vitamin D inadequacy (25-
hydroxyvitamin D 30 to < 50nmol/L), and sufficient in vitamin D (25-hydroxyvitamin D 50 to ≤ 
125nmol/L).  
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 In table 4.3b, study subjects were stratified into sufficient (25-hydroxyvitamin D 
equal or more than 75nmol/L and less than 250nmol/L), insufficient (25-hydroxyvitamin 
D equal or more than 50nmol/L and less than 75nmol/L), and deficient (25-
hydroxyvitamin less than 50nmol/L) vitamin D levels as defined by the Endocrine 
Society and vitamin D experts (Holick et al., 2011). According to this classification, 
almost half of the sample was considered vitamin D insufficient, while 40.6% of study 
subjects were vitamin D deficient, and 10.2% were vitamin D sufficient. The percent of 
study subjects with vitamin D deficiency (25-hydroxyvitamin less than 50nmol/L) in this 
study sample (40.6%) is comparable to what have been previously reported for healthy 
normal weight adolescents 11-18 years (55.2%) and obese children and adolescents 7-18 
years (42.0%) in the U.S. (Smotkin-Tangorra et al., 2007; Gordon et al., 2004). 
Furthermore, the percent of study subjects with vitamin D insufficiency (25-
hydroxyvitamin D equal or more than 50nmol/L and less than 75nmol/L) in this study 
sample (49.2%) is similar to what has been reported by the NHANES study 2001-2006 
for healthy children 6-11 years (52.0%) (Mansbach et al., 2009).  
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Table 4.3b Stratification of final sample into sufficient, insufficient and deficient vitamin D 
status according to the Endocrine Society recommendations (n=197)  
  25-hydroxyvitamin D (25-(OH)D; nmol/L) Ϯ C                    
   N             Mean       Deficiency  Insufficiency   Sufficiency   P-value    
                25-(OH)D        (%)               (%)              (%) 
           
All Sample     197  54.6±17.8       40.6             49.2             10.2        
 
Age at examination, years C         0.001** 
 
Age at examination, years CAT         0.001** 
 7-12        88      59.3±17.3       29.5               55.7              14.8        
 13-18      109      50.8±17.4       49.5               44.0                6.4        
 
Sex CAT           0.034* 
 Male     112      56.9±16.7      35.7                53.6               10.7        
 Female                                85      51.5±18.8      47.1                43.5                 9.4        
                 
Ethnicity CAT                        0.195 
 Caucasian    108       59.3±16.3      30.6                57.4               12.0        
 African-American     66       45.0±15.6      59.1                37.9                 3.0        
 Hispanic       15       55.9±21.4      46.7                33.3                20.0       
 Others         8       68.7±15.0       12.5               62.5                25.0        
   
Insurance status CAT                               0.022* 
 Private                 138       56.5±18.0      36.2                51.4               12.3        
 Medicaid      59       50.1±16.8      50.8                44.1                 5.1        
 
BMI z-score C          0.486 
 
BMI Percentile CAT                    0.696  
 Healthy weight      125      54.8±18.9      44.0                43.2               12.8        
 (< 85th)  
 Overweight         46      54.9±16.6      32.6                58.7                  8.7        
 (≥ 85th & < 95th) 
 Obese (≥ 95th)          26      53.0±15.1       38.5               61.5                   -        
 
Type of Insulin Regimen CAT                     0.001** 
 Insulin Pump       71      58.8±19.2       32.4              53.5               14.1       
 MDI, Lantus                 59      54.9±16.1       42.4              47.5               10.2       
 MDI, NPH       43      52.8±16.3       44.2              48.8                 7.0        
 Mixed Insulin 2x/day      24      44.6±17.0       54.2               41.7                4.2        
 
Average Total Daily Insulin Dose, units/kg/day C                  0.002** 
 
Season CAT          0.091 
 Winter                 78        53.5±17.5     44.9               46.2                 9.0        
 Spring        103       53.7±16.9     41.7               49.5                 8.7        
 Summer         16       65.5±22.3     12.5               62.5                25.0        
88 
 
 
Log Mean Glucose, mg/dl C                   0.195 
 
Log IL-6, pg/ml C                   0.031* 
                          
Log IL-10, pg/ml C                    0.730 
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess univariate associations between 25-hydroxyvitamin D (treated 
as continuous) and select variables. P-value <0.05 is considered significant. 
 
Ϯ Study sample was stratified into three quartiles according to the Endocrine Society classification for 
vitamin D status: vitamin D deficiency (25-hydroxyvitamin D < 50 nmol/L), vitamin D insufficiency (25-
hydroxyvitamin D 50 to < 75nmol/L), and vitamin D sufficiency (25-hydroxyvitamin D 75 to ≤ 
250nmol/L).  
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Stratification of Final Sample by Inflammatory Cytokines (Tables 4.4a, 4.4b, and 
4.4c) 
 Systemic levels of pro-inflammatory cytokine IL-8 were not detected in this study 
sample. Mean pro-inflammatory cytokine IL-6 was 1.1±1.2pg/ml for the final study 
sample (n=197). Pro-inflammatory cytokine IL-6 levels were significantly correlated with 
age (P=0.038), BMI z-score (P=0.006), anti-inflammatory cytokine IL-10 (P=0.037), and 
25-hydroxyvitamin D (P=0.032). Serum IL-6 levels were significantly higher in females 
as compared to males (P=0.001) and in subjects at risk of vitamin D deficiency as 
compared to subjects at risk of vitamin D inadequacy or sufficiency (P=0.045). Serum 
IL-6 levels were not significantly different by race/ethnicity (P=0.244). 
 Since the primary focus of this study relates to glycemic control which 
significantly varied by race/ethnicity, univariate associations between serum IL-6 and 
socio-demographic and disease-related covariates were re-examined separately for 
Caucasians and African Americans (tables 4.4b and 4.4c). In both Caucasians and 
African Americans, serum IL-6 levels remained significantly higher in females as 
compared to males (P=0.007 and P=0.064; respectively). Associations between serum IL-
6 and age, anti-inflammatory cytokine IL-10, and 25-hydroxyvitamin D were no longer 
significant in either subgroup. Interestingly, serum IL-6 retained statistical significance 
with BMI z-score (P=0.036) in African Americans but not in Caucasians (P=0.239).  
 Mean anti-inflammatory cytokine IL-10 was 10.5±20.3pg/ml for the final study 
sample (n=197). Serum IL-10 levels were significantly associated with pro-inflammatory 
cytokine IL-6 (P=0.037), and HbA1c (P=0.015). Serum IL-10 levels showed a trend 
towards significance for subjects with diabetes duration ≥ 48 months as compared to 
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subjects with diabetes duration ≤48 months (P=0.063). In Caucasians, serum IL-10 was 
no longer associated with HbA1c (P=0.695) or IL-6 (P=0.125). In African Americans, 
serum IL-10 retained statistical significance with HbA1c (P=0.006) but not with serum 
IL-6 (P=0.200). 
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Table 4.4a Univariate associations between inflammatory cytokines and socio-demographic 
and disease-related characteristics in the final sample (n=197)  
         IL-6 (pg/ml) C                          IL-10 (pg/ml) C                            
                            N           Mean           P-value                 Mean            P-value                                                                                           
                                                                             
All Sample       197   1.1±1.2                               10.5±20.3         
 
Age at examination, years C                                      0.038*      0.206 
 
Age at examination, years CAT              0.288      0.451    
 7-12        88      1.1±1.4                                 9.5±20.0         
 13-18      109      1.1±1.1                               11.3±20.6         
 
Sex CAT               0.001**      0.917 
 Male     112       0.9±1.1                               9.8±18.5         
 Female                                85      1.3±1.4                               11.4±22.6                         
 
Ethnicity CAT             0.244       0.637             
 Caucasian    108       1.0±1.0                               10.2±22.1         
 African-American     66       1.3±1.7                               11.9±20.1              
 Hispanic       15       0.7±0.4                                 6.8±9.0         
 Others         8       0.6±0.3                                 9.5±7.3         
   
BMI z-score C           0.006**       0.839              
 
BMI Percentile CAT                      0.068       0.541         
 Healthy weight     125      1.0±1.2                               11.5±23.5         
 (< 85th)  
 Overweight         46      1.2±1.5                                 9.6±14.6         
 (≥ 85th & < 95th) 
 Obese (≥ 95th)          26      1.2±1.0                                 7.3±10.8         
 
Diabetes duration, months CAT             0.098                              0.063            
 12-23            29    0.9±1.0                                 7.5±9.5         
 24-47            54    1.0±1.0                                 6.9±14.4         
 ≥ 48         114    1.2±1.4                               13.0±24.2         
 
Average Total Daily Insulin Dose, units/kg/day C     0.385                              0.982 
 
Log Mean Glucose, mg/dl C       0.464                                         0.695   
                
Log IL-6, pg/ml C              0.037* 
                                         
Log IL-10, pg/ml C         0.037 *           
 
25-hydroxyvitamin D, nmol/L C                               0.032*                                        0.730 
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25-hydroxyvitamin D, nmol/L CAT  0.045*               0.781 
At risk of deficiency£    18    1.3±1.2                               27.7±44.4         
 Risk of Inadequacy£      62    1.1±1.1                                 6.2±11.0         
 Sufficient-1£     97    1.2±1.4                               10.0±15.9         
 Sufficient-2£       20    0.6±0.4                               12.1±24.8            
 
HbA1c, % C                                                                 0.253                                                0.015* 
 
HbA1c, % CAT                                                            0.172                                                 0.103 
 GoodϮ            55    0.9±0.97                                   9.3±21.5         
 IntermediateϮ           95    1.1±1.0                                   10.0±20.8         
 PoorϮ            45    1.3±1.8                                   13.3±18.5         
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess univariate associations between Log-IL-6 (treated as 
continuous) and select variables. P-value <0.05 is considered significant. 
 
General linear modeling was used to assess univariate associations between Log-IL-10 (treated as 
continuous) and select variables. P-value <0.05 is considered significant. 
 
£ The study sample was stratified into four quartiles according to the IOM classification for vitamin D 
status: at risk of deficiency (25-hydroxyvitamin D < 30 nmol/L), risk of inadequacy (25-hydroxyvitamin D 
30 to < 50nmol/L), sufficient-1 (25-hydroxyvitamin D 50 to < 75nmol/L), and sufficient-2 (25-
hydroxyvitamin D 75nmol/L to ≤ 125nmol/L). Patients classified sufficient in vitamin D were divided into 
two groups since they displayed a different relationship between 25-hydroxyvitamin D and HbA1c. 
 
ϮAmerican Diabetes Association target values for HbA1c stratified by age: HbA1c < 8.0% at age 6 to 12 
years and HbA1c < 7.5% at age 13-18 years is classified as good control. HbA1c ≥ 9.5 is classified as poor 
control for all age groups. HbA1c values between good and poor control are classified as intermediate 
control.   
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Table 4.4b Univariate associations between inflammatory cytokines and socio-demographic 
and disease-related characteristics in Caucasians (n=108)  
        IL-6 (pg/ml) C                          IL-10 (pg/ml) C                           
                            N           Mean           P-value                 Mean            P-value                                                                                           
                                                                             
Caucasian       108   1.0±1.0                               10.2±22.1         
 
Age at examination, years C                                      0.060      0.671 
 
Age at examination, years CAT             0.244      0.767    
 7-12        48      0.9±0.9                               11.2±25.8         
 13-18        60      1.1±1.1                                 9.4±18.8         
 
Sex CAT               0.007**      0.550 
 Male       69       0.9±1.0                                9.6±20.5         
 Female                                39      1.2±0.9                               11.2±25.1                         
 
BMI z-score C           0.239       0.966              
 
BMI Percentile CAT                      0.485       0.266         
 Healthy weight       72      1.0±0.9                               12.4±26.7         
 (< 85th)  
 Overweight         22      1.2±1.4                                 6.4±5.6         
 (≥ 85th & < 95th) 
 Obese (≥ 95th)          14      0.9±0.5                                 4.7±2.7         
 
Diabetes duration, months CAT            0.223                              0.334            
 12-23            16   0.6±0.4                                  8.4±10.7         
 24-47            30    1.1±0.9                                 5.4±4.4         
 ≥ 48           62    1.1±1.1                               13.0±28.4         
 
Average Total Daily Insulin Dose, units/kg/day C     0.579                              0.465 
 
Log Mean Glucose, mg/dl C       0.266                                         0.272   
                
Log IL-6, pg/ml C              0.125  
                                         
Log IL-10, pg/ml C         0.125            
 
25-hydroxyvitamin D, nmol/L C                               0.249                                          0.061 
 
25-hydroxyvitamin D, nmol/L CAT     0.332                 0.064 
At risk of deficiency£           2   0.7±0.5                               77.1±107.1         
 Risk of Inadequacy£              31   1.1±1.2                                 4.0±3.0         
 Sufficient-1£          62   1.1±1.0                               10.0±18.2         
 Sufficient-2£            13   0.5±0.3                               17.2±30.7            
 
HbA1c, % C                                                                0.596                                          0.695 
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HbA1c, % CAT                                                                 0.361                                         0.712 
 GoodϮ            40    1.0±1.0                                   10.9±25.5         
 IntermediateϮ           59    1.0±1.1                                     9.5±22.0         
 PoorϮ              9    0.9±0.5                                   11.1±10.8         
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess univariate associations between Log-IL-6 (treated as 
continuous) and select variables. P-value <0.05 is considered significant. 
 
General linear modeling was used to assess univariate associations between Log-IL-10 (treated as 
continuous) and select variables. P-value <0.05 is considered significant. 
 
£ The study sample was stratified into four quartiles according to the IOM classification for vitamin D 
status: at risk of deficiency (25-hydroxyvitamin D < 30 nmol/L), risk of inadequacy (25-hydroxyvitamin D 
30 to < 50nmol/L), sufficient-1 (25-hydroxyvitamin D 50 to < 75nmol/L), and sufficient-2 (25-
hydroxyvitamin D 75nmol/L to ≤ 125nmol/L). Patients classified sufficient in vitamin D were divided into 
two groups since they displayed a different relationship between 25-hydroxyvitamin D and HbA1c. 
 
ϮAmerican Diabetes Association target values for HbA1c stratified by age: HbA1c < 8.0% at age 6 to 12 
years and HbA1c < 7.5% at age 13-18 years is classified as good control. HbA1c ≥ 9.5 is classified as poor 
control for all age groups. HbA1c values between good and poor control are classified as intermediate 
control.   
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Table 4.4c Univariate associations between inflammatory cytokines and socio-demographic 
and disease-related characteristics in African Americans (n=66)  
        IL-6 (pg/ml) C                          IL-10 (pg/ml) C                           
                            N           Mean           P-value                 Mean            P-value                                                                                           
                                                                             
African Americans       66       1.3±1.7                                11.9±20.1              
 
Age at examination, years C                                      0.160      0.132 
 
Age at examination, years CAT              0.486      0.279    
 7-12        29      1.4±2.1                                 7.5±9.2         
 13-18        37      1.3±1.3                               15.5±25.3         
 
Sex CAT               0.064      0.933 
 Male        29      1.1±1.5                               10.2±16.6         
 Female                                37      1.6±1.8                               13.3±22.6                         
 
BMI z-score C           0.036*       0.884              
 
BMI Percentile CAT                      0.116       0.520         
 Healthy weight       40      1.2±1.7                               10.9±20.5         
 (< 85th)  
 Overweight         16      1.4±1.8                                14.4±22.0         
 (≥ 85th & < 95th) 
 Obese (≥ 95th)          10      1.7±1.4                                 11.7±16.7         
 
Diabetes duration, months CAT            0.579                              0.139            
 12-23            12   1.2±1.3                                  6.3±8.5         
 24-47            16   1.1±1.4                                10.9±25.5         
 ≥ 48           38   1.5±1.9                                14.2±20.3         
 
Average Total Daily Insulin Dose, units/kg/day C     0.546                              0.300 
 
Log Mean Glucose, mg/dl C       0.910                                         0.685   
                
Log IL-6, pg/ml C              0.200  
                                         
Log IL-10, pg/ml C         0.200           
 
25-hydroxyvitamin D, nmol/L C                              0.438                                         0.091 
 
25-hydroxyvitamin D, nmol/L CAT    0.349     0.153 
At risk of deficiency£         14   1.5±1.3                               23.9±34.0         
 Risk of Inadequacy£              25   1.1±1.2                                 8.7±16.7         
 Sufficient-1£          25   1.5±2.2                                 9.6±10.8         
 Sufficient-2£              2   1.1±1.2                                 1.7±0.82            
 
HbA1c, % C                                                                 0.655                                         0.006** 
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HbA1c, % CAT                                                                  0.588                                      0.085 
 GoodϮ            10    1.0±1.0                                     4.4±4.0         
 IntermediateϮ           26    1.3±1.1                                   12.0±21.5         
 PoorϮ            28    1.6±2.3                                   15.2±22.5         
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess univariate associations between Log-IL-6 (treated as 
continuous) and select variables. P-value <0.05 is considered significant. 
 
General linear modeling was used to assess univariate associations between Log-IL-10 (treated as 
continuous) and select variables. P-value <0.05 is considered significant. 
 
£ The study sample was stratified into four quartiles according to the IOM classification for vitamin D 
status: at risk of deficiency (25-hydroxyvitamin D < 30 nmol/L), risk of inadequacy (25-hydroxyvitamin D 
30 to < 50nmol/L), sufficient-1 (25-hydroxyvitamin D 50 to < 75nmol/L), and sufficient-2 (25-
hydroxyvitamin D 75nmol/L to ≤ 125nmol/L). Patients classified sufficient in vitamin D were divided into 
two groups since they displayed a different relationship between 25-hydroxyvitamin D and HbA1c. 
 
ϮAmerican Diabetes Association target values for HbA1c stratified by age: HbA1c < 8.0% at age 6 to 12 
years and HbA1c < 7.5% at age 13-18 years is classified as good control. HbA1c ≥ 9.5 is classified as poor 
control for all age groups. HbA1c values between good and poor control are classified as intermediate 
control.   
 
 
 
 
 
Table 4.5 Bivariate correlations between continuous variables using Pearson product-
moment coefficient (r) 
        
HbA1c  1       
Age  
(years) 
r = 0.11 
P = 0.14 
n = 195 
1      
BMI z-score  r = 0.10 
P = 0.17 
n = 195 
r = 0.15 
P = 0.027 
n = 197 
1     
Insulin Dose  
(units/kg/day) 
r = 0.26 
P = 0.002 
n = 195 
r = 0.24 
P = 0.0007 
n = 197 
r = 0.04 
P = 0.57 
n = 197 
1    
25-hydroxyvitamin D  
(nmol/L)  
r = -0.15 
P = 0.037 
n = 195 
r = -0.24 
P = 0.0008 
n = 197 
r = -0.05 
P = 0.48 
n = 197 
r = -0.22 
P = 0.002 
n = 197 
1   
Log Glucose level  r = 0.20 
P = 0.005 
n = 190 
r = -0.08 
P = 0.25 
n = 192 
r = 0.002 
P = 0.97 
n = 192 
r = 0.11 
P = 0.13 
n = 192 
r = -0.09 
P = 0.20 
n = 192 
1  
Log IL-6  r = 0.06 
P = 0.37 
n = 191 
r = 0.14 
P = 0.054 
n = 193 
r = 0.19 
P = 0.007 
n = 193 
r = 0.05 
P = 0.46 
n = 193 
r = -0.14 
P = 0.053 
n = 193 
r = -0.06 
P = 0.38 
n = 192 
1 
Log IL-10  r = 0.18 
P = 0.012 
n = 189 
r = 0.09 
P = 0.19 
n = 191 
r = -0.01 
P = 0.85 
n = 191 
r = -0.001 
P = 0.99 
n = 191 
r = 0.02 
P = 0.79 
n = 191 
r = -0.02 
P = 0.8 
n = 190 
r = 0.15 
P = 0.034 
n = 191 
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Aim One (Tables 4.6a, 4.6b and 4.6c)  
The primary aim of this study was to quantify the relationship between 25-
hydroxyvitamin D and HbA1c excluding inflammatory cytokines (IL-6, IL-8, and IL-10). 
It was hypothesized that 25-hydroxyvitamin D is inversely related to HbA1c (table 4.6a). 
General linear modeling (GLM) was used to examine this relationship. Assumptions 
required for inferences from GLM analyses were met. The histogram of estimated 
residuals was closer to a bell-shape and the normal probability plots (P-P plot and Q-Q 
plot) of estimated residuals approximated a straight line suggesting no significant 
departures from normality. Also the scatter plot of residuals versus fitted values showed 
constant variance of residuals across the range of fitted values. Statistical significance 
was set at P< 0.05. 
In the unadjusted model; 25-hydroxyvitamin D was inversely correlated to 
HbA1c, and almost reached statistical significance (β=-0.01; P=0.055). In model 2; after 
adjusting for socio-demographic covariates, 25-hydroxyvitamin D remained inversely 
correlated to HbA1c but was not statistically significant (β=-0.005; P=0.377). Also, in 
model 3, after adjusting for socio-demographic and disease-related covariates, the 
relationship between 25-hydroxyvitamin D and HbA1c was not significant (β=0.008; 
P=0.108).  
Based on univariate analyses, both HbA1c and 25-hydroxyvitamin D were 
significantly different by race/ethnicity (tables 4.2b and 4.2c). Furthermore, a previous 
study examining the relationship between 25-hydroxyvitamin D and HbA1c in obese 
children and adolescent across three different races, showed an inverse and significant 
association in Caucasians, a trend towards significance in Hispanics, and a non-
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significant association in African Americans (Alemzadeh et al., 2008). For this study 
sample, it may be plausible that the significant relationship between 25-hydroxyvitamin 
D and HbA1c observed in the unadjusted model (β=-0.01; P=0.055) is modified by 
race/ethnicity. Therefore, the relationship between 25-hydroxyvitamin D and HbA1c was 
re-examined in Caucasians and African Americans separately (tables 4.6b and 4.6c; 
Figure 4.6). Similar to the final study sample, the adjusted relationship between 25-
hydroxyvitamin D and HbA1c was not significant for both Caucasians and African 
Americans. Figure 4.6 showed no significant difference in the slope of 25-
hydroxyvitamin D by race (β=-0.003; P=0.775).  
In the multivariate model for final study sample (n = 197; table 4.6a), HbA1c was 
significantly associated with ethnicity (β=0.24; P=0.023), insurance status (β =0.40; 
P=0.031), diabetes duration (β =0.38; P=0.001), type of insulin regimen (β=0.28; 
P=0.001), average total daily insulin dose (β=0.68; P=0.014), FBGM (β=-0.58; P=0.000), 
frequency of nurse practitioner clinic visit over the past year (β=-0.34; P=0.042), and 
blood glucose level (β=0.30; P=0.028). Furthermore, predictors of glycemic control as 
measured by HbA1c were different for Caucasians and African Americans (tables 4.6b 
and table 4.6c). In adjusted model for Caucasians, HbA1c was significantly associated 
with insurance status (β=0.55; P=0.047), BMI z-score (β=0.26; P=0.042), average total 
daily insulin dose (β=0.76; P=0.014), and FBGM (β=-0.65; P<0.000). Conversely, in 
adjusted model for African Americans, HbA1c was significantly associated with diabetes 
duration (β=0.58; P=0.010), type of insulin regimen (β=0.38; P=0.013), FBGM (β=-0.53; 
P=0.055), and frequency of nurse practitioner clinic visit over the past year (β=-0.77; 
P=0.030).  
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Table 4.6a HbA1c regressed on 25-hydroxyvitamin D in the final sample (n = 197) 
 
            Model 1             Model 2                  Model 3                      
                                   (F=3.68, P=0.055)    (F=5.10, P=0.000)    (F=9.71, P=0.000)     
                                              Coefficient, P           Coefficient, P           Coefficient, P               
 
Age at examination, years C     0.05, 0.129             -0.02, 0.632 
                                                   
Sex CAT                                                                   0.33, 0.078              -0.01, 0.957 
                
Ethnicity CAT                                                                   0.38, 0.001**           0.24, 0.023*           
                  
Insurance status CAT                                                             0.70, 0.001**     0.40, 0.031*     
                             
BMI z-score C                      0.08, 0.490    0.02, 0.831  
    
Season CAT                                                             -0.09, 0.571             -0.15, 0.281 
 
Diabetes duration, months CAT                                                                          0.38, 0.001**            
 
Type of Insulin Regimen CAT                                                                       0.28, 0.001**              
 
Average Total Daily                                                                      0.68, 0.014*                  
Insulin Dose, units/kg/day C               
 
Frequency of Blood                                                                    -0.58, 0.000**             
Glucose Monitoring 
per Day CAT                          
 
Frequency of CRNP                                                                   -0.34, 0.042*                 
Clinic Visit over the   
past Year CAT                        
 
25-hydroxyvitamin D, nmol/LC      -0.01, 0.055*             -0.005, 0.377          0.008, 0.108                    
                           
Log Mean Glucose, mg/dl C                                                                             0.30, 0.028*               
             
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
 
 
 
 
 
 
 
 
100 
 
Table 4.6b HbA1c regressed on 25-hydroxyvitamin D in Caucasians (n = 108) 
 
            Model 1             Model 2                  Model 3                      
                                   (F=0.00, P=0.966)    (F=2.87, P=0.009)    (F=4.13, P=0.000)     
                                              Coefficient, P           Coefficient, P           Coefficient, P               
 
Age at examination, years C     0.04, 0.264     -0.01, 0.818 
                                                   
Sex CAT                                                                   0.40, 0.056              0.22, 0.263 
                                 
Insurance status CAT                                                             0.60, 0.035*   0.55, 0.047*     
                             
BMI z-score C                      0.26, 0.056   0.26, 0.042*  
    
Season CAT                                                             -0.24, 0.188      -0.25, 0.147 
 
Diabetes duration, months CAT                                                                        0.11, 0.443        
 
Type of Insulin Regimen CAT                                                                        -0.09, 0.500        
  
Average Total Daily                                                                     0.76, 0.014*                  
Insulin Dose, units/kg/day C              
 
Frequency of Blood                                                                  -0.65, 0.000**             
Glucose Monitoring 
per Day CAT                          
 
Frequency of CRNP                                                      -0.13, 0.494                                                         
Clinic Visit over the   
past Year CAT                        
 
25-hydroxyvitamin D, nmol/LC     -0.0002, 0.966            0.03, 0.682           0.009, 0.109                    
                           
Log Mean Glucose, mg/dl C                                                                           0.27, 0.090              
             
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
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Table 4.6c HbA1c regressed on 25-hydroxyvitamin D in African Americans (n = 66) 
 
            Model 1             Model 2                  Model 3                      
                                   (F=0.31, P=0.576)    (F=0.47, P=0.828)    (F=3.33, P=0.000)     
                                              Coefficient, P           Coefficient, P           Coefficient, P               
 
Age at examination, years C     0.08, 0.290    -0.05, 0.474 
                                                   
Sex CAT                                                                   0.09, 0.818           -0.31, 0.363     
                                 
Insurance status  CAT                                                            0.33, 0.393   0.36, 0.263       
                             
BMI z-score C                     -0.12, 0.612 -0.23, 0.259    
   
Season CAT                                                              0.25, 0.412 -0.21, 0.464 
 
Diabetes duration, months CAT                                                                       0.58, 0.010*                                                   
 
Type of Insulin Regimen CAT                                           0.38, 0.013*                                        
 
Average Total Daily                                                                    0.97, 0.105   
Insulin Dose, units/kg/day C               
 
Frequency of Blood                                                                  -0.53, 0.055*             
Glucose Monitoring 
per Day CAT                          
 
Frequency of CRNP                                          -0.77, 0.030                         
Clinic Visit over the   
past Year CAT                        
 
25-hydroxyvitamin D, nmol/LC     0.007, 0.576            0.01, 0.411            0.012, 0.300                    
                           
Log Mean Glucose, mg/dl C                                                                          0.45, 0.093              
             
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
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Figure 4.6 Examining the relationship between 25-hydroxyvitamin D and HbA1c by Race 
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Although the relationship between 25-hydroxyvitamin D and HbA1c was not 
significant based on previous analyses, the following sections re-examine this 
relationship across different vitamin D levels. The study sample was stratified into four 
quartiles according to the IOM classification for vitamin D status: at risk of deficiency 
(25-hydroxyvitamin D less than 30 nmol/L), risk of inadequacy (25-hydroxyvitamin D 
equal or more than 30nmol/L and less than 50nmol/L), sufficient-1 (25-hydroxyvitamin 
D equal or more than 50 and less than 75nmol/L), and sufficient-2 (25-hydroxyvitamin D 
equal or more than 75nmol/L and less or equal to 125nmol/L). Patients classified 
sufficient in vitamin D were divided into two groups since the relationship between 25-
hydroxyvitamin D and HbA1c changed at 25-hydroxyvitamin D level of 75nmol/L. 
These findings may be interesting given the definition of vitamin D sufficiency (25-
hydroxyvitamin D equal ore more than 75 and equal or less than 250nmol/L) by the 
Endocrine Society and vitamin D experts. However, experimental research is needed to 
confirm these results.    
Table 4.7a shows the best model examining the relationship between 25-
hydroxyvitamin D and HbA1c in individuals at risk of vitamin D deficiency (25-
hydroxyvitamin D less than 30nmol/L). Only 18 study subjects had 25-hydroxyvitamin D 
levels less than 30nmol/L. After close examination of the racial/ethnic distribution; two 
out 18 were Caucasian, two out of 18 were Hispanic, and the remaining majority were 
African American (14 out of 18). Furthermore, from figure 4.7a which is a scatter plot 
that graphically displays the relationship between 25-hydroxyvitamin D and HbA1c, the 
majority of study subjects had HbA1c levels higher than 8.0% i.e. had either intermediate 
or poor glycemic control. In this subgroup, the relationship between 25-hydroxyvitamin 
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D and HbA1c was significant (P=0.035) suggesting that African Americans are more 
likely to have poor glycemic control and low levels of 25-hydroxyvitamin D 
concurrently. However, the strength and directionality of this relationship (β=0.17) 
should be interpreted with caution since the sample size is small (n=18) and therefore 
lacks the statistical power to detect meaningful associations.   
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Table 4.7a HbA1c regressed on 25-hydroxyvitamin D in individuals at risk of vitamin D 
deficiency (25-hydroxyvitamin D less than 30nmol/L) (n =18) 
 
Best fit Model    
                  (F=4.81, P=0.000)     
                                                          Coefficient, P               
                                
Insurance status  CAT                                               1.18, 0.038*          
                             
Diabetes duration, months CAT                               1.02, 0.020*                                                   
 
Type of Insulin Regimen CAT                                 0.45, 0.056                                        
 
Average Total Daily                                              2.00, 0.028*                                                        
Insulin Dose, units/kg/day C              
 
25-hydroxyvitamin D, nmol/LC                      0.17, 0.035*                    
                           
Log Mean Glucose, mg/dl C                                  1.10, 0.030*                           
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
Figure 4.7a Scatter plot examining the relationship between 25-hydroxyvitamin D and 
HbA1c in individuals at risk of vitamin D deficiency (25-hydroxyvitamin D less than 
30nmol/L) 
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Table 4.7b shows the best model examining the relationship between 25-
hydroxyvitamin D and HbA1c in individuals at risk of vitamin D inadequacy (25-
hydroxyvitamin D equal or more than 30nmol/L and less than 50nmol/L). A total of 62 
study subjects were at risk of vitamin D inadequacy. In this subgroup, 25-hydroxyvitamin 
D was not associated with HbA1c (β=-0.008, P=0.772). However, after examining the 
relationship between 25-hydroxyvitamin D and HbA1c by race the relationship was 
found to be significant for Caucasians (n=31; β=-0.07; P=0.023) but remained not 
significant for African Americans (n=25; β=0.06; P=0.276) (tables 4.7b1 and 4.7b2). 
Although there is no statistical power at such small sample size to make a definitive 
conclusion about observed relationships; however, if those relationships do exist it may 
be reasonable to conclude that Caucasians and African Americans may have different 
physiologic mechanisms that regulate the relationship between 25-hydroxyvitamin D and 
HbA1c.  
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Table 4.7b HbA1c regressed on 25-hydroxyvitamin D in individuals at risk of vitamin D 
inadequacy (25-hydroxyvitamin D equal or more than 30nmol/L and less than 50nmol/L) (n 
=62) 
 
Best fit Model    
                  (F=5.22, P=0.000)     
                                                          Coefficient, P               
                                
Ethnicity CAT                                                  0.74, 0.001*        
 
Average Total Daily                                               1.13, 0.018*                                                        
Insulin Dose, units/kg/day C               
 
Frequency of Blood                                               -0.54, 0.025*             
Glucose Monitoring 
per Day CAT            
 
25-hydroxyvitamin D, nmol/LC                        -0.008, 0.772                    
                           
Log Mean Glucose, mg/dl C                                      0.49, 0.063                           
 
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
Figure 4.7b Scatter plot examining the relationship between 25-hydroxyvitamin D and 
HbA1c in individuals at risk of vitamin D inadequacy (25-hydroxyvitamin D equal or more 
than 30nmol/L and less than 50nmol/L) 
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Table 4.7b1 HbA1c regressed on 25-hydroxyvitamin D in individuals at risk of vitamin D 
inadequacy (25-hydroxyvitamin D equal or more than 30nmol/L and less than 50nmol/L) in 
Caucasians (n =31) 
 
Best fit Model    
                  (F=6.18, P=0.000)     
                                                          Coefficient, P               
                                
Average Total Daily                                               1.38, 0.011*                                                        
Insulin Dose, units/kg/day C               
 
25-hydroxyvitamin D, nmol/LC                      -0.07, 0.023*                       
                                       
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
Figure 4.7b1 Scatter plot examining the relationship between 25-hydroxyvitamin D and 
HbA1c in individuals at risk of vitamin D inadequacy (25-hydroxyvitamin D equal or more 
than 30nmol/L and less than 50nmol/L) in Caucasians 
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Table 4.7b2 HbA1c regressed on 25-hydroxyvitamin D in individuals at risk of vitamin D 
inadequacy (25-hydroxyvitamin D equal or more than 30nmol/L and less than 50nmol/L) in 
African Americans (n =25) 
 
Best fit Model    
                  (F=2.18, P=0.113)     
                                                          Coefficient, P               
                                
25-hydroxyvitamin D, nmol/LC                        0.06, 0.276                        
 
Log Mean Glucose, mg/dl C                              0.92, 0.050*                                    
               
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
 
Figure 4.7b2 Scatter plot examining the relationship between 25-hydroxyvitamin D and 
HbA1c in individuals at risk of vitamin D inadequacy (25-hydroxyvitamin D equal or more 
than 30nmol/L and less than 50nmol/L) in African Americans 
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Table 4.7c reports the best fit model examining the relationship between 25-
hydroxyvitamin D and HbA1c in individuals who are vitamin D sufficient-1 (25-
hydroxyvitamin D equal or more than 50nmol/L and less than 75nmol/L). A total of 97 
study subjects were vitamin D sufficient. In this subgroup 25-hydroxyvitamin D was 
inversely associated with HbA1c (β=-0.04, P=0.014). When looking at this relationship 
by ethnicity, 25-hydroxyvitamin D remained statistically significant for African 
Americans (n=25; β=-0.08; P=0.044) but lost significance for Caucasians (n=62; β=-
0.0009; P=0.961) (tables 4.7c1 and 4.7c2). Similar to prior analyses, there is no statistical 
power at such small sample size to make a definitive conclusion about observed 
relationships. However, it may be hypothesized that African Americans require higher 
levels of vitamin D as compared to Caucasians to observe an effect on glycemic control. 
Interventions studies are needed to test this hypothesis. 
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Table 4.7c HbA1c regressed on 25-hydroxyvitamin D in individuals who are vitamin D 
sufficient-1 (25-hydroxyvitamin D equal to or more than 50nmol/L and less than 75nmol/L) 
(n =97) 
 
Best fit Model    
                  (F=19.53, P=0.000)     
                                                         Coefficient, P               
                                
Diabetes duration, months CAT                                0.31, 0.037*                                                   
 
Type of Insulin Regimen CAT                                 0.43, 0.000**                                        
  
Frequency of Blood                                              -0.73, 0.000**             
Glucose Monitoring 
per Day CAT            
 
25-hydroxyvitamin D, nmol/LC                        -0.04, 0.014*                      
                                  
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
Figure 4.7c Scatter plot examining the relationship between 25-hydroxyvitamin D and 
HbA1c in individuals who are vitamin D sufficient-1 (25-hydroxyvitamin D equal to or 
more than 50nmol/L and less than 75nmol/L) 
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Table 4.7c1 HbA1c regressed on 25-hydroxyvitamin D in individuals who are vitamin D 
sufficient-1 (25-hydroxyvitamin D equal to or more than 50nmol/L and less than 75nmol/L) 
in Caucasians (n =62) 
 
Best fit Model    
                  (F=8.32, P=0.000)     
                                                         Coefficient, P               
                                
Type of Insulin Regimen CAT                                 0.34, 0.022*                                        
 
Frequency of Blood                                              -0.82, 0.000**             
Glucose Monitoring 
per Day CAT            
 
25-hydroxyvitamin D, nmol/LC                     -0.0009, 0.961*                      
                                   
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
 
Figure 4.7c1 Scatter plot examining the relationship between 25-hydroxyvitamin D and 
HbA1c in individuals who are vitamin D sufficient-1 (25-hydroxyvitamin D equal to or 
more than 50nmol/L and less than 75nmol/L) in Caucasians 
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Table 4.7c2 HbA1c regressed on 25-hydroxyvitamin D in individuals who are vitamin D 
sufficient-1 (25-hydroxyvitamin D equal to or more than 50nmol/L and less than 75nmol/L) 
in African Americans (n=25) 
 
Best fit Model    
                  (F=6.37, P=0.000)     
                                                         Coefficient, P               
                                
Diabetes duration, months CAT                                0.71, 0.023*                                                   
 
Type of Insulin Regimen CAT                                  0.53, 0.003**                                        
 
25-hydroxyvitamin D, nmol/LC                       -0.08, 0.044*                       
                                  
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
Figure 4.7c2 Scatter plot examining the relationship between 25-hydroxyvitamin D and 
HbA1c in individuals who are vitamin D sufficient-1 (25-hydroxyvitamin D equal to or 
more than 50nmol/L and less than 75nmol/L) in African Americans 
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Table 4.7d shows the best model examining the relationship between 25-
hydroxyvitamin D and HbA1c in individuals who are vitamin D sufficient-2 (25-
hydroxyvitamin D greater than 75nmol/L). A total of 20 study subjects had 25-
hydroxyvitamin D levels greater than 75nmol/L. 13 were Caucasians, 2 were African 
Americans, 3 were Hispanic, and 2 were Others. In this subgroup 25-hydroxyvitamin D 
was not significantly associated with HbA1c (β =-0.02, P=0.424) although the β 
coefficient was negative. Intervention studies are needed to confirm these results.  
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Table 4.7d HbA1c regressed on 25-hydroxyvitamin D in individuals who are vitamin D 
sufficient-2 (25-hydroxyvitamin D greater than 75nmol/L) (n =20) 
 
Best fit Model    
                  (F=2.73, P=0.028)     
                                                         Coefficient, P               
                                
Type of Insulin Regimen CAT                                 0.66, 0.028*                                        
 
Frequency of CRNP                          -1.87, 0.035*                         
Clinic Visit over the   
past Year CAT           
  
25-hydroxyvitamin D, nmol/LC                     -0.02, 0.424                        
 
Log Mean Glucose, mg/dl C                            1.28, 0.036*                                  
            
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between HbA1c (treated as continuous) and 25-
hydroxyvitamin D (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
 
Figure 4.7d Scatter plot examining the relationship between 25-hydroxyvitamin D and 
HbA1c in individuals who are vitamin D sufficient-2 (25-hydroxyvitamin D greater than 
75nmol/L)  
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Aim Two (Table 4.8)  
The secondary aim of this study was to quantify the relationship between 25-
hydroxyvitamin D and IL-6 while excluding HbA1c and other inflammatory markers (IL-
10). It was hypothesized that 25-hydroxyvitamin D is inversely correlated to IL-6 (table 
4.8). GLM was used to examine this relationship. Assumptions required for inferences 
from GLM analyses were met. The histogram of estimated residuals was closer to a bell-
shape and the normal probability plots (P-P plot and Q-Q plot) of estimated residuals 
approximated a straight line suggesting no significant departures from normality. Also 
the scatter plot of residuals versus fitted values showed constant variance of residuals 
across the range of fitted values. Statistical significance was set at P< 0.05. 
In the unadjusted model; 25-hydroxyvitamin D was inversely correlated to IL-6 
(β=-0.007; P=0.030). In model 2; after adjusting for socio-demographic covariates, 25-
hydroxyvitamin D remained inversely correlated to IL-6 but was no longer statistically 
significant (β=-0.005; P=0.179). In model 3, the relationship between 25-hydroxyvitamin 
D and IL-6 was not significant after adjusting for socio-demographic and disease-related 
covariates (β=-0.005; P=0.175).  
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Table 4.8 Log IL-6 regressed on 25-hydroxyvitamin D in the final sample (n = 197) 
 
            Model 1             Model 2                  Model 3                      
                                   (F=4.73, P=0.030)    (F=3.97, P=0.000)    (F=3.51, P=0.000)     
                                              Coefficient, P           Coefficient, P           Coefficient, P               
 
Age at examination, years C     0.02, 0.311      0.01, 0.666 
                                                   
Sex CAT                                                                   -0.34, 0.003**        -0.36, 0.002**                   
                
Ethnicity CAT                                                                   -0.10, 0.185            -0.11, 0.153           
                  
Insurance status  CAT                                                            -0.002, 0.988    0.03; 0.815      
                             
BMI z-score C                       0.16, 0.030*    0.14, 0.053*  
    
Season CAT                                                              -0.14, 0.140       -0.17, 0.076  
 
Diabetes duration, months CAT                                                                         0.11, 0.164 
 
25-hydroxyvitamin D, nmol/LC     -0.007, 0.030            -0.005, 0.179          -0.005, 0.175                    
                           
Log Mean Glucose, mg/dl C                                                                           -0.11, 0.232               
             
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between 25-hydroxyvitamin D (treated as 
continuous) and IL-6 (treated as continuous) while adjusting for select covariates. P-value <0.05 is 
considered significant. 
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Aim Two (Table 4.9)  
The secondary aim of this study was to quantify the relationship between 25-
hydroxyvitamin D and IL-10 while excluding HbA1c and other inflammatory markers 
(IL-6). It was hypothesized that 25-hydroxyvitamin D is directly correlated to IL-10 
(table 4.9). GLM was use to examine this relationship. Assumptions required for 
inferences from GLM analyses were met. The histogram of estimated residuals was 
closer to a bell-shape and the normal probability plots (P-P plot and Q-Q plot) of 
estimated residuals approximated a straight line suggesting no significant departures from 
normality. Also the scatter plot of residuals versus fitted values showed constant variance 
of residuals across the range of fitted values. Statistical significance was set at P< 0.05. 
In the unadjusted model; 25-hydroxyvitamin D was inversely correlated to IL-10, 
although the relationship was not significant (β=-0.002; P=0.729). In model 2; after 
adjusting for socio-demographic covariates, the relationship between 25-hydroxyvitamin 
D remained not significant (β=0.004; P=0.426). In model 3, the relationship between 25-
hydroxyvitamin D and IL-10 was also not significant after adjusting for socio-
demographic and disease-related covariates (β=0.004; P=0.356).  
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Table 4.9 Log IL-10 regressed on 25-hydroxyvitamin D in the final sample (n = 197) 
 
            Model 1             Model 2                  Model 3                      
                                   (F=0.12, P=0.729)    (F=0.56, P=0.787)    (F=0.91, P=0.505)     
                                              Coefficient, P           Coefficient, P           Coefficient, P               
 
Age at examination, years C     0.04, 0.185     0.02, 0.474 
                                                   
Sex CAT                                                                   -0.03, 0.852            -0.06; 0.691                    
                
Ethnicity CAT                                                                    0.09, 0.382             0.08, 0.410           
                  
Insurance status  CAT                                                            -0.02, 0.897   -0.003, 0.986 
                             
BMI z-score C                      -0.04, 0.669   -0.07, 0.470  
    
Season CAT                                                             -0.15, 0.255             -0.18, 0.153 
 
Diabetes duration, months CAT                                                                         0.20, 0.062 
 
25-hydroxyvitamin D, nmol/LC     -0.002, 0.729              0.004, 0.426           0.004, 0.356                    
                           
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between 25-hydroxyvitamin D (treated as 
continuous) and IL-10 (treated as continuous) while adjusting for select covariates. P-value <0.05 is 
considered significant. 
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Aim Three (Table 4.10)  
The secondary aim of this study was to quantify the relationship between HbA1c 
and IL-6 while excluding 25-hydroxyvitamin D and other inflammatory markers (IL-10). 
It was hypothesized that IL-6 is directly correlated to HbA1c (table 4.10). GLM was used 
to examine this relationship. Assumptions required for inferences from GLM analyses 
were met. The histogram of estimated residuals was closer to a bell-shape and the normal 
probability plots (P-P plot and Q-Q plot) of estimated residuals approximated a straight 
line suggesting no significant departures from normality. Also the scatter plot of residuals 
versus fitted values showed constant variance of residuals across the range of fitted 
values. Statistical significance was set at P< 0.05. 
In the unadjusted model; IL-6 was directly correlated to HbA1c, although the 
relationship was not significant (β=0.14; P=0.252). In model 2; after adjusting for socio-
demographic covariates, IL-6 remained directly correlated to HbA1c and the relationship 
was not significant (β=0.17; P=0.145). In model 3, the relationship between IL-6 and 
HbA1c remained not significant after adjusting for socio-demographic and disease-
related covariates (β=0.09; P=0.418).  
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Table 4.10 HbA1c regressed on Log IL-6 in the final sample (n = 197) 
 
            Model 1             Model 2                  Model 3                      
                                   (F=1.31, P=0.252)    (F=6.19, P=0.000)    (F=10.13, P=0.000)     
                                              Coefficient, P           Coefficient, P           Coefficient, P               
 
Age at examination, years C     0.06, 0.080    -0.02, 0.568          
                                                   
Sex CAT                                                                   0.37, 0.052               0.08, 0.630         
                
Ethnicity CAT                                                                   0.40, 0.001**           0.23, 0.030*           
                  
Insurance status CAT                                                             0.73, 0.000**     0.39, 0.036*     
                             
BMI z-score C                      0.05, 0.678    0.02, 0.877          
     
Diabetes duration, months CAT                                                                          0.35, 0.003**            
 
Type of Insulin Regimen CAT                                                                       0.26, 0.002**              
 
Average Total Daily                                                                      0.59, 0.030*                  
Insulin Dose, units/kg/day C               
 
Frequency of Blood                                                                    -0.54, 0.000**             
Glucose Monitoring 
per Day CAT                          
 
Frequency of CRNP                                                                   -0.30, 0.066                 
Clinic Visit over the   
past Year CAT                        
 
Log IL-6C          0.14, 0.252                  0.17, 0.145             0.09, 0.418                    
                           
Log Mean Glucose, mg/dl C                                                                            0.31, 0.025*               
             
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between IL-6 (treated as continuous) and 
HbA1c (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
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Aim Three (Table 4.11)  
The secondary aim of this study was to quantify the relationship between HbA1c 
and IL-10 while excluding 25-hydroxyvitamin D and other inflammatory markers (IL-6). 
It was hypothesized that IL-10 is inversely correlated to HbA1c (table 4.11). GLM was 
used to examine this relationship. Assumptions required for inferences from GLM 
analyses were met. The histogram of estimated residuals was closer to a bell-shape and 
the normal probability plots (P-P plot and Q-Q plot) of estimated residuals approximated 
a straight line suggesting no significant departures from normality. Also the scatter plot 
of residuals versus fitted values showed constant variance of residuals across the range of 
fitted values. Statistical significance was set at P< 0.05. 
In the unadjusted model; HbA1c was directly correlated to IL-10 (β=0.24; 
P=0.015). In model 2; after adjusting for socio-demographic covariates, HbA1c remained 
directly correlated to IL-10 (β=0.22; P=0.018). In model 3, the relationship between 
HbA1c and IL-10 remained significant after adjusting for socio-demographic and 
disease-related covariates (β=0.21; P=0.008).  
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Table 4.11 HbA1c regressed on Log IL-10 in the final sample (n = 197) 
 
            Model 1             Model 2                  Model 3                      
                                   (F=5.96, P=0.015)    (F=6.88, P=0.000)    (F=11.06, P=0.000)     
                                              Coefficient, P           Coefficient, P           Coefficient, P               
 
Age at examination, years C     0.06, 0.087    -0.02, 0.449          
                                                   
Sex CAT                                                                   0.31, 0.091               0.05, 0.764         
                
Ethnicity CAT                                                                   0.37, 0.002**           0.21, 0.043*           
                  
Insurance status CAT                                                             0.75, 0.000**     0.39, 0.029*     
                             
BMI z-score C                      0.09, 0.469    0.04, 0.692          
     
Diabetes duration, months CAT                                                                          0.32, 0.007**            
 
Type of Insulin Regimen CAT                                                                       0.24, 0.004**              
 
Average Total Daily                                                                      0.62, 0.020*                  
Insulin Dose, units/kg/day C               
 
Frequency of Blood                                                                    -0.58, 0.000**             
Glucose Monitoring 
per Day CAT                          
 
Frequency of CRNP                                                                   -0.33, 0.039*                 
Clinic Visit over the   
past Year CAT                        
 
Log IL-10C          0.24, 0.015*                  0.22, 0.018*          0.21, 0.008**                    
                           
Log Mean Glucose, mg/dl C                                                                            0.31, 0.022*               
             
C, continuous variables; CAT, categorical variables; *P <0.05, ** P < 0.01 
 
General linear modeling was used to assess the relationship between IL-10 (treated as continuous) and 
HbA1c (treated as continuous) while adjusting for select covariates. P-value <0.05 is considered 
significant. 
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CHAPTER FIVE: DISCUSSION AND CONCLUSIONS 
 The purpose of this study was to examine the relationship between 25-
hydroxyvitamin D (the functional indicator of vitamin D status) and HbA1c (the 
standardized index of glycemic control); and to determine whether inflammatory 
cytokines IL-6, IL-8, and IL-10 mediate this relationship in metabolically stable children 
and adolescents with T1DM. A cross-sectional design was used to examine these 
relationships in a convenience sample of 197 children and adolescents with T1DM 7-18 
years recruited from the Diabetes Center for Children at the Children’s Hospital of 
Philadelphia. Study subjects were recruited between January and June, 2011. In this study 
sample of children and adolescents with T1DM, neither 25-hydroxyvitamin D nor pro-
inflammatory cytokine IL-6 were significantly associated with HbA1c. Conversely, anti-
inflammatory cytokine IL-10 was positively associated with HbA1c (β=0.12, P=0.039). 
Furthermore, serum levels of pro-inflammatory cytokine IL-8 were not detected in this 
sample.      
Key Findings 
The Relationship between 25-hydroxyvitamin D and HbA1c in Metabolically Stable 
Children and Adolescents with T1DM  
 The primary aim of this study was to examine whether there is a significantly 
inverse relationship between 25-hydroxyvitamin D and HbA1c in metabolically stable 
children and adolescents with T1DM. This relationship has been previously reported in 
obese/Caucasian children and adolescents (Alemzadeh et al., 2008). Also, 25-
hydroxyvitamin D has been linked to fasting glucose levels and proxy measures of 
insulin sensitivity/resistance in healthy children and adolescents (Delvin et al., 2010; 
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Johnson et al., 2010). Furthermore, vitamin D deficiency has been associated with the 
increased risk of developing T1DM where the immune modulatory role of 25-
hydroxyvitamin D has been suggested as the underlying mechanism explaining this 
relationship (Levy-Marchal et al., 1995; Mohr et al., 2008; Gysemans et al., 2005; 
Mathieu et al., 1992; Giulietti et al., 2004; Gregori et al., 2002; Mathieu et al., 1994; 
Simpson et al., 2011). In addition, vitamin D deficiency has been considered one of many 
environmental risk factors involved in the pathogenesis of T2DM through its effect on 
insulin secretion and insulin sensitivity (Scragg et al., 2004; Chiu et al., 2004; Knekt et 
al., 2008; Liu et al., 2010).  
To my knowledge, this is the first study to examine the relationship between 25-
hydroxyvitamin D and HbA1c in metabolically stable children and adolescents with 
T1DM after the first year of diagnosis. Only one previous study examined the 
relationship between 25-hydroxyvitamin D and HbA1c in youth recently diagnosed with 
T1DM and youth with established T1DM (Svoren et al., 2009). In bivariate analyses, 
vitamin D deficiency (25-hydroxyvitamin D less than 50 nmol/L) was associated with 
lower levels of HbA1c (P=0.05), although the relationship was no longer significant after 
adjusting for age, sex, ethnicity, season, BMI z-score, and diabetes duration (Svoren et 
al., 2009). Similarly, in this study sample, there was a trend of decreasing levels of 
HbA1c as 25-hydroxyvitamin D levels improved from levels at risk of deficiency (25-
hydroxyvitamin D less than 30nmol/L) towards sufficient states (25-hydroxyvitamin D 
equal to or more than 50nmol/L and less than 125nmol/L). The unadjusted relationship 
between HbA1c and 25-hydroxyvitamin D almost reached statistical significance (β=-
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0.01, P=0.055), but was no longer significant after adjusting for socio-demographic and 
disease-related covariates (β=0.008, P=0.108).  
Several reasons may explain the non-significant association observed between 25-
hydroxyvitamin D and HbA1c in this study sample. I excluded patients with HbA1c 
levels ≥12.0% and therefore my study sample was not reflective of the full spectrum of 
patients with poor glycemic control in T1DM population (HbA1c ≥ 9.5%). In addition, 
very few patients had 25-hydroxyvitamin D levels ≥75nmol/L (10.2%) which may have 
masked the hypothesized inverse relationship between 25-hydroxyvitamin D and HbA1c. 
25-hydroxyvitamin D levels ≥75nmol/L has been selected by the Endocrine Society and 
vitamin D experts as the cut off point for vitamin D sufficiency beyond which non-
calcemic functions of 25-hydroxyvitamin D may be observed (Holick et al., 2011).  
Looking at the relationship between 25-hydroxyvitamin D and HbA1c by vitamin 
D status and by ethnicity, I found a negative association between 25-hydroxyvitamin D 
and HbA1c in Caucasians with 25-hydroxyvitamin D levels equal to or greater than 
30nmom/L and less than 50nmol/L (n=31; β=-0.07, P=0.023). Also, there was a negative 
association between 25-hydroxyvitamin D and HbA1c in African Americans with 25-
hydroxyvitamin D levels equal to or greater than 50nmom/L and less than 75nmol/L 
(n=25; β=-0.08, P=0.044). Despite these interesting findings, I cannot make definitive 
conclusions about the observed associations in both Caucasians and African Americans 
given the small sample size. However, these findings may be hypotheses generating and 
need to be tested in future studies.   
 Furthermore, although these finding were overall negative, this study identified 
22.8% subjects with poor glycemic control, 48.2% subjects with intermediate glycemic 
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control, 40.6% subjects with vitamin D deficiency, and 49.2% subjects with vitamin D 
insufficiency. Poor glycemic control and vitamin D deficiency or insufficiency may be 
considered as prognostic biomarker in metabolically stable children and adolescents with 
T1DM. Poor glycemic control have been associated with the increased risk of developing 
micro- and macro-vascular complications such as nephropathy, neuropathy, retinopathy, 
and coronary and peripheral vascular disease, later in life (Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and Complications 
(DCCT/EDIC) Research Group et al., 2009). Furthermore, severe vitamin D deficiency 
(25-hydroxyvitamin D levels less than 15.5nmom/L) has been identified as an 
independent predictor of all-cause mortality in adolescents and adults with T1DM 
(Joergensen et al., 2011).   
 In addition, these findings showed no correlation between 25-hydroxyvitamin D 
levels and BMI z-scores (P=0.486). Similarly, Svoren and colleagues observed no 
association between 25-hydroxyvitamin D and BMI z-scores in youth recently diagnosed 
with T1DM and youth with established T1DM (Svoren et al., 2009). However; these 
findings are contradictory to what have been reported in healthy, overweight, and obese 
children and adolescents (Kelly et al., 2011; Delvin et al., 2010; Johnson et al., 2010; 
Reis et al., 2009). The reason may be the unequal distribution of subjects across BMI 
percentiles (63.5% healthy weight; 23.3% overweight; and 13.2% obese) and the 
relatively low number of subjects stratified as obese.  
Also, this is the first study to examine the relationship between 25-
hydroxyvitamin D and blood glucose level in T1DM (P=0.195). This finding is 
contradictory to what has been previously reported in healthy, overweight, and obese 
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children and adolescents (Delvin et al., 2010; Johnson et al., 2010). One reason for the 
negative result may be the non-fasting blood glucose level used for this. Another reason 
may be the wide fluctuation of blood glucose level in individuals with T1DM. The 
glucose level used in this study was based on a single measurement and therefore may 
not reflect the true average of glucose level over the past week or even the past month.  
The Relationship between 25-hydroxyvitamin D and Inflammatory cytokines in 
Metabolically Stable Children and Adolescents with T1DM  
 In animal studies, 25-hydroxyvitamin D has been established as an immune 
modulator that shifts the differentiation of CD4+ T cells towards a Th2, thereby 
decreasing the production of  pro-inflammatory cytokines including IL-6 and up-
regulating the production of anti-inflammatory cytokines including IL-10 (Bouillon et al., 
2008; van Etten & Mathieu, 2005). Furthermore, the addition of vitamin D to activated 
monocytes from individuals with T1DM was shown to down-regulate the expression of 
TNF-α, IL-6, IL-1, and IL-8 (Giulietti et al., 2007). Also, the effect of vitamin D 
supplementations on inflammation has been reported in patients with end-stage renal 
disease, hip-fracture, chronic kidney disease, and congestive heart failure (Stubbs, 
Idiculla, Slusser, Menard, & Quarles, 2010; Miller et al., 2007; Neves et al., 2010; 
Schleithoff et al., 2006). In this sample of children and adolescents with T1DM, 25-
hydroxyviatmin D was inversely associated with IL-6 (β=-0.007, P=0.030); however, this 
relationship was no longer significant after adjusting for socio-demographic and disease-
related characteristics (β=-0.005, P=0.175). Similarly, I found no significant association 
between 25-hydroxyvitamin D and IL-10 in this sample (β=-0.002, P=0.729 and β=0.004, 
P=0.356; for unadjusted and adjusted models, respectively). Although these findings are 
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negative, they do not exclude the effect of vitamin D supplementation on inflammatory 
cytokines in T1DM. Intervention studies are needed to test these hypotheses.  
The Relationship between HbA1c and Inflammatory cytokines in Metabolically Stable 
Children and Adolescents with T1DM  
 It is well established that hyperglycemia is linked to inflammation in T1DM 
(Erbagci et al., 2001; Foss-Freitas et al., 2008; Lo et al., 2004; Van Sickle et al., 2009; 
Zozulinska et al., 1999). I hypothesized that HbA1c is positively associated with IL-6 in 
metabolically stable children and adolescents with T1DM. In this sample, HbA1c was not 
associated with IL-6 even after adjusting for select socio-demographic and disease-
related covariates (β=0.09, P=0.418). Interestingly, these findings are similar to the 
SEARCH case-control study where inflammation as evident by elevated levels of IL-6 
was independent of glycemic control in adolescents and young adults with T1DM (10-22 
years) (Snell-Bergeon et al., 2010).  
 An interesting finding was the positive association between anti-inflammatory 
cytokine IL-10 and HbA1c (β=0.21, P=0.008), adjusting for socio-demographic and 
disease-related covariates. A prospective study following newly diagnosed individuals 
with T1DM showed an association between higher mean number of IL-10 producing 
cells, measured at the time of T1DM diagnosis, and improved glycemic control (r2=0.68 
P=0.08) measured three months after diagnosis (Sanda, Roep, & von Herrath, 2008). 
Another study reported significantly elevated serum levels of IL-10 in T1DM children 
with ketoacidosis as compared to T1DM children with no ketoacidosis (P<0.01) (Dai et 
al., 2010). These study findings and those of others suggest that IL-10 is an independent 
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predictor of glycemic control in T1DM. IL-10 may be the target of immune modulatory 
gene therapy in this population (Goudy et al., 2003).   
Other Findings 
Glycemic Control in Metabolically Stable Children and Adolescents with T1DM  
Poor glycemic control was found in 28.0% of the final sample. This number is 
higher than what has been previously reported (16.8%) in a nationally representative 
study of youth of T1DM (Petitti et al., 2009). The reason may be the high percent of 
African Americans with poor glycemic control (42.4%) represented in this study sample. 
Based on multivariate model; ethnicity, insurance, diabetes duration, type of insulin 
regimen, average total daily insulin dose, frequency of blood glucose monitoring per day, 
frequency of nurse practitioner clinic visit over the past year, and blood glucose level 
were all independent predictors of glycemic control. Although previous reports have 
shown age and sex to predict glycemic control this study failed to replicate these findings 
(Paris et al., 2009; Petitti et al., 2009; Levine et al., 2001). Reasons may be the relatively 
small sample size (n=197) and the truncated age range 7-18 years. Conversely, this study 
was similar to the SEARCH or Diabetes in Youth Study in that I found no association 
between BMI and HbA1c a relationship rather significant in youth with T2DM (Petitti et 
al., 2009). Furthermore, similar to published data, subjects on insulin pump had the 
lowest mean HbA1c (8.1% ± 1.1) as compared to subjects on MDI (8.4±1.2% to 
8.7±1.4%) or mixed insulin twice per day (10.1±1.3%) (Paris et al., 2009).  
Vitamin D Status in Metabolically Stable Children and Adolescents with T1DM  
 Based on functional studies of calcium absorption and parathyroid hormone in 
adults, serum 25-hydroxyvitamin D level equal to 75nmol/L has been selected as the cut 
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off point for vitamin D sufficiency (McKenna et al., 1998; Heaney et al., 2008). Despite 
the scarcity of research in children and adolescents; recently the Endocrine Society has 
adopted the same threshold for vitamin D sufficiency in this young population. Serum 25-
hydroxyvitamin D levels less than 50nmol/L were considered deficient, and serum 25-
hydroxyvitamin D levels equal to or greater than 50nmol/L or less than 75nmol/L were 
considered insufficient (Holick et al., 2011). For this study sample, 25-hydroxyvitamin D 
levels less than 75nmol/L were identified in 90.0% of study subjects; of which 40.6% 
were vitamin D deficient and 49.2% were vitamin D insufficient. This percent of subjects 
with 25-hydroxyvitamin D levels than 75nmol/L (90.0%) is higher than what has been 
previously reported for healthy and overweight youth 6-21 years (55.0%), and non-obese 
and obese youth 4-18 years (74.0%) recruited from the primary care practices at the 
Children’s Hospital of Philadelphia (at latitude 40°N) (Kelly et al., 2011; Weng et al., 
2007). It may be that the higher percent of vitamin D deficiency and insufficiency in this 
sample is due to the time of data collection from January to June when vitamin D 
cutaneous production is relatively low (Holick et al., 2007).  
 The IOM have challenged the current cut off point for vitamin D sufficiency and 
lowered the threshold from 75nmol/L to 50nmol/L based on studies of vitamin D and 
calcium. The IOM argues that the relationship between 25-hydroxyvitamin D and 
parathyroid hormone is not curvilinear and that peak calcium absorption occurs when 25-
hydroxyvitamin D levels are between 50 and 75nmo/L (Rosen, 2011). The interpretation 
of my study findings in light of the current IOM recommendations can have significant 
clinical implications. According to the IOM classification of vitamin D status; 9.1% of 
subjects are at risk of deficiency, 31.5% of subjects are at risk of vitamin D inadequacy 
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and 59.4% are sufficient. Based on these cut off points, only 40.6% of study subjects will 
be advised vitamin D supplements. Whereas 90.0% of study subjects will be advised 
vitamin D supplements if clinical management was based on the Endocrine Society 
recommendations. Until there is evidence from well-powered studies linking serum 25-
hydroxyvitamin D levels ≥75nmol/L to non-calcemic health outcomes, the cut off point 
for vitamin D sufficiency will remain controversial.  
 From the unadjusted model, 25-hydroxyvitamin D was significantly associated 
with age, sex, insurance status, type of insulin regimen, average total daily insulin dose, 
and pro-inflammatory cytokine IL-6. In a multivariate model controlling for age, sex, 
ethnicity, insurance status, BMI z-score, type of insulin regimen, average total daily 
insulin dose, diabetes duration, and pro-inflammatory cytokine IL-6; only age (β=-1.19; 
P=0.008), sex (β=5.13; P=0.042), type of insulin regimen (β=-3.33; P=0.007), and 
average total daily insulin dose (β=-9.39; P=0.018) were significantly associated with 25-
hydroxyvitamin D. In another study examining these relationships in youth recently 
diagnosed with T1DM and youth with established T1DM; only age and ethnicity were 
significantly associated with 25-hydroxyvitamin D (Svoren et al., 2009). In healthy and 
overweight children and adolescents from the same latitude (40°N) as this study sample, 
25-hydroxyvitamin D was significantly associated with vitamin D intake, race, and 
season (Weng et al., 2007). Also, in non-obese and obese children and adolescents at 
latitude 40°N, 25-hydroxyvitamin D was significantly associated with age, BMI, race, 
and season (Kelly et al., 2011). These findings suggest that race/ethnicity is a strong 
predictor of 25-hydroxyvitamin D in children and adolescents; however, this relationship 
did not hold true in this study sample (P=0.195).  
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Given the discrepancy between this study results and what was previously 
reported about the relationship between 25-hydroxyvitamin D and race/ethnicity, I re-
examined this relationship in this study sample after excluding Hispanics and Others (n = 
23). Furthermore, there was a notable difference in mean 25-hydroxyvitamin D across 
different racial/ethnic groups: 59.3±16.3nmoml/L for Caucasians, 45.0±15.6nmoml/L for 
African Americans, 55.9±21.4nmoml/L for Hispanics, and 68.7±15.0nmoml/L for 
Others.  
In the unadjusted model, the relationship between 25-hydroxyvitamin D and 
ethnicity was significant (β=-14.28; P<0.000). Furthermore, after adjusting for age, sex, 
ethnicity, insurance status, BMI z-score, type of insulin regimen, average total daily 
insulin dose, diabetes duration, and pro-inflammatory cytokine IL-6; only age (β=-1.39; 
P=0.002), ethnicity (β=-13.20; P< 0.000), and average total daily insulin dose (β=-9.06; 
P= 0.018) were significantly associated with 25-hydroxyvitamin D. The findings on age 
and ethnicity are similar to what has been previously reported in youth with T1DM, and 
healthy, overweight, and obese youth at latitude 40°N. However, to my knowledge, the 
significant relationship observed between 25-hydroxyvitamin D and average total daily 
insulin dose is new. This relationship should be taken with caution since average total 
daily insulin dose was a self-reported measure and therefore may not reflect the true 
average insulin dose in this sample.   
Inflammation in Metabolically Stable Children and Adolescents with T1DM  
Pro-inflammatory Cytokine IL-8  
 Increased levels of inflammatory markers have been consistently reported in 
T1DM and further associated with diabetes-related micro-vascular complications (King, 
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2008). In this study sample of metabolically stable children and adolescents with T1DM, 
serum levels of pro-inflammatory cytokine IL-8 were not detected. These findings are not 
consistent with what has been previously reported. One study reported mean IL-8 of 
3.7±4.0pg/ml in adolescents with HbA1c less than 9.0% and 7.4±4.3pg/ml in adolescents 
with HbA1c greater than 9.0% (Van Sickle et al., 2009). In the same study, serum levels 
of IL-8 were significantly associated with HbA1c (β=0.36, P=0.03). Another study 
reported elevated mean IL-8 (12.7±1.7pg/ml) in children with newly diagnosed T1DM 
and children with established T1DM as compared to non-diabetic controls (5.5±0.3pg/ml) 
(Erbagci et al., 2001). It is highly probable that I did not detect serum IL-8 levels in this 
study sample due to the low sensitivity of the R&D human CXCL8/IL-8 Immunoassay. 
The lowest standard for the R&D human CXCL8/IL-8 Immunoassay was 31.2pg/ml 
which may have been significantly higher than serum IL-8 levels present in this study 
sample.  
Pro-inflammatory Cytokine IL-6 
  Elevated serum levels of IL-6 have been associated with acute and chronic 
hyperglycemia, onset of T1DM diagnosis, and diabetes-related micro-vascular 
complications (Erbagci et al., 2001; Rosa et al., 2008; Devaraj et al., 2007; Schram et al., 
2005). Mean IL-6 was 1.1±1.2pg/ml for this study sample. These results are comparable 
to what has been previously reported in non-fasting children with T1DM ranging from 
0.86±0.10pg/ml to 1.20±0.16pg/ml (Rosa et al., 2008). Interestingly, mean IL-6 level in 
this sample is significantly lower than what has been previously reported in glucose 
intolerant obese children and adolescents (2.7±1.1pg/ml) (Yeste et al., 2007). Also, these 
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data showed that serum IL-6 was significantly higher in females than males 
(1.3±1.4pg/ml versus 0.9±1.1pg/ml; respectively).  
Table 5.1 Mean IL-6 of the final sample by BMI and by age  
 
Normal weight 7-12 years 13-18years 
Females 1.25±1.78 1.19±1.13 
Males 0.83±0.85    0.96±1.08 
 
Overweight/Obese 7-12 years 13-18years 
Females 0.95±0.63 1.57±1.29 
Males 1.26±1.86 0.59±0.31 
 
After stratification of the sample by BMI and age; mean IL-6 was highest in 
overweight/obese adolescent females (1.57±1.29pg/ml) as compared to other subgroups 
(table 5.1). Furthermore, these results in normal weight (0.83±0.85pg/ml) and 
overweight/obese (1.26±1.86pg/ml) males 7-12 years are comparable to IL-6 levels 
reported in normal weight (1.3pg/ml; range 0 to 2.5pg/ml), and overweight/obese 
(1.4pg/ml; range 0.2 to 3.6pg/ml) boys aged 8 years (Charmaine et al., 2010). 
Conversely, these results in normal weight (0.96±1.08pg/ml) and overweight/obese 
(0.59±0.31pg/ml) adolescent males are much lower than what have been reported in 
normal weight (7.9pg/ml; range zero to 9.2pg/ml), and overweight/obese (8.5pg/ml; 
range 7.1 to 10.4pg/ml) adolescent males aged 15 years (Charmaine et al., 2010).  
In essence, overweight/obese females (mean IL-6; 1.57±1.29pg/ml) may be at a 
higher risk of developing diabetes-related micro-vascular complications as compared to 
overweight/obese males within the same age group (mean IL-6; 0.59±0.31pg/ml), and 
overweight/obese males and females 7-12 years (mean IL-6; 1.26±1.86pg/ml and 
0.95±0.63pg/ml, respectively).  
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Anti-inflammatory Cytokine IL-10 
 Mean anti-inflammatory cytokine IL-10 was 10.5±20.3pg/ml in this study sample 
of metabolically stable children and adolescents with T1DM. These findings are 
comparable to mean IL-10 levels (ranged from 5.4 to 7.6pg/ml) measured at baseline and 
at short time intervals during exercise for normal weight T1DM children 13.9±0.3years 
(Rosa et al., 2011). Also, mean IL-10 levels in this sample were higher than what has 
been reported for normal weight (0.6pg/ml; range 0.2 to 0.9pg/ml) and overweight/obese 
(0.6pg/ml; range 0.03 to 1.1pg/ml) boys aged 8 years, and for normal weight (7.7pg/ml; 
range 0.9 to 7.9pg/ml) and overweight/obese (7.9pg/ml; range 7.3 to 8.1pg/ml) adolescent 
males aged 15years (Charmaine et al., 2010).  
 The moderately elevated levels of serum IL-10 in this study sample is not an 
unlikely finding given the chronic state of inflammations associated with T1DM. IL-10 is 
known to inhibit Th1 responses, inhibit pro-inflammatory cytokines, and increase the 
expression of Foxp3+ in T cells, thus changing their phenotype into T regulatory cells. 
Furthermore, studies have shown that vitamin D enhances the development of IL-10 
producing cells which then reduces the number of IL-6 producing cells (Correale, 
Ysrraelit, & Gaitan, 2009). In bivariate analysis, serum IL-10 was positively correlated to 
IL-6 (P=0.037); however, the relationship was no longer significant after adjusting for 
age, sex, ethnicity, BMI, and HbA1c.  
 Furthermore, mean IL-10 was significantly correlated to HbA1c (P=0.015); 
however, after stratifying the sample by race/ethnicity, this relationship was no longer 
significant for Caucasians (P=0.695) but remained significant for African Americans 
(P=0.006). Also, serum IL-10 levels were not significantly different across levels of 
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glycemic control for Caucasians (P=0.712) but showed a trend towards significance for 
African Americans (P=0.085) (figure 5.1). The significant correlation observed between 
HbA1c and IL-10 in African Americans is most likely due to the high percentage of 
African Americans with poor glycemic control in this study sample. Furthermore, these 
data suggest that the relationship between HbA1c and IL-10 in this sample is not linear. 
A threshold value for HbA1c beyond which increases in serum levels of IL-10 are 
expected should be determined. In this sample, this may not be feasible since I have 
excluded all patients with HbA1c greater than 12.0%. 
Figure 5.1 Mean IL-10 of the final sample by ethnicity and by glycemic control 
 
Limitations of the Study 
The main limitation of this study is its cross-sectional design, and therefore the 
causative nature of observed significant associations could not be established. In addition, 
a larger and more ethnically diverse sample may be needed to examine whether the 
relationships observed vary by ethnicity. Moreover, this study was based on a single 
0 
5 
10 
15 
Mean  
IL-10  
(pg/ml) 
Good Intermediate Poor 
Caucasians African Americans 
138 
 
blood draw to measure 25-hydroxyvitamin D, inflammatory cytokines, blood glucose 
level, and HbA1c and therefore, it does not take into account within-person variation. 
Furthermore, covariates including vitamin D supplementation, diet, exercise, adherence, 
and family diabetes-management that may explain a significant percent of variance in 
HbA1c and/or 25-hydroxyvitamn D were not included in this study. Lastly, the study 
sample was recruited at a single site, and therefore the results of this study may not be 
generalizable.  
Conclusions and Clinical Implications 
The knowledge gained from the study has increased our understanding on the 
relationships among vitamin D status, glycemic control, and inflammation in 
metabolically stable children and adolescents with T1DM. This study confirmed what is 
already known on the marked prevalence of vitamin D deficiency in children and 
adolescents with T1DM. Also, this study showed that a significant number of children 
and adolescents with T1DM have poor glycemic control. These findings are alarming 
given that this study sample includes T1DM individuals motivated to volunteer for 
research and attends a specialty diabetes center.  
In this study sample, 25-hydroxyvitamin D was not associated with HbA1c. 
Despite this negative finding, clinical controlled trials are still needed to assess the short-
term and long-term effect of varied doses of vitamin D supplements on HbA1c in 
children and adolescents with T1DM. The possibility that vitamin D may be involved in 
glucose homeostasis in T1DM has potential implications for a) establishing vitamin D 
testing as “standard of care” in T1DM, and b) recommendations regarding the use of 
vitamin D supplements and sun exposure in T1DM.   
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Until there is sufficient evidence to support the inverse relationship between 25-
hydroxyvitamin D and HbA1c in T1DM, the findings of this study may be used to 
highlight the significantly high prevalence of vitamin D deficiency and insufficiency in 
children and adolescents with T1DM. Future studies assessing the prevalence of vitamin 
D deficiency and insufficiency across the full spectrum of HbA1c are needed. In addition, 
since this study enrolled patients from January through June, it is important to assess 
vitamin D status in children and adolescents with T1DM across four seasons (fall, winter, 
spring, and summer). It is also of relevance to look into the effect of vitamin D deficiency 
and insufficiency on bone health in T1DM. 
Mean serum IL-6 was highest in overweight/obese females (1.57±1.29pg/ml). 
Mean serum IL-10 was highest in African American subjects with poor glycemic control 
(15.2±22.5pg/ml). Serum levels of pro-inflammatory cytokine IL-8 were not detected in 
this study sample. Pro-inflammatory cytokine IL-6 was not associated with HbA1c. 
Conversely, anti-inflammatory cytokine IL-10 was positively associated with HbA1c 
(β=0.12, P=0.039). These findings call for a special attention to overweight/obese 
females with T1DM since high IL-6 levels have been linked to the development of micro- 
and macro-vascular complications in this population. Furthermore, anti-inflammatory 
cytokine IL-10 may be a potential prognostic biomarker for poor glycemic control in this 
population. Unfortunately, I did not find a significant association between 25-
hydroxyvitamin D, IL-6 and IL-10 in this study sample. Physiologically, poor glycemic 
control is associated with elevated levels of pro-inflammatory cytokines. In addition, it is 
well established that elevated levels of anti-inflammatory cytokine IL-10 down-regulate 
the production of pro-inflammatory cytokines including IL-6 in vivo and in vitro. Studies 
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have also shown that vitamin D enhances the development of IL-10 producing cells in 
vivo and in vitro. In essence, intervention studies are needed to assess the effect of varied 
doses of vitamin D supplements on pro- and anti-inflammatory cytokines and ultimately 
measure the effect of inflammatory cytokines on HbA1c in T1DM.  
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APPENDIX 
 
INFORMED CONSENT FORM AND HIPAA AUTHORIZATION 
Study Title: The Relationship between Vitamin D Status and Glycemic Control in 
Children and Adolescents with Type 1 Diabetes Mellitus: Role of Inflammatory 
Mediators 
IRB #: 10-007770   
Version Date:                     October 18, 2010 - Version 2          
Principal Investigator: Terri H Lipman, PhD, 
CRNP,       FAAN             
Telephone: (215) 590-6587 
                   (215) 898-2259 
                            
Affiliations: 
The Children’s Hospital of Philadelphia,  
Division of Endocrinology 
 
Study Sponsor:                            Office of Nursing Research 
at the University of 
Pennsylvania, School of 
Nursing 
 
 
You may be eligible to take part in a research study. This form gives you important 
information about the study. It describes the purpose of this research study, and the risks 
and possible benefits of participating.  
If there is anything in this form you do not understand, please ask questions. Please take 
your time. You do not have to take part in this study if you do not want to. If you take 
part, you can leave the study at any time.  
Parents or legal guardians, who are giving permission for a child, please note: in the 
sections that follow the word ‘you’ refers to your child. 
Why are you being asked to take part in this study? 
You are being invited to take part in this research study because you have had type 1 
diabetes mellitus for more than one year, your age is between 7 and 18 years, and you 
may be doing your yearly screening blood tests today.  
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What is the purpose of this research study?  
The purpose of this research study is to find out whether vitamin D level is related to 
blood glucose level in children and adolescents with type 1 diabetes mellitus. Previous 
studies have shown that keeping vitamin D levels within the normal range is important 
for bone growth and development, and may be helpful in blood glucose control.  
 
The study will also look at how inflammation affects the relationship between vitamin D 
level and blood glucose level in young people with type 1 diabetes. 
How many people will take part? 
About 204 participants will take part in the study. All participants will be children or 
adolescents with type 1 diabetes mellitus, who have had diabetes longer than one year, 
and are being followed at the Diabetes Center for Children (DCC) at the Children’s 
Hospital of Philadelphia (CHOP).   
What is involved in the study? 
If you agree to take part in this study, the following procedures will be performed: 
 
Medical Record Review: We will review your medical record to collect some 
demographic information (e.g. age, sex, ethnicity, and insurance) as well as information 
about your blood glucose control (HbA1c) and other information about your diabetes. 
 
Blood Test: We will collect two teaspoons of your blood to measure vitamin D level and 
markers of inflammation at the same time you are having blood drawn for your regular 
yearly blood tests. If the blood is being drawn at CHOP today, you will NOT need an 
extra needle stick for the two teaspoons of blood that will be collected for this study. 
 
If you go to an outside lab for blood drawing you may still participate in the study. 
However, this would require an extra needle stick for the two teaspoon of blood in the 
CHOP laboratory. 
 
Your Vitamin D levels will be shared with your diabetes provider. If the results are 
abnormal, your diabetes provider may check your vitamin D level one more time at a 
local laboratory.  
 
Your participation will end once you give two teaspoons of blood.   
 Visit Schedule 
The table below provides a brief description of the purpose and duration of each study 
visit.  
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Visit Purpose Procedures Duration 
Visit 1 (only 
visit) 
Screening and 
enrollment visit  
Blood test 1 hour 
What are the risks of this study? 
Taking part in a research study involves inconveniences and risks. If you have any 
questions about any of the possible risks listed below, you should talk to the study 
investigators Terri Lipman, PhD, CRNP, FAAN and Sarah Sawah, PhD(c), MSc, RN.  
You can also talk to your regular nurse practitioner or doctor. 
 
Taking blood may cause some pain, bleeding or bruising at the spot where the needle 
enters your body. Rarely, taking blood may cause fainting or infection. As stated above, 
we will take your blood at the same time you are having blood drawn for clinical 
purposes. The amount of blood we will take is minimal and you will not need a separate 
needle stick. 
 
If you go to an outside lab for blood draw and you wish to participate in this study, you 
will have to undergo an additional blood draw procedure at CHOP laboratory. The risks 
of taking blood are the same as stated above. 
 
As with any study involving collection of data, there is the possibility of loss of 
confidentiality of data. Every precaution will be taken to secure participants' personal 
information to ensure confidentiality.  
 
At the time of participation, each participant will be assigned a study identification 
number. This number will be used on data collection forms, on your blood sample and in 
the study database instead of names and other private information. A separate list will be 
maintained that will link each participant's name to the study identification number for 
future reference and communication. 
Are there any benefits to taking part in this study? 
There will be no direct benefit to you from taking part in this study. We hope that 
the information learned from this study will help us understand more about type 1 
diabetes and possibly benefit other children and adolescents with the same 
condition in the future. If the results of the study show that vitamin D is related to 
blood glucose levels, the results may encourage diabetes providers to include 
vitamin D in yearly screening tests. 
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Do you need to give your consent in order to participate?  
Once you read this form and have your questions answered, you will be asked to decide if 
you wish to participate. If you wish to participate in this study, you must sign this form. 
A copy will be given to you to keep as a record.  
What happens if you decide not to take part in this study?  
Participation in this study is voluntary; you do not have to take part in order to receive 
care at CHOP. If you decide not take part or if you change your mind there will be no 
penalties or loss of any benefits to which you are otherwise entitled.  Your current and 
future medical care at CHOP will not be affected by your decision. 
What about privacy, authorization for use of Personal Health Information (PHI) 
and confidentiality?  
We need to collect health information about you in order to conduct this study. This 
includes information about you from medical records and from the tests that are part of 
this research. Routine clinical laboratory tests performed as part of this study will appear 
in your medical record. We will do our best to keep your personal information private 
and confidential. However, we cannot guarantee absolute confidentiality. Your personal 
information may be disclosed if required by law.  
The results of this study may be shown at meetings or published in journals to inform 
other doctors and health professionals. We will keep your identity private in any 
publication or presentation about the study. 
People and organizations that may inspect and/or copy your research records to conduct 
this research, assure the quality of the data and to analyze the data include:  
Members of the research team at CHOP and UPenn; 
Medical staff who are directly or indirectly involved in your care related to this research; 
People who oversee or evaluate research and care activities at CHOP; 
People from agencies and organizations that perform independent accreditation and/or 
oversight of research; such as the Department of Health and Human Services, Office for 
Human Research Protections. 
By law, CHOP is required to protect your health information. The research staff will only 
allow access to your health information to the groups listed above.  By signing this 
document, you are authorizing CHOP to use and/or release your health information for 
this research. Some of the organizations listed above may not be required to protect your 
information under Federal privacy laws. If permitted by law, they may be allowed to 
share it with others without your permission.   
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There is no set time for destroying the information that will be collected for this study. 
Your permission to use and share the information and data from this study will continue 
until the research study ends and will not expire. Researchers continue to analyze data for 
many years and it is not possible to know when they will be completely done.  
What are my rights and responsibilities as a research subject? 
Taking part in a research study involves time and responsibilities. Please consider the 
study time commitments and responsibilities as a research subject when making your 
decision about participating in this study. 
You may change your mind and take back your authorization to use and disclose your 
health information at any time.  Even if you take back your authorization, we may still 
use and disclose the health information we have already obtained about you as necessary 
to maintain the integrity or reliability of the current research.  To take back your 
authorization, you must send a letter to Terri Lipman, PhD, CRNP, who is also a nurse 
practitioner in the Diabetes Center.  In the letter, you must say that you changed your 
mind and do not want us to collect any more health information about you.  If you ask 
that we no longer collect your health information you will have to leave the study. 
Financial Information  
Will you be paid for taking part in this study? 
You will be given a $5 gift card as a token of appreciation for taking part in this study.   
Who is funding this research study?  
The Office of Nursing Research at the University of Pennsylvania, School of Nursing and 
the Pediatric Endocrine Nursing Society are providing funding for this study. 
Please ask Terri Lipman, PhD, CRNP, FAAN or Sarah Sawah, PhD(c), MSc, RN if you 
have any questions about how this study is funded.  
What if you have questions about the study? 
If you have questions about the study, call the study investigator Terri Lipman, PhD, 
CRNP, FAAN at 215-590-6587 or Sarah Sawah, PhD(c), MSc, RN at 215-909-0833. 
You may also talk to your own nurse practitioner or doctor if you have questions or 
concerns. 
The Institutional Review Board (IRB) at The Children’s Hospital of Philadelphia has 
reviewed and approved this study. The IRB looks at research studies like these and makes 
sure your rights and welfare are protected. You can talk to a person from this group if you 
have questions about your rights as someone taking part in a research study. You can call 
the IRB Office at 215-590-2830 if you have questions or complaints about the study. 
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Consent to Take Part in this Research Study and Authorization to Disclose Health 
Information 
 
The research study and consent form have been explained to you by: 
   
Person Obtaining Consent  Signature of Person Obtaining Consent 
  Date: 
By signing this form, you are indicating that you have had your questions answered, you 
agree to take part in this research study and you are legally authorized to consent to your 
child’s participation. You are also agreeing to let CHOP use and share your health 
information as explained above. If you don’t agree to our collecting, using and sharing 
your health information, you cannot participate in this study. NOTE: A foster parent is 
not legally authorized to consent for a foster child’s participation. 
   
Name of Subject   
  
 Date 
   
Name of Authorized Representative  
(if different than subject) 
 Relation to subject: 
 Parent  Legal Guardian 
   
Signature of Authorized Representative  Date 
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Child Assent to Take Part in this Research Study 
For children capable of providing assent: 
I have explained this study and the procedures involved to __________________ in 
terms he/she could understand and that he/she freely assented to take part in this study. 
 
   
Person Obtaining Assent   
   
Signature of Person Obtaining Assent  Date 
 
This study has been explained to me and I agree to take part. 
   
Signature of Subject (optional)  Date 
 
 
For children unable to assent:  
I certify that __________________ was not capable of understanding the procedures 
involved in the study sufficiently to assent to study participation.  
   
Person Responsible for Obtaining 
Assent 
  
   
Signature of Person Responsible  Date 
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